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Abstract 
The area of MRI/optical imaging has received a lot of attention as their combination 
brings together the high spatial resolution of MRI with the high sensitivity of optical imaging. 
Changes in pancreatic β-cell mass contribute to the development of both type 1 and type 2 
diabetes. Whilst the processes of β-cell loss are fairly well established for type 1, both the 
extent of the loss and the underlying mechanisms are relatively unknown for type 2. Zinc ions 
are highly concentrated in the insulin granules that are contained within β-cells. Few robust 
approaches currently exist to monitor changes in β-cell mass in vivo, and as such, this project 
aims to develop responsive lanthanide complexes to bind selectively and respond to zinc 
levels in this target area. 
The introductory chapter considers the fundamental aspects of molecular imaging, with a 
particular focus on magnetic resonance and optical imaging, as well as the intrinsic properties 
of the lanthanide elements, such as magnetism and luminescence. The subsequent results 
chapters contain more detailed introductions, relevant to the topics covered within the chapter. 
The synthesis of dual-modal MR/optical probes is described in chapter two. Three 
rhodamine-based [GdDO3A] complexes are described and their relaxivity and fluorescence 
properties are established. The Eu3+ and Tb3+ analogues are also studied. Two of the 
complexes, which show superior water solubilities, are further studied in in vitro and in vivo 
experiments. One probe displays a fluorescence pH sensitivity that allows for the 
differentiation of healthy cells from malignant cells due to their difference in pH whilst the 
other probe displays fluorescence at all pH’s. Both probes show accumulation in the 
mitochondria. 
Chapter three discusses the synthesis of an MR zinc sensor using a BPEN chelator as the 
zinc-binding moiety. Showing high selectivity for zinc, this probe is then further 
functionalised with the rhodamine fluorophore derivative previously described to give a dual-
modal MR/fluorescent zinc sensor. This probe only shows an MR response in the presence of 
zinc. In vitro experiments show the localisation of the probe to differ from the results of the 
dual-modal probes discussed in chapter two, showing cytosol localisation. 
Finally, chapter four concerns the synthesis of a fluorescent zinc sensor and its 
conjugation to a [GdDO3A] scaffold to give a dual-modal MR/optical zinc sensor. This probe 
displays an improved response to zinc showing increases in both relaxivity and fluorescence. 
In vitro experiments with both INS1 and HEK cells show the probe to localise in the 
lysosome and mitochondria respectively. 
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r1  relaxivity 
RES  reticule-endothelial system 
RF  radio frequency 
rGdH  Gd3+-water proton distance 
ROESY  rotating frame nuclear overhauser effect 
s  second 
s-1  per second 
S0  singlet ground state 
S1  singlet excited state 
SAP  square antiprismatic 
SBM  Solomon, Bloembergen and Morgan theory 
SHIN3  cell line obtained originally from human ovarian cancer 
SPECT  single photon emission computed tomography 
T  tesla 
T1  longitudinal relaxation time 
T1  triplet excited state 
τ1e  electron relaxation time 
T2  transverse relaxation time 
TFA  trifluoroacetic acid 
TLC  thin layer chromatography 
τM  rotational correlation time 
TSAP  twisted antiprismatic 
U87MG  grade IV glioma cell line 
US  ultrasound 
UV  ultraviolet 
v/v  volume/volume 
via  by means of 
vs.  versus 
Δψm  mitochondrial potential 
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This introduction will cover the fundamentals of the imaging modalities involved in this 
project: magnetic resonance imaging (MRI) and optical imaging. The lanthanides and their 
properties will also be discussed. The subsequent chapters will then contain more detailed 
discussions that relate more closely to their subject matters, i.e. chapter two will explore the 
use of rhodamine dyes, dual-modal MR/optical imaging agents and imaging of tumour cells; 
chapter three will review the importance of biological zinc and the design of MR agents to 
sense it; and finally chapter four will consider optical zinc sensors and the design of dual-
modal MR/optical zinc sensors. 
1.1 Molecular Imaging 
Taking off in the early 1990’s, the field of molecular imaging has brought together a vast 
variety of scientists from multiple disciplines ranging from the core subjects of chemistry, 
biology, medicine and mathematics to the specialised areas of cell biology, biomedical 
engineering and pharmacology. Molecular imaging is commonly defined as the non-invasive, 
real-time visualisation of biochemical events occurring on the cellular and molecular level, 
and the ongoing research in this area is greatly enhancing the way researchers visualise and 
investigate the complexities of biochemistry.1 One of the principle objectives of molecular 
imaging is to overcome the inherent problems associated with established in vitro bioassay 
techniques.2 These include, the removal of tissue samples from their natural environment 
rendering results non-representative of the physiological condition and the unavoidable 
euthanasia of test animals prohibiting the extended study of the same animal, which makes 
the appreciation of a full description of a biochemical process difficult.3 Molecular imaging 
attempts to overcome these obstacles by employing in vivo techniques that allow for the study 
of cells in their natural microenvironment, the collection of data over time from the same test 
subject and the tracing of cell movements that inform on important biological processes. 
Although some aspects of the field are relatively new, a range of molecular imaging 
techniques are currently being employed in the clinical environment as diagnostic tools, 
including Magnetic Resonance Imaging (MRI), Optical Imaging, Positron Emission 
Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), Ultrasound 
(US) and Computed Tomography (CT). Each modality offers its own strengths and 
weaknesses (Table 1.1) and as such some techniques are more suited to certain applications 
than others. For example CT is the classic anatomical imaging modality4 whereas PET offers 
the sensitivity required to monitor, for example, drug distribution.5 No one imaging modality 
can provide information on all aspects of structure and function, and as such it is becoming 
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increasingly common to combine two or more complementary techniques to provide broader 
applicability. One combination of modalities is that of MR/optical. MR imaging offers deep 
tissue penetration and excellent spacial resolution but the technique is inherently insensitive.6 
Optical techniques on the other hand are extremely sensitive being able to detect variations in 
luminescence emission intensities at the cellular and sub-cellular levels.7 Its drawback 
however is that data acquisition to only a few cm into tissue can be attained, even with 
wavelengths longer than 650 nm. This limits whole body imaging mainly to small rodents, 
although advancements in fibreoptics means that the technique is still valuable for the 
imaging of vital internal organs.8 In the following sections, these two techniques will be 
discussed in more detail as they are the only modalities relevant to the work in this thesis. 
 
 Type of EM 
radiation used 
Spatial 
resolution 
Depth Scan time Sensitivity 
 
Radiowaves 
< 10-5 eV 4 – 100 µm No limit 
Minutes to 
hours Low 
 
Visible to NIR 
2 – 3 eV 15 – 1000 nm < 1 cm Seconds High 
 
High energy γ rays 
511 keV 1 – 2 mm No limit Minutes High 
 
Lower energy γ 
rays 70 – 370 keV 1 – 2 mm No limit Minutes High 
 
High frequency 
sounds < 10-7 eV 50 – 500 µm mm to cm Seconds High 
 
X-rays 
103 – 105 eV 
15 – 50 µm 
50 – 200 µm 
No limit Minutes Low 
 
Table 1.1: Overview of various properties of molecular imaging modalities.9 Image 
references: MRI10, Optical11, PET12, SPECT13, US14 and X-ray CT15. 
MRI 
Optical 
PET 
SPECT 
US 
X-ray 
CT 
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1.2 MRI and T1 contrast agents 
Magnetic resonance imaging is an imaging modality that is based on the principles of 
nuclear magnetic resonance (NMR), and its concept was first developed in 1972 by Paul 
Lauterbur at the University of Illinois, USA, and Sir Peter Mansfield at the University of 
Nottingham, UK.16,17 Their joint discovery won them the Nobel Prize for Physiology or 
Medicine in 2003.18,19 Using NMR we can obtain chemical and physical information about 
molecules via changes in chemical shifts and coupling constants, whereas with MRI one 
obtains information on the spatial distribution of the intensity of water proton signals in the 
body. Just like NMR, MRI is a technique that takes advantage of the spin property of nuclei. 
Not all nuclei exhibit spin, only those with an odd number of neutrons or protons. Nuclei with 
spin will have two important properties: angular momentum (as it is a rotating mass) and a 
magnetic moment (it is a rotating mass with an electrical charge).20 Therefore, the spinning 
nuclei are affected by external magnetic fields and electromagnetic waves. In the case of 
clinical MRI, the majority of imaging is based on the nucleus of hydrogen i.e. the single 
proton (nuclear spin quantum number, I = ½). This is due to its high concentration in vivo in 
the form of water and fat (body made up of ~ 63% hydrogen atoms).21 Other elements such as 
sodium and phosphorus are MR active but their concentrations are much too low compared to 
hydrogen; with a high abundance of protons greater spatial resolution and image quality can 
be acquired in a shorter time. 
Much like in an NMR experiment, during an MRI scan, a sample of interest is placed 
inside a magnet. For NMR this would involve placing a compound of interest in solution in an 
NMR tube and suspending the sample vertically in the magnetic field, whereas in MRI the 
sample is usually a living subject and the magnet is a great deal larger and lying horizontally. 
Placing the body in this large magnetic field aligns all the proton nuclei (which are behaving 
like small magnets) either parallel or anti-parallel to the field.22 The MR signal is produced 
from the very small net difference in the number of nuclei that align parallel vs. those that 
align anti-parallel. It is this small difference in populations that makes MR imaging such a 
low sensitivity modality.23 The proton nuclei are then exposed to a sequence of 
radiofrequency (RF) pulses, exciting them from the lower energy state (parallel) to the higher 
energy state (anti-parallel). Upon ceasing of the RF pulses, the nuclei relax back to the ground 
state whilst re-emitting RF at their Larmor frequency.22 The Larmor frequency is a function of 
the applied magnetic field, B0 and the gyromagnetic ratio of the proton, γ (42.6 MHz/Tesla).24 
A strong uniform magnetic field of 1.5 or 3 Tesla is commonly used in clinics.25 The nuclei 
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then undergo two forms of relaxation back to equilibrium known as spin-lattice (longitudinal) 
relaxation or spin-spin (transverse) relaxation.26 These signals are detected and converted into 
greyscale 3D images, showing how the proton nuclei in the body relax back to their ground 
states: the shorter the longitudinal relaxation rate (T1, brightening of image) / transverse 
relaxation rate (T2, darkening of image) the greater the MR signal. Even though the technique 
is inherently low in sensitivity, the relaxation times of water in different environments are 
sufficiently different to produce a contrast, for example T1 (muscle) = 1.023 s vs. T1 (liver) = 
0.570 s.27 Around two thirds of clinical MRI scans are based solely on the contrast observed 
due to the difference of T1 in different tissues.28 The rest however have employed the use of 
contrast agents to improve the quality of the image. 
1.2.1 T1 Contrast agents 
Unlike other imaging modalities, the use of a contrast agent is not always required in 
MRI: the contrast agent itself is not ‘visible’. The agents function by interacting with H2O 
protons: they either modify their relaxation times or are directly involved in the level of H2O 
magnetisation.29 As the works described in this thesis concern only gadolinium complexes as 
T1 contrast agents, the function and use of T2 probes will not be discussed here, and which are 
in any case, reviewed elsewhere.30,31 The introduction of molecules with unpaired electrons 
into a H2O molecule environment triggers the more effective longitudinal relaxation (T1) of 
H2O protons. It is this shortening of the T1 of water molecules that leads to the ‘positive’ 
contrast enhancement observed from small molecule T1 agents.  
A number of paramagnetic metal ions can be used to increase contrast, including Mn2+, 
Mn3+, Fe3+, Cu2+ and Gd3+. Gd3+ is the metal ion most commonly used in T1 contrast agents as 
it has an unmatched 7 unpaired electrons, a symmetric 8S ground state that gives a long 
electronic relaxation rate that is in tune with a proton’s frequency and a large effective 
magnetic moment, µeff = 7.94 B.M. (Bohr Magneton)32 The metal ion however is extremely 
toxic as it has a similar size to the calcium ion but with a higher charge so that it disrupts 
critical calcium required signaling.33 As such, it is a primary concern when preparing Gd3+-
based contrast agents to ensure that the metal ion is in the form of a kinetically and 
thermodynamically stable complex. This is achieved through complexation with appropriate 
polydentate ligands, i.e. charged polydentate or macrocyclic ligands. Only with these ligands 
will stable complexes form with lanthanides where bonding is primarily ionic in nature (due 
to the lack of participation of the contracted 4f orbitals in bonding).34 The eight-coordinate 
ligands DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and DTPA 
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(diethylene triamine pentaacetic acid) and their derivatives have become the ‘go-to’ ligands in 
this field. A selection of clinically approved Gd3+-based contrast agents based on these 
ligands is shown in Figure 1.1. The ligands bind to the trivalent gadolinium ion through three 
or four amine nitrogen atoms and five or four carboxylate oxygen atoms respectively. This 
leaves a ninth coordination site free allowing it to bind labile water molecules. Having only 
one water molecule binding to the gadolinium ion greatly reduces its efficiency as a contrast 
centre compared to hydrated aqua ion. This is why very high doses (typically 0.1 – 0.2 
mmolkg-1) of contrast agent are required clinically.35 It is of the upmost importance however 
to keep the gadolinium ion in a stable complex to prevent its toxic effects. 
 
Figure 1.1: Structures of Gd3+-based MRI contrast agents currently used in clinical practice.36 
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1.2.2 Water proton relaxivity, r1 
The theory of relaxation in the presence of paramagnetic ions was first described by 
Solomon, Bloembergen and Morgan (SBM).37,38 Relaxivity refers to the efficiency of a 
paramagnetic substance to enhance the relaxation rate of water protons, i.e. how effective a 
complex is as a contrast agent. The best contrast agents will have larger relaxivity values per 
mmol of gadolinium allowing for lower concentrations of the paramagnetic compound to be 
used. The relaxivity, ri is defined by the observed concentration dependence of (1/Ti,obs) 
according to equation (1.1).  
 
1
Ti,obs
=
1
Ti,d
+ ri[Gd]  where i = 1, 2   (1.1) 
 
Thus, the relaxivity of a contrast agent can be determined from the plot of 1/Ti,obs against 
concentration. The observed relaxation rate, 1/Ti,obs, is the sum of the diamagnetic (1/Ti,d) and 
paramagnetic (1/Ti,p) relaxation rates as seen in equation (1.2). 
 
1
Ti,obs
=
1
Ti,d
+
1
Ti,p
     (1.2) 
where i = 1,2   
1
Ti,p
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1
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&
outer−sphere
    (1.3) 
 
The diamagnetic term arises from the relaxation rate of water proton nuclei in the absence 
of a paramagnetic ion. The paramagnetic contribution is dependent on the concentration of the 
paramagnetic species, and it can be divided into two components, inner-sphere and outer-
sphere. The inner-sphere contribution is a result of water molecules coordinated directly to the 
metal centre whilst the outer-sphere contribution results from closely diffusing water 
molecules in the bulk solvent. This dividing of the paramagnetic contribution allows for a 
more detailed understanding of contrast agent behaviour. 
The inner-sphere contribution to the overall proton relaxation rate is much greater than 
the outer-sphere contribution, and this is due to dipole-dipole interactions between the nuclear 
spins and the fluctuating local magnetic field caused by the unpaired electron spins rapidly 
vanishing with distance.29 The longitudinal inner-sphere relaxation rate is given by equation 
(1.4): 
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T1m +τm
        (1.4) 
 
where C is the concentration of paramagnetic ion, q is the number of coordinated water 
molecules, T1m is the longitudinal relaxation time of the inner sphere waters and τm is the 
water exchange lifetime. This specific inner-sphere interaction corresponds to the binding of 
the water molecule(s) in the first coordination sphere of the metal, which then exchange with 
bulk solvent protons, thus propagating the paramagnetic influence. A schematic 
representation is shown in Figure 1.2. The T1m term is further controlled by a number of 
factors as shown in equation (1.5). This equation, where γH is the proton gyromagnetic ratio, 
ge is the electron g-factor, µB is the Bohr magneton and S in the spin quantum number (7/2 for 
Gd3+, shows that the relaxation is also dependent on the Gd-H distance (rGdH), the proton 
Larmor frequency (ωH), the electron Larmor frequency (ωS, = 658.ωH) and the correlation 
time (τc1 and τc2). These components themselves comprise of the rotational correlation time 
(τR), the water exchange lifetime (τm) and the electronic relaxation time of the Gd3+ metal ion 
(T1e), as seen in equation (1.6). 
 
1
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=
2
15
γH
2 ge2µB2S(S +1)
rGdH6
7τ c2
1+ωS2τ c22
+
3τ c1
1+ωH2 τ c12
!
"
#
$
%
&    (1.5) 
 
1
τ ci
=
1
τm
+
1
τ R
+
1
T1e
 where i = 1, 2    (1.6) 
 
The outer sphere contribution accounts for around 40% of the overall relaxivity of 
monoaqua Gd3+ complexes at imaging fields.39 For the development of contrast agents 
however, the outer-sphere term cannot be modified and as such the majority effort from 
experts in the field has focused on the enhancement of relaxivity via the modulation of factors 
that affect the inner-sphere contribution. This is where chemists can influence the properties 
of a contrast agent. Contrast agents that are currently in use clinically have relaxivities that are 
much lower than the theoretically attainable values; their rotational correlation time (~ 100 
ps) and their proton exchange rate (~ 106 s-1) are far from optimal.29 The next section will 
discuss strategies for increasing relaxivity. 
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Figure 1.2: Schematic representation of a Gd3+ chelate with one inner sphere water molecule, 
surrounded by bulk water. 
1.2.3 Strategies for increasing relaxivity 
From equations (1.4), (1.5) and (1.6) it can be seen that the relaxivity of a contrast agent 
can by influenced by a few selected parameters. These include the hydration state (q), the 
residence time of coordinated waters (τm), the separation between the gadolinium ion and a 
proton on the coordinated water (rGdH), the electron relaxation time (τ1e) and the rotational 
correlation time (τR). Of these parameters, only the electron relaxation time cannot be 
controlled. Gadolinium complexes have been shown to exhibit very different electronic 
relaxation times and only until a larger body of data is collected will a rational design 
approach be developed to optimise this variable.40 
1.2.3.1 Hydration state, q 
The inner-sphere relaxivity is linearly proportional to the hydration number, q, of the 
paramagnetic complex. The gadolinium aqua ion itself would display a very high relaxation 
enhancement but due to its toxicity the metal ion must be contained in a multidentate ligand. 
The toxicity of a contrast agent is determined by its thermodynamic and kinetic stabilities, i.e. 
if the metal is firmly attached to the ligand (thermodynamic stability) or the metal is very 
slow at dissociating from the ligand (kinetic inertness). In all clinically used contrast agents, q 
= 1. An obvious way to increase the relaxivity would be to have a ligand that allows for a q = 
2 complex. However, with such ligands, it can be anticipated that the stability will be reduced. 
Gd3+! T1M!
τR! 1/τm!
H2O!
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Therefore a balance must be maintained when lowering the denticity of a ligand, the stability 
of the complex must be increased to counter. An example of the effect of increasing q is 
shown in the cases of GdDOTA, GdDO3A and GdDO2A (Figure 1.3). The relaxivities of the 
complexes were observed as 4.3, 6.2 and 6.5 mM-1s-1 respectively.41 As expected, an increase 
in relaxivity was observed on going from the q = 1 to the q = 2 complex. The value was 
however expected to double, but this is not the case as roughly 40% of the GdDOTA r1 arises 
from outer-sphere relaxation. On removing a second acetate group to give GdDO2A, the 
relaxivity only increases to 6.5 mM-1s-1 even though q is now 3. This demonstrates that other 
factors such as overall charge on the complexes (GdDOTA-, GdDO3A0, GdDO2A+) also play 
important roles. Another challenge facing the use of q > 1 complexes in vivo is the 
coordination of endogenous ligands such as bicarbonate, citrate, lactate and phosphate. These 
ligands actually decrease relaxivity by displacing coordinated water molecules. The direct 
proportional relaxivity boost upon increasing q however still motivates many researchers to 
revisit the challenge of increasing q without considerable loss of kinetic inertness. This is 
exemplified in the works of Caravan et al. with their [Gd(CyPic3A)(H2O)2]- complex and 
Raymond et al.’s Gd-HOPO (hydroxypyridinone) based contrast agents.42,43 The hydration 
number of a complex can be assessed using a number of techniques: in the solid state using 
X-ray structure analysis, or in solution using NMR (Dysprosium Induced Shift)44 or 
luminescence45.  
 
Figure 1.3: Structures of [GdDOTA], [GdDO3A] and [GdDO2A]. 
1.2.3.2 Gd3+-water distance, rGdH 
The variation of the Gd3+-water proton distance is a difficult parameter to adjust. A small 
change of the distance however is enough to induce large changes in the relaxivity of a 
complex. This is due to the dipole-dipole interaction between the magnetic field cause by the 
electrons of the gadolinium centre and the nuclei of the water protons having a sixth-order 
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distance dependence. This dependency results in a 50% increase in relaxivity if a decrease of 
0.2 Å occurs (rGdH ≈ 3.1 Å). Being a difficult parameter to alter, not much work has been 
carried out to increase relaxivity via decreasing rGdH. There is however one possibility to 
shorten the metal-H distance in gadolinium complexes, and this is by introducing a side group 
onto the chelate that will hydrogen bond to the coordinated water proton, bringing the proton 
closer to the metal centre (higher tilt angle).29 rGdH can be determined using X-ray diffraction 
or calculated indirectly using relaxivity studies. Some DOTA and DTPA derivatives have also 
been studied by ENDOR (electron nuclear double resonance) spectroscopy.46 
1.2.3.3 Water residence time, τM 
The rate at which water molecules bound to a paramagnetic gadolinium centre are 
exchanged with the bulk water is of great importance, as it is this exchange process which 
allows for the propagation of the gadolinium’s magnetic influence to the bulk solvent. The 
residence time of water molecules in the inner sphere of Gd3+ complexes scopes from 
nanoseconds (e.g. [Gd-BPEDP]2- where τM ~ 1.3 ns) to microseconds (e.g. DOTA-tetraamide 
derivatives where τM ~ 8-20 µs) 47,48 There are a number of factors that have been identified 
as essential for the acceleration of water exchange. These include, increasing the negative 
charge of the complex and increasing the steric compression around the coordination site of 
the bound water.49,50 Both these effects facilitate the departure of the coordinated water 
molecule in a dissociative process, which is the most common mechanism responsible for the 
water exchange reaction in nine-coordinate Gd3+ complexes.51 According to SBM theory, 
longer τR values and shorter water exchange rates (kex = 1/τM) lead to high relaxivities, but 
Desreux et al. highlighted that a subtle interplay between the parameters is required. They 
explained that when τR is short the observed modest relaxivities do not change greatly if the 
water exchange rate changes, but when τR is much higher, the relaxivity is much more 
sensitive to the water exchange rate, and values that are too high or even too low have adverse 
effects on the observed relaxivity.52 The water exchange rate values themselves can be 
obtained from variable temperature transverse 17O NMR relaxation rates in the Gd3+ complex 
solutions. 
1.2.3.4 Rotational correlation time, τR 
In Gd3+ complex systems with optimised τM, the overall relaxivity is controlled by the 
rotational correlation time. Simulated 1H nuclear magnetic resonance dispersion (NMRD) 
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profiles were reported by Lukeš et al. which depicted how every magnetic field requires 
different optimal parameters of τM and τR, with maximum relaxivities being achieved at fields 
corresponding to the proton Larmor frequency 10 – 70 MHz.53 Within this range (which 
covers the range of imaging fields currently used in medical diagnostics, shown in grey in 
Figure 1.4) τR is high and τM is low, in the range of 10 – 50 ns. Looking at high frequencies 
though (100 – 400 MHz), it can be seen that shorter τM and intermediate τR lead to greater 
relaxivity values. 
 
Figure 1.4: Simulations of relaxivity as a function of proton Larmor frequency (1H NMRD 
profile). Fixed electron parameters: 298τv = 40 ps, d2 = 1019 s-2, rGdH = 3.1 Å. The grey area 
shows the range of imaging fields currently used in medical diagnostic applications. Image 
taken from reference 36. 
For spherical molecules, τR is directly related to the size of the molecule. For a sphere of 
radius a in solution in a medium with viscosity η (where k = Boltzmann constant, and T = 
temperature in Kelvin),34  
τ R =
4πηa3
3kT      (1.7) 
 
This equation predicts τR to be proportional to a3, thus large effects are expected from 
changing the size of the molecule. This purely theoretical approach however fails to take into 
account that solvated molecules are not spherical and that as a molecule’s size increases, it 
tends to become less spherical.  
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Figure 1.5: Structures of [Gd.DENgDOTA]- and [MS-325]3-, complexes that have high 
relaxivities due to increased τR. 
In order to reduce the tumbling rate of Gd3+ based contrast agents, several techniques 
have been employed. These include increasing the molecular size of the agent and binding of 
the agent to a larger structure such as a protein. The first method is demonstrated in the works 
of Parker et al. whereby they placed the lanthanide binding motif at the centre of a dendritic 
architecture.54 This structure ensured that the motion relating to the lanthanide centre was 
coupled to the molecular tumbling of the dendrimer. Their best system [Gd.DENgDOTA]- 
(Figure 1.5) displayed a relaxivity of 23.5 mM-1s-1.  
The latter method has received a lot of attention, with the most common target for the 
non-covalent interaction of a complex being with human serum albumin (HSA). The best 
known example of this effect is the clinically used contrast agent MS-325 (Vasovist®, Figure 
1.5). It’s hydrophobic diphenylcyclohexyl moiety interacts with the blood protein to give an 
increase in relaxivity from 5 (free complex) to 40 mM-1s-1 (bound complex). An important 
aspect to remember when attempting to lower the tumbling rate is the nature of the linker 
between the contrast agent and the target moiety. If the linker is flexible (i.e. an alkyl chain) 
then the local molecular motion of the agent may dominate τR even when the agent has bound 
to its target. Therefore, rigid linkers should be considered. τR values are commonly 
determined using data calculated from NMRD profiles by fitting parameters from equation 
(1.5), although this does require the prior knowledge of additional information such as rGdH 
and τM. 
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The manipulation of the parameters detailed above is the current focus of many 
prominent researchers in the field. Their works show that relaxivity properties of a complex 
can be fine tuned on a chemical basis by ligand design. The following section will cover the 
ubiquitous DOTA ligand, and how the understanding of structural and stability properties has 
allowed researchers to design new ligands with the aim of making more effective contrast 
agents. 
1.3 Lanthanide complexes of DOTA 
The lanthanide complexes of the octadentate ligand DOTA have received a lot of interest 
over the last 30 years. The metal chelate has not only impacted the field of MRI, but also all 
of the other major imaging modalities such as PET, SPECT and fluorescence imaging. DOTA 
is a four-carboxylate derivative of cyclen which was first synthesised in 1976.55 It was first 
applied to the field of MRI by complexation with gadolinium by Magerstadt et al. and Caille 
et al. in 1986.56,57 The DOTA macrocyclic ligand itself is very flexible, deducible from the 
broad signals of its 1H NMR spectrum. Upon coordination to a lanthanide ion however, the 
macrocycle adopts a [3333] conformation whereby the four nitrogen donors adopt a co-planar 
arrangement with the four carboxylate oxygens displaying a similar co-planar arrangement 
below. This effectively sandwiches the lanthanide ion, which is then capped at the bottom 
face by a water molecule, filling the metal’s coordination sphere. 
The [3333] conformation, consisting of the repetition of gauche conformations of the 
same sign for all the ethylene groups, is chiral. This gives rise to two enantiomers, which are 
known as (λλλλ) and (δδδδ) according to the geometries of the four NCCN moieties, as seen 
in Figure 1.6. A second stereochemical element is introduced upon metal binding, involving 
the helical arrangement of the carboxylic pendant arms. Metal coordination through the side 
arm donor group imposes the same conformation to all the pendant arms, either Λ or Δ, as 
shown in Figure 1.7. The two conformational chirality elements (λλλλ)/(δδδδ) and Λ/Δ then 
combine to provide four stereoisomers, which are two pairs of enantiomers and otherwise 
diastereoisomers. In all [LnDOTA] complexes, the rate of interconversion at room 
temperature is on the second scale and thus NMR spectroscopy can be used to study the 
dynamic process mixing the various species. 
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Figure 1.6: Enantiomeric cyclen [3333] ring conformations. 
 
Figure 1.7: Λ and Δ metal coordination. 
1.3.1 The two diastereoisomers of DOTA 
As shown above, four possible stereoisomers exist for [LnDOTA] complexes. They can 
be interconverted through two possible processes: an inversion of the ring conformation or a 
rotation of the arm orientation. Sequential arm rotation and ring inversion interconverts 
enantiomers (Figure 1.8). [LnDOTA] complexes actually exist as a major and minor form, 
namely Λ(δδδδ) and Λ(λλλλ). These two stereoisomers are quite different in their geometry: 
in the former, the four nitrogen and the four oxygen atoms reside in an almost regular square 
antiprism (SAP) while the latter is similar yet strongly twisted (TSAP). This geometric 
difference can be expressed by the angle between the two squares that form the bases of the 
coordination polyhedron, (Figure 1.9). The SAP major isomer has a twist angle between the 
two planes of ~ 40° while the minor isomer has a twist angle of ~ 30°.58 The coordination 
polyhedron of the SAP geometry is more compressed than for TSAP and this results in a 
wider bite angle (O-Ln-O) in the former. This has important implications on the relaxivity  
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Figure 1.8: [LnDOTA] stereoisomeric structures present in solution. 
properties of [GdDOTA] complexes, as faster water exchange rates are achieved with smaller 
bite angles, i.e. the TSAP geometry is preferred over SAP for improved relaxivity properties. 
In virtually all octadentate cyclen derived ligands, the SAP isomers predominate. As such, a 
considerable amount of research currently focuses on the manipulation of DOTA/cyclen 
structures to reverse the isomer preference, in particular by the groups of Woods and 
Merbach.59,60  
 
Figure 1.9: SAP and TSAP forms of [LnDOTA]. 
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Merbach et al. synthesised novel DOTA-like ligands with phosphonate moieties (Figure 
1.10).60 When coordinated to lanthanide ions, the complexes exhibited isomerism as observed 
in LnDOTA complexes, but as a consequence of the chirality on the phosphorus atom, four 
enantiomeric pairs were now possible in solution. The molar fraction of TSAP species in 
solution increased due to the presence of the phosphorus containing group, and it was also 
found to grow with increasing negative charge of the complex. This lead to an increase in 
effective water exchange rate in the sequence of ligands H4DOTA ≤ H3do3apOEt2 < 
H4do3apOEt < H5do3ap. This modification lead to an almost optimal exchange rate value 
(especially for [Gd(do3apOEt)(H2O)]-, but relaxivity values were found to not increase 
significantly when compared to [GdDOTA]-. The authors argue that the rotational correlation 
time (τR) must still be optimized (i.e. increased) in order to obtain very high relaxivity values.  
 
Figure 1.10: Structure of monophosphonic acid derivatives of DOTA synthesised by 
Merbach et al.60 
By considering the chirality when substituting both the macrocycle and pendant arms in 
DOTA-type lanthanide complexes, Woods et al. were able to control the coordination 
geometries of the resulting complexes. In 2003, the two stereoisomeric complexes of the 
ligand NO2BnDOTMA, S-RRRR-LnNO2BnDOTMA- and S-SSSS-LnNO2BnDOTMA- were 
shown to adopt SAP and TSAP coordination geometries, respectively (Figure 1.11).61 They 
displayed significantly different water residence lifetimes of τM = 120 ns (S-RRRR) and 15 ns 
(S-SSSS). Although the latter stereoisomer exhibited near ideal water exchange kinetics, the 
use of the complex was found to be hampered by synthetic problems. A more simple and 
effective synthetic route to a ligand that adopted the TSAP geometry was then devised in 
2005. The authors found that methyl substituents on just three of the pendant arms were 
enough to control the orientation of the pendant arms.59 S-SSS-GdNO2BnDO3MA- was found 
to show slightly faster water exchange kinetics with τM = 6 ns. The authors accept that this 
value is faster than optimal for high relaxivity properties, but then argue that this could 
become an advantage when new generation clinical scanners with higher operating fields 
become common. 
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Figure 1.11: Structures of stereoisomeric complexes of NO2BnDOTMA. 
1.4 Optical imaging 
Luminescence is the emission of ultraviolet, visible or infrared light from electronically 
excited species. Luminescence can be achieved by a variety of different compounds such as 
organic compounds (e.g. naphthalene, fluorescein and coumarin), inorganic compounds (e.g. 
uranyl ion, doped glasses and crystals) and organometallic complexes (e.g. Ru(bipy)3 and 
complexes with lanthanide ions). Over the last 20 years there has been a dramatic increase in 
the application of fluorescent probes in a wide range of biological disciplines. The significant 
increase in popularity is a consequence of the modality’s extraordinary sensitivity and it has 
facilitated the study of biological materials, in particular cellular structures and their dynamic 
processes.62 To study the various aspects of biological systems, many thousands of organic 
based fluorescent probes have been synthesised with a wide spectral range allowing for the 
simultaneous imaging of different cellular components.  
The understanding of the principles of fluorescence have allowed chemists and biologists 
to synthesise and use ever more complex and effective probes. These principles will be 
discussed in the following section. 
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1.4.1 Principles of fluorescence 
Fluorescence is the emission of light that occurs after the absorption of a photon. Both the 
wavelengths of absorption and emission, and the efficiency of a fluorophore are determined 
by the outermost electron orbitals of the molecule.63 When electrons in the highest occupied 
molecular orbital (HOMO), also known as the ground state, S0, absorb a photon, alterations in 
the electronic, vibrational and rotational states of the molecule can occur. If the energy is of 
the correct wavelength, electron promotion to the lowest unoccupied molecular orbital 
(LUMO), the singlet excited state, S1, can occur. In this excited state, the fluorophore can 
undergo conformational changes and is subject to possible interactions with its molecular 
environment. This leads to two significant consequences. Firstly, some of the original 
excitation energy will have dissipated, as the molecule will have relaxed via various 
vibrational and rotational pathways, leaving the molecule in the lowest S1 level from which 
fluorescence emission originates. Secondly, not all the molecules initially excited by 
absorption will return to the ground state (S0) via fluorescence emission. Processes such as 
intersystem crossing (ISC, which then gives rise to phosphorescence, principally in the 
presence of a heavy atom) and collisional quenching may depopulate S1. The extent to which 
these processes occur can be determined by the fluorescence quantum yield (ratio of the 
number of fluorescence photons emitted to the number of photons absorbed). On returning to 
the ground state S0, a photon is emitted, and due to the energy dissipation during the excited-
state lifetime, the energy of this photon is lower, i.e. longer wavelength, than the excitation 
photon. The difference between the excited and emitted wavelengths is known as the Stokes 
shift. The entire excitation-emission process can be repeated indefinitely unless the 
fluorophore is irreversibly destroyed in the excited state, i.e. photobleaching. This process is 
described pictorially using a Jablonski diagram, as seen in Figure 1.12. 
Significant advances in optical physics, probe design, molecular biology and labelling 
techniques have launched fluorescence imaging into new realms of spatiotemporal resolution 
and sensitivity.64 The most widely used technique for imaging of live cells is the application 
of fluorescent proteins. They have been particularly successful due to their exquisite labelling 
specificity. Much effort has also focused on methods for labelling biomolecules with small-
molecule fluorescence probes thus extending fluorescent tagging to more diverse 
biomolecules. As these chemical probes are not intrinsic to the cellular environment, it is 
imperative to ensure that some critical rules are followed. As well as being bright and 
photostable, the probe must be non-toxic, cell-membrane permeable and compatible with the 
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cellular environment. To remove nonspecific background, fluorophores should preferably be 
non-fluorescent until labelling has occurred. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: Jablonski diagram and illustration of the relative positions of absorption, 
fluorescence and phosphorescence spectra. IC = internal conversion, ISC = intersystem 
crossing, S0 = singlet ground state, S1-2 = excited singlet state, T1-2 = excited triplet state. 
Historically, the first fluorescent organic molecule to be identified was quinine sulphate 
as reported by Sir John Herschel in 1845.65 This molecule emits blue fluorescent light when 
irradiated with ultraviolet (UV) light; since then many other organic compounds have been 
discovered and synthesised that display fluorescence in a variety of colours. These include 
fluorescein, rhodamine, BODIPY (boron dipyrromethene) and cyanine dyes (Figure 1.13), all 
of which have played important roles as fluorescent labels. These classic dyes have been 
continuously modified and enhanced by a vast number of research groups to improve their 
fluorescence properties such as quantum yields and emission wavelengths. For example, 
Nagano and co-workers replaced the oxygen atom in TokyoGreen (a fluorescein derivative) 
with a dimethylsilyl group to obtain novel fluorescent molecules with red emission.66 They 
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named these TokyoMagentas. Today, a variety of probes are available that target metal ions, 
pH67, enzyme activities68 and signalling molecules.69 
 
Figure 1.13: Structures of various organic fluorescent molecules. The colours of the 
molecules roughly represent their emission colours. 
A range of fluorescent labelling and cell staining agents are now commercially available 
that selectively localise and stain particular cellular organelles, such as mitochondria, 
lysosomes and endoplasmic reticulum, and are used routinely for in vitro cell analyses.70 In 
the last decade, in vivo imaging of specific tissues using antibodies and peptides labelled with 
fluorescent dyes has attracted attention.71 For example, Nagano et al. labelled a tumour-
specific antibody with a rhodamine based-NIR dye.72 Currently, most fluorescence imaging 
experiments are carried out in vitro or ex vivo, with in vivo work only being carried out on a 
pre-clinical setting using animal models.  
It has been argued that optical imaging is a ‘weaker technique’ than other imaging 
modalities such as PET and SPECT, as tissue penetration prevents whole-body imaging. The 
range of fluorescent probes that can be excited in the near infrared (NIR) part of the 
electromagnetic spectrum however continues to expand. The wavelength of light with most 
value for in vivo use is beyond 630 nm, as since absorption of light by tissue sharply 
decreases at longer wavelengths.73 Whole-body in vivo fluorescence imaging still has a lot to 
achieve in terms of improving imaging technology before it can be routinely used in large-
N
O
HO N
H
H
H2SO4
O
COOH
OHO O N+N
COO-
N B N
FF
N
SO3Na
N
-O3S
Quinine sulfate Fluorescein Rhodamine B
BODIPY Indocyanine green
 Chapter 1 
41 
scale preclinical studies. Today however, progress with microscopic methodologies for in 
vivo imaging is ongoing, in particular with intravital confocal74 and two-photon 
microscopies.75 Some of these technologies have been adapted to flexible fibre probes that 
can be used endoscopically allowing for the visualization of sites that were previously 
inaccessible.76  
An interesting example of the progression of a fluorescent imaging probe through in vitro, 
ex vivo, and in vivo experiments is given by Urano and co-workers. They developed an 
activatable, cancer-selective probe, γ-glutamyl hydroxymethyl rhodamine green (gGlu-
HMRG) that became fluorescent upon contact with γ-glutamyltranspeptidase, an enzyme that 
is overexpressed on the cell membrane of various cancer cells (Figure 1.14).77 In vitro 
experiments showed that the probe was successful in staining SHIN3 cancer cells and did not 
show any fluorescence signal in normal HUVEC cells. The probe was then injected into 
SHIN3 tumour bearing mice, which were killed 10 min after injection. The tumour site was 
visualised within 10 min after probe injection with a high signal-to-noise ratio. In fact, the 
fluorescence intensity was high enough to be detected with the naked eye. Finally, the probe 
was sprayed on to peritoneal tumour surfaces through a small abdominal incision. The tumour 
was detected within minutes after spraying the probe, with the fluorescence signal increasing 
over the first 10 min. 
 
Figure 1.14: Progression of testing of fluorescent probe gGlu-HMRG through in vitro, ex 
vivo and in vivo experiments (images taken from ref. 74). 
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In this work, the organic fluorophore of interest is rhodamine B (Figure 1.13). A detailed 
discussion of its properties and applications, in particular in pH sensing is given in chapter 
two. Rhodamine derivatives have also had great success in the field of metal ion sensing, and 
this will be discussed further in chapter four. 
1.5 Dual-modal MR/optical probes 
As discussed earlier, the combination of MR and optical methods is a successful pairing 
as the physical limitations of the individual modalities can be overcome to result in broader 
applicability. MRI displays excellent spatial resolution but lacks in sensitivity requiring 
millimolar concentrations of the commercial Gd-based contrast agents for efficient detection, 
whereas optical imaging is highly sensitive (only micromolar concentrations needed) but 
lacks in its ability to penetrate through deep tissue. There has been an increasing interest in 
the development of dual-modal imaging agents as they allow for the colocalisation of the 
images acquired by the two modalities leading to more facile interpretation and validation of 
in vivo imaging experiments. In fact, a number of reviews have been written covering the 
applications of these probes, with the most recent covering the small time frame of just four 
years. This shows how dynamic the field is and that work towards the complete understanding 
and potential improvement of these probes is still highly pertinent.78,79,80  
The idea of covalently attaching organic fluorescent probes to gadolinium chelates is a 
relatively new one, with the first reported example appearing in 1998 when Hüber et al. 
prepared monomeric and polymeric probes based on the conjugation of tetramethylrhodamine 
to gadolinium DOTA (Figure 1.15 (a)) and DTPA complexes.81 When applied to imaging 
living embryos however, only the fluorescence signal was observed and it was hypothesised 
that the hydrophobic nature of the probe led to its absorption into fatty tissue where little 
water exchange could take place. This resulted in no observable MR signal. Later examples of 
gadolinium chelates and organic fluorophores include Gd-DO3A-ethylthioureido-
fluorescein82, cyanine-DTPA conjugates83 (Figure 1.15 (b)) and a multimeric probe that 
contains three Gd3+ chelates conjugated to a fluorescein moiety.84  
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Figure 1.15: Literature examples of dual-modal MRI/optical probes (a78, b80, c83, d84). 
More recently, an interesting investigation into enhancing cell penetration of gadolinium 
chelates by conjugation with hydrophobic organic fluorophores was carried out.85 Nagano et 
al. chose boron dipyrromethene (BDP), fluorescein (FL), rhodamine B (Rhoda) and cyanine 7 
(Cy7) due to their differences in chemical properties such as hydrophilicity, charge and 
molecular weight. They then conjugated them to p-NH2-Bn-DOTA as their isothiocyanate 
derivatives (Figure 1.16). Their structures were shown to accumulate in lysosomes and 
mitochondria. The localisation of Gd(Rhoda-DOTA) was not specified. Additionally, no 
toxicity from the dye-Gd conjugates was observed under the conditions used. Firstly, their 
relaxivity values were assessed in PBS buffer solution. It was revealed that both BDP-Gd and 
Cy7-Gd complexes displayed significantly higher values than those of Gd(Rhoda-DOTA) and 
FL-Gd (22, 32, 6.3 and 4.1 mM-1s-1 respectively). These values were attributed to the dyes’ 
high hydrophobicity that led to stacking in aqueous solution. The cell permeability of dye-
Gds was then examined by incubating HeLa cells with 10 mM of the probes for 2 h. 
Fluorescence microscopic analysis revealed efficient cell permeation of all probes except FL-
Gd and it was hypothesised that this was a consequence of fluorescein’s hydrophilic and 
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anionic nature. Interestingly, each dye-Gd showed a different distribution inside cells; BDP-
Gd showed specific accumulation in Golgi apparatus and Cy7-Gd was shown to accumulate 
in lysosomes and mitochondria. The localisation of Gd(Rhoda-DOTA) was not specified. 
Additionally, no toxicity from the dye-Gd conjugates was observed under the conditions used. 
 
Figure 1.16: Structures of gadolinium complexes conjugated with BODIPY (BDP-Gd), Cy7 
(Cy7-Gd), fluorescein (FL-Gd) and rhodamine B (Gd(Rhoda-DOTA)).82 
A more recent example is given by the conjugation of a coumarin based dye to a 
GdDO3A mono amide fragment to give a myelin (layer that forms around nerves) specific 
contrast agent (Figure 1.15 (c)).86 The probe displayed an r1 value of 5.8 mM-1s-1 (0.47 T, 40 
°C), which corresponded well with the size of the molecule. The specificity of the probe was 
verified by overlapping of fluorescence of brain slices treated with the probe with known 
myelin staining agents. Finally, upon intraventricular injection, the probe was able to bind 
myelinated fibres in vivo, which allowed for the detection of demyelinated lesions by T1 
mapping. 
One final example is the conjugation of 4-(6-methoxy-1,3-benzothiazol-2-yl)aniline to a 
GdDO3A mono amide fragment (Figure 1.15 (d)).87 This probe was used to selectively label 
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β-amyloid plaques and monitor the fluorescence increase upon binding. The probe also 
displayed an increase in relaxivity upon binding to plaques, and this was attributed to reduced 
rotational motion. 
1.6 The Lanthanides 
The chemistry of the lanthanides, often referred to as the ‘rare earth’ elements, began in 
Scandinavia in 1794 when Johann Gadolin succeeded in obtaining an ‘earth’ (oxide) from a 
black mineral later to be known as gadolinite. After this time, a number of oxides were 
obtained but many of their components were misidentified and unreliable information about 
atomic mass made the correct positioning of the elements in Mendeleev’s Periodic Table 
difficult. It was not until Henry Moseley (1887 – 1915) analysed the X-ray spectra of the 
elements giving meaning to the concept of the atomic number that the 15 elements, lanthanum 
to lutetium, successfully took their place in the periodic table.88 Interestingly, the name 
‘lanthanide’ comes from the Greek lanthanein meaing ‘to escape notice’, which reflects quite 
well the fact that the lanthanides are commonly listed separately at the bottom of the periodic 
table. Even though these elements are commonly called the ‘rare earths’, they are actually not 
that rare at being more abundant than elements such as arsenic and mercury.  
It was the lanthanides marked similarity to each other, especially with their neighbours 
that caused their classification and separation to be extremely difficult. Their similarity was 
primarily due to their general adoption of the +3 oxidation states in aqueous solution. It 
wasn’t until the development of ion-exchange methods in the 1950’s that the isolation of 
individual lanthanides was achieved.89 It is only in the last ~ 40 years that scientists have 
taken interest in the lanthanides and before this time they and their chemistry were deemed 
‘boring’.90 This probably stemmed from their modest redox chemistry and small ligand 
effects in comparison to the d-transition metals. The past 25 years however have seen the 
emergence of many exciting areas linked to the coordination chemistry of the lanthanides 
including catalysis, medicine and material sciences, which is attributable to their unique 
characteristics, including their magnetic and spectroscopic properties. 
1.6.1 Characteristics of the Lanthanides 
The chemistry of the lanthanides is markedly different from that of the d-block metals, 
their reactivity being greater and more akin to the Group II metals.88 They have a wide range 
of coordination numbers with 8 or 9 being the most common although numbers of up to 12 
have been observed. They usually exist as trivalent cations where their electron configuration 
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is (Xe)4fn, with n varying from 1 (Ce3+) to 14 (Lu3+). These 4f orbitals do not participate 
directly in bonding (the bonding in lanthanide complexes is exclusively electrostatic) as they 
are well shielded by the 5s2 and 5p6 orbitals.91 This has important implications on the 
spectroscopic and magnetic properties of their complexes as ligand-field effects are small. 
Additionally, coordination geometries are therefore determined by ligand steric factors rather 
than crystal field effects. The lanthanides are strong, hard acids and favour bonding with hard 
donors such as nitrogen, oxygen and fluorine. They form labile complexes that undergo facile 
ligand exchange thus most stable complexes involve rigid multidentate chelating agents.  
1.6.2 Electronic configurations 
The chemistry of the lanthanides is largely based on the +3 oxidation state, although 
selected metals show additional oxidation states (Eu2+, Tb2+, Ce4+, Sm2+ and Yb2+). The 
trivalent state results in sequential loss of the 5d16s2 electrons from the [Xe]5d16s24fn core. In 
general the electronic configurations of the lanthanides are of the form [Xe]5d06s24fn apart 
from three exceptions, namely La and Ce where the 4f orbitals have not contracted enough to 
bring the energy of the 4f electron below that of the 5d electrons; Gd, where the effect of the 
half-filled 4f subshell dominates; and Lu where the 4f subshell has already been filled at Yb.88 
A steady contraction in ionic radius is observed across the series, with the decrease being 
greater than expected. This is attributed to the poor shielding properties of the 4f orbitals.92 
1.6.3 Coordination chemistry 
The coordination chemistry of the lanthanide metals is well understood as evidenced by 
several books and review articles on the subject.93,94 The hydration enthalpies of the 
lanthanides are high and so strongly coordinating ligands are required if a highly stable 
complex is to be formed.95 As discussed earlier, Ln3+ ions are hard Lewis acids and so hard 
bases such as carboxylates are preferred as they form strong ionic bonds. Additionally, 
stabilisation is commonly achieved with large favourable entropic effects i.e. with the use of 
multidentate ligands.  
In the field of MRI, it is extremely important to determine stability constants of 
gadolinium complexes as their stability in vivo is paramount. Gd3+ has to be complexed with 
chelating ligands to prevent the free metal from interacting with the in vivo environment 
therefore minimizing toxic side effects. The toxic metal however may still be released from 
some chelates by transmetallation with endogenous metal ions such as Zn2+, Ca2+ and Cu2+ 
and furthermore, protonation of ligands at low pH may cause chelate dissociation in vivo.96,97 
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When the use of gadolinium based contrast agents started to become common practice in 
clinics, the probes were deemed safe leading to their liberal use.32 Over time however, it 
became clear that a small number of patients who were administered the probes contracted the 
syndrome nephrogenic systemic fibrosis (NSF).98 These patients had reduced renal function 
and the disease was associated to the incomplete excretion and possible chelate dissociation 
of the probes.36 Therefore today, gadolinium based contrast agents must show excellent 
thermodynamic and kinetic stability. 
The stability of a complex is determined by considering the reaction between a metal ion 
and a ligand: 
M + nL          MLn     (1.7) 
 
where the stability constant can be determined approximately by: 
KML =
[MLn ]
[M ][L]n           (1.8) 
 
The stability of a gadolinium complex have been further determined by conditional stability 
constants, protonation constants and kinetic stability of the complex.99 The thermodynamic 
stability constant indicates the affinity of an unprotonated ligand for a metal ion. This does 
not take into account the pH of solution, unlike the protonation constant.29 The conditional 
stability constant (KML’) on the other hand reflects the competition between the gadolinium 
metal ion and protons for the ligand, as well as endogenous metal ions.50 It is suggested that 
the conditional stability constant should be considered a more relevant parameter when 
evaluating the stability of a contrast agent at physiological pH (these constants are 
substantially lower in all cases than the overall thermodynamic constant).100 Finally, the 
kinetic lability of the complexes is an extremely important factor to consider when analysing 
a contrast agent’s suitability for use in vivo.101 The half-life of elimination of a contrast agent 
after its administration is about 1.5 hours.102 The kinetic stability of a complex is evaluated as 
an extent of its transmetallation in the presence of zinc at pH 7 as evaluated for a number of 
gadolinium complexes by Tweedle and Laurent et al.103,104 Macrocyclic ligands based on the 
DOTA motif show much greater kinetic stability compared to DTPA derivatives as evidenced 
by their dissociation rates. A summary of some of these stability constants and dissociation 
rates are shown in Table 1.2. 
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Contrast agent Chemical name log KML103,105,106,107 log KML’103,105,107,108 kobs (s-1)105 
Dotarem® Gd-DOTA 25.4 19.0  2.1 x 10-5  
Prohance® Gd(HP-DO3A) 22.8 16.9  6.3 x 10-5  
Gadovist® Gd(DO3A-butrol) 21.8 15.5  - 
Magnevist® Gd-DTPA 22.1 17.7  1.2 x 10-3  
Omniscan® Gd(DTPA-BMA) 16.8 14.9  > 2 x 10-2  
Multihance® Gd-BOPTA 22.6 18.4  - 
 
Table 1.2: Thermodynamic and conditional stability constants (log KML and log KML’ 
respectively) and dissociation rates (kobs) of clinically used contrast agents. 
1.6.4 Electronic and magnetic properties 
The valence electrons in the 4f orbitals give the lanthanide elements remarkable optical 
and magnetic properties that are widely exploited in contemporary technologies. As discussed 
earlier, ligand crystal field splitting is weak due to the shielding of the 4f electrons by the 
filled 5s and 5p orbitals. This leads to very characteristic magnetic and electronic properties 
of the lanthanides which are unaffected by coordinating ligands. These properties are often 
accounted for using the Russell-Saunders coupling scheme, which describe the energy levels 
of the lanthanides. Spin-orbit coupling (a coupling between the electronic orbital angular 
momentum L and spin angular momentum S)109 is much larger in energy compared to the 
ligand field for the lanthanides.110 Russell-Saunders coupling describes the combination of 
spin and orbital angular momenta into one term symbol J, which then helps to explain and 
predict the electronic behaviour of the lanthanides to a good approximation.111 Using this 
approach, each lanthanide can be assigned a specific ground state electronic configuration 
(using Hund’s rule) and the effective magnetic moment of each ion can be calculated. The 
energy levels of the lanthanides pertinent to this thesis are shown in Figure 1.17. 
1.6.4.1 Magnetic properties 
Apart from La3+ (4f0) and Lu3+ (4f14) all of the lanthanides in their +3 oxidation state 
contain unpaired electrons and are therefore paramagnetic. Lanthanides have been the key 
components of hard magnets for more than 40 years112, and they continue to play an 
important part in molecular magnetism due their large magnetic moments and large 
anisotropy.113 The magnetic properties of the majority of the lanthanides are determined by 
the ground state, as the excited states are well separated from the ground state therefore being 
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thermally inaccessible. Because of the significant spin-orbit coupling of these elements, the 
‘spin-only’ formula, which is commonly applied to first row transition metals, is not 
applicable. The effective magnetic moment for these elements is given by the equation91:  
µeff = gJ J(J +1)     (1.9) 
where the Landé g-factor is defined by: 
gJ =
3
2 +
S(S +1)− L(L +1)
2J(J +1)     (1.10) 
 
 
Figure 1.17: Partial energy levels of selected lanthanide aqua ions. The ground levels are 
shown in blue and the excited levels from which luminescence is frequently observed are 
indicated by red lines.114  
The magnetic moments of the trivalent lanthanide ions range from 0 to 10.5 Bohr 
magnetons (B.M.). This allows the use of some of the metals in NMR studies due to their 
diamagnetic nature (e.g. La3+ and Lu3+) and others in high power magnets used in transport 
vehicles and appliances (SmCO5 and Nd2Fe14B).115 In this work, only the magnetic moment 
of the gadolinium ion is of importance, due to its impact on the field of MRI. It has a high 
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magnetic moment of 7.94 B.M, although other lanthanide ions such as Dy3+ and Ho3+ have 
values greater than 10 B.M. One of the primary reasons for the success of Gd3+ as the basis of 
MRI contrast agents is its relatively long electronic relaxation time (τ1e).116 Long τ1e’s allow 
for more efficient transfer of the magnetic properties of the gadolinium ion to the water 
protons and in general, increasing τ1e will lead to higher relaxivity.117 
1.6.4.2 NMR of lanthanide complexes 
When an NMR active nucleus interacts with a lanthanide ion, it experiences the metal’s 
magnetic moment. In lanthanide complexes, this causes a change in both the shift and 
relaxation effects of the NMR-active nuclei of the ligand. This interaction only occurs for 
systems in which an anisotropic distribution of the 4f electrons occurs, i.e. all lanthanides 
apart from gadolinium. This effect is known as the Lanthanide Induced Shift (LIS).118 LIS is a 
sum of three effects: diamagnetic, contact and pseudocontact shifts119: 
 
Δobs = Δdia +Δcon +Δ pseud     (1.11) 
The diamagnetic contribution is usually small originating from conformational changes and 
direct field effects, and it can be determined from the shifts induced by the diamagnetic La3+ 
and Lu3+ complexes. The contact contribution is a result of through-bond transmission of 
unpaired spin density of the Ln3+ to the ligand nucleus, and finally the pseudocontact shift is 
the result of through-space dipolar interactions.118 All these contributions can be described 
and determined using a series of equations which were derived by Bleaney120 and have since 
been used extensively by Aime121 and Geraldes122 to determine important parameters of 
paramagnetic metal complexes such as metal-proton distances and electronic relaxation times. 
The most widely used lanthanides for this application are Eu3+, Yb3+, Pr3+ and Dy3+ as they all 
show limited line-broadening as a result of short electron relaxation times.123 
The LIS technique has been employed in a number of applications, for example in the 
determination of biological structures such as proteins116, for the separation of NMR signals 
from intracellular and extracellular alkali metal ions124 and as chiral shift reagents for the 
NMR separation of enantiomers.125 It has been particularly useful in the field of MRI as it can 
be used to distinguish between SAP and TSAP isomers of cyclen-derived complexes such as 
DOTA. Because of gadolinium’s long electron relaxation times (which make its complexes 
excellent relaxivity agents) significant line broadening is observed in 1H spectra. When 
studying the coordination properties of MR contrast agent complexes, Gd3+ is therefore often 
substituted for its neighbours in the f-series, e.g. Eu3+ and Tb3+, which display much shorter 
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electron relaxation times. In the 1H NMR spectra of these complexes the most shifted proton 
environment will correspond to one of the pseudo-axial ring protons (ax1, Figure 1.18).126 By 
comparing with known crystal structures, it has been identified that this pseudo-axial ring 
proton always belongs to the SAP isomer and this a result of its closer proximity to the 
lanthanide ion in comparison to the pseudo-axial protons in the TSAP isomer.127  
 
 
 
 
 
Figure 1.18: Assignments of ethylene and acetate protons of a [LnDOTA] molecule, where 
ax = pseudo-axial proton, eq = pseudo-equatorial proton and ac = acetate arm proton. 
One can assess the ratio between SAP and TSAP isomers in a complex solution by 
comparing the integrations of the SAP pseudo-axial protons (~ 35 – 45 ppm) with those of the 
TSAP pseudo-axial protons (~ 15 – 20 ppm). [GdDOTA], exists predominantly (~ 85%) in 
the SAP form, with similar structures retaining this isomer ratio.128 A number of researchers 
have shown that it is possible to halt the intramolecular exchange process that leads to 
interconversion of the two coordination isomers. For example Woods et al. have assessed the 
effect of substitution at the cyclen ring and at the acetate methylene moieties with benzylic 
and methyl substituents respectively.129 They found that they could successfully reverse the 
isomer preference in particular structures so that the TSAP isomer was dominant in solution. 
This has obvious important ramifications on the relaxivity properties of the complexes as the 
TSAP isomer is known to display much improved water exchange rates and thus greater r1 
values.130 
1.6.4.3 Luminescence properties 
The luminescent lanthanides play important roles in a number of technologies including 
the lighting industry131, telecommunications132 and in medical imaging.133 The majority of the 
lanthanides are luminescent, although some are more emissive than others, and this is related 
to the facility with which a lanthanide’s excited state can be populated and the non-radiative 
de-activation pathways minimised.114 The most important ions in the context of optical 
imaging are currently Eu3+ and Tb3+.134 Looking at the energy gap between the excited states 
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and the ground states of the lanthanides (as seen for Eu3+, Gd3+, Tb3+ and Yb3+ in Figure 1.17) 
it is clear that Eu3+, Gd3+ and Tb3+ have relatively large energy gaps: ΔE = 12,300 (5D0 ! 
7F6), 32,200 (6P7/2 ! 8S7/2) and 14,800 (5D4 ! 7F0) cm-1 respectively. This favours de-
activation via luminescence emission as opposed to non-radiative de-activation pathways. 
Gd3+ however, has such a large energy gap that it emits in the UV and thus is not appropriate 
for biological imaging as its luminescence interferes with emission/absorption processes of 
small organic molecules.135 
 
Figure 1.19: Jablonski diagram for an emissive lanthanide complex sensitised via a ligand-
centred triplet excited state. ET = energy transfer.138 
Luminescence from the emissive lanthanides originates from 4f-4f transitions, being 
observably sharp in appearance and characteristic of the specific lanthanide ion. Their 
lifetimes are extremely long in comparison to organic fluorophores (µ-ms vs. ns) and this is 
due to the forbidden nature of the f-f relaxation. These transitions have very low molar 
absorptivities due to their being Laporte forbidden and so a sensitising chromophore (or 
antenna) must be used to absorb light and transfer energy to the 4f excited state.136 This 
antenna group can either be covalently attached to the lanthanide ligand structure or it can be 
a co-ligand, and it must absorb light effectively, possessing a triplet state energy level that is 
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of appropriate energy above the accepting Ln3+ excited state. These antenna molecules are 
usually based on aromatic or heterocyclic molecules such as naphthalene, bypridine and 
quinoline.137 The mechanism by which energy is transferred to the lanthanide ion is presented 
in Figure 1.19. 
Using an appropriate wavelength, the antenna will convert to its singlet electronically 
excited state (S1), which can undergo radiative decay to give fluorescence (as observed for 
organic fluorophores in section 1.4.1). This emission is typically short lived (ns regime). 
Intersystem crossing (ISC) can however occur to the lower lying triplet excited state (T1), and 
as this is a spin-forbidden process (both electrons are now parallel in spin) radiative decay 
from this triplet state is slow (ms regime), occurring via phosphorescence.138 Both the singlet 
and triplet excited states of the ligand/antenna may transfer energy to the lanthanide metal 
ion, but since the singlet state is so short-lived, the energy transfer is more efficient from the 
triplet state. Upon energy transfer from the triplet state to the lanthanide excited state, metal-
centred radiative emission occurs. The energy transfer is favoured by a short distance between 
the antenna and the lanthanide ion, whilst the efficiency is dependent on the energy difference 
between the triplet state of the organic moiety and the emissive state of the lanthanide.139 This 
energy difference should ideally be ≥ 1500 cm-1 to prevent thermally activated back energy 
transfer from the lanthanide to the triplet state.140  
Not only does the use of an organic chromophore enhance the luminescence of a Ln3+ 
complex, but it does so with negligible interference from background fluorescence. Organic 
aromatic chromophores typically absorb light and fluoresce in the high-energy section of the 
visible spectrum (λex = 270-300 nm, λem = 350-400 nm) displaying short Stokes shifts. 
Lanthanide luminescence however occurs at lower energies, with all the lanthanides apart 
from gadolinium emitting at wavelengths greater than 500 nm. This results in a large Stokes 
shift, which is extremely desirable in the field of cellular imaging as higher signal-to-noise 
ratios can be achieved with lower background fluorescence.141 Additionally, the long-lived 
nature of lanthanide emission (ms regime) allows for their selective detection in time-resolved 
measurements, further avoiding the experimental complications that occur from light 
scattering or interference from endogenous fluorophores.142 
The transfer of energy from the triplet state to the lanthanide excited state usually occurs 
via one of two mechanisms: (i) Dexter’s (or exchange) mechanism143, an electron exchange 
process involving physical overlap between the orbitals of the antenna and the lanthanide ion, 
and (ii) Förster’s (or dipole-dipole) mechanism144 where the dipole moment associated with 
the T1 state couples with the dipole moment of the 4f orbitals. The two mechanisms have 
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specific dependences on the distance (d) separating the antenna from the lanthanide ion: e−d
for the Dexter mechanism and d-6 for the Förster mechanism. This therefore limits the Dexter 
mechanism effective only at short distances (usually 30 – 50 pm) at which orbital overlap is 
significant, while the Förster mechanism extends over much longer distances (up to 1000 
pm).145 The latter mechanism is more likely for the lanthanide ions due to the distance at 
which antennas commonly reside.114 
1.6.5 Emission of europium and terbium 
To date, most reports of Ln3+ probes have utilized europium or terbium ions.134 Europium 
emits in the red region of the visible spectrum, with the 5D0 – 7FJ (where J = 0 – 6) transitions 
being observed, and terbium emits in the green region with the 5D4 – 7FJ (where J = 6 – 0) 
observable transitions (Figure 1.20).146  
 
Figure 1.20: Partial energy level diagram and typical emission spectra for Eu3+ (left) and Tb3+ 
(right).149,150 
Europium compounds show intense luminescence from the 5D0 excited state to the J 
levels of the ground state term 7F. Due to limitations of the wavelength range of the detectors 
of spectrofluorimeters, the 7F5 and 7F6 transitions are very rarely seen, i.e. they are in the 
infrared. The strongest peaks originate from the 5D0 ! 7F1 and 5D0 ! 7F2 transitions. The 
intensity of the 5D0 ! 7F1 transition is often considered to be constant and therefore it is used 
to calibrate the intensity of Eu3+ luminescence spectra.147 The 5D0 ! 7F2 is often termed the 
‘hypersensitive transition’ as its intensity is influenced by the local symmetry of the Eu3+ ion 
and the nature of the ligands.148 The terbium emissive state is 5D4 with the four main emission 
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bands that are commonly observed originating from the 7FJ (J = 6 – 3) transitions. The 5D4 ! 
7F5 transition is the most intense, centred at 545 nm. The transitions to the 7F2,1,0 levels are 
rarely seen as they are extremely weak.148 
1.6.6 Luminescence lifetime studies 
As discussed earlier, the lanthanides display long luminescence lifetimes due to the 
forbidden nature of the f-f transitions. This allows for their signals to be separated from 
background biological fluorescence (also known as autofluorescence) using time-gating 
techniques (Figure 1.21).133 
These long lifetimes however, render the excited states of the lanthanides particularly 
susceptible to quenching via non-radiative energy transfer to nearby O-H and N-H oscillators 
of lower energy.151 The third and fourth overtones of the O-H oscillators of water are slightly 
lower in energy than the excited 5D states of europium and terbium respectively, hence any 
water molecules coordinated to these lanthanides are excellent quenchers of the metal’s 
luminescence. Although this effect is detrimental to the emission intensity, it allows one to 
assess the number of water molecules q interacting in the inner-coordination sphere.145 This is 
of particular use when considering an MR active Gd3+ probe as inner sphere hydration plays a 
very important role in determining its water proton relaxivity. Therefore, when designing and 
synthesising a given ligand it is very common to isolate both the Gd3+ and the luminescent 
Eu3+/Tb3+ analogues, allowing for correlation between the luminescence and relaxometric 
assessments with respect to understanding lanthanide hydration.138  
Figure 1.21: Principle of time-gated spectroscopy.151 
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A method was developed by Horrocks in the late 1970’s that allowed for the 
determination of the hydration state of a luminescence lanthanide complex.152 Since then the 
method has been much refined and it successfully calculates the number of inner sphere O-H 
oscillators by measuring the difference in luminescence lifetimes in H2O and in D2O.45 The 
quenching effect of D2O is significantly lower than that for H2O as there is less effective 
overlap in its energy levels with a lanthanide ion, therefore much longer lifetimes are 
observed in the deuterated solutions (Figure 1.22).153  
Plotting the emission intensity of a luminescent lanthanide and against time for both H2O 
and D2O solutions allows the first order decay constants kH2O and kD2O to be calculated. When 
applied to equations (1.12) and (1.13) the hydration states can be calculated (the correction 
factors take into account quenching of outer-sphere waters).45 
 
qEu =1.2[(kH2O − kD2O )− 0.25]      (1.12) 
 
qTb = 5[(kH2O − kD2O )− 0.06]       (1.13) 
 
 
Figure 1.22: Vibrational quenching of Eu3+ and Tb3+ excited states by H2O and D2O. 
1.7 Aims and objectives 
Following on from previous work in the Long group154, the aim of this project was to 
synthesise and characterise dual-modal MR/optical probes that selectively bind zinc, for 
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potential monitoring of zinc levels within pancreatic β-cells. As molecules of this type are 
fairly complex, both in their function and synthesis, a ‘bottom-up’ design strategy was 
employed whereby the piecing together of smaller systems gave rise to more complex 
systems. 
The first task therefore was to develop a dual-modal MR/optical probe. This is discussed 
in chapter two, whereby a series of rhodamine-[GdDO3A] conjugates are investigated (A, 
Scheme 1.1). In chapter three, an MR zinc sensing probe is developed to understand if an MR 
response is achieved upon the selective binding of zinc (B, Scheme 1.1). This probe is then 
further functionalised by incorporating a rhodamine moiety from chapter two to give a dual-
modal MR/optical zinc sensor (D, Scheme 1.1). Chapter four explores the design and 
synthesis of a fluorescent zinc sensor based on the rhodamine scaffold (C, Scheme 1.1), 
which is then conjugated to a [GdDO3A] chelate to give a second dual-modal MR/optical 
zinc sensor (E, Scheme 1.1). The europium and terbium analogues of these complexes were 
also synthesised to further aid in the understanding of the resulting complexes’ functions.  
To be successful, in general and within this research project probes must meet a number 
of critera: 
• They must be water soluble and functional in aqueous solution; 
• They must show cell permeability; 
• They should be sensitive to the analyte of study, i.e. zinc over the appropriate 
biological concentration range; 
•  They must be selective for zinc over other biologically relevant cations; 
• They must display a similar or greater relaxivity value than clinically used 
complexes (i.e. Dotarem®); 
• They must exhibit selective and well-defined cellular localization; 
• They should show a defined change in either their relaxivity value, fluorescence 
intensity or both upon binding of zinc.  
The complexes will be studied both in vitro and in vivo where possible to assess the 
viability of these compounds on a biological setting. By synthesising these complexes in a 
successive manner, it is hoped that a greater understanding of the relaxivity and fluorescence 
properties of the final target compounds will be gained.  
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Scheme 1.1: Design strategy employed to synthesise dual-modal MR/optical zinc sensors. 
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2.1 Introduction 
The study of biological function has been greatly enhanced by the use of organic optical 
dyes. Many fluorescent dyes can be obtained commercially as ‘ready-to-use’ dyes that have 
specific localisation and fluorescence properties. It is becoming increasingly common, 
however, to incorporate these dyes as part of a larger construct that has increased function, for 
example in the labelling of biomolecules or as part of a multi-modal contrast agent. 
2.1.1 Rhodamine dyes 
Rhodamine dyes have been commonly used for these applications.1 The xanthene-based 
dyes are actually among the oldest synthetically produced dyes that have also found 
application in the dyeing of fabrics.2 Their high molar absorptivities (~ 4 x 104 dm3mol-1cm-1)  
and high fluorescence quantum yields (0.7 – 1) make them attractive dyes3, and the ability to 
alter their absorption and emission properties by changing the substituents on the xanthene 
core has led to the synthesis of a vast number of rhodamine derivatives.4 The synthesis of 
these rhodamine conjugates usually requires the reaction between an activated rhodamine 
(e.g. an activated ester or acyl chloride as seen in Figure 2.1 b: G or Z) and a nucleophilic 
functionality in a molecule of interest.5 A number of activated rhodamine derivatives are 
commercially available, but their extremely high costs prevent their use in multi-gram/multi-
step syntheses. For example, the commonly used rhodamine B isothiocyanate purchased from 
Sigma Aldrich (2015) will cost £136.50/500 mg, whereas the non-functionalised rhodamine B 
hydrochloride (Figure 2.1 c) will cost £12.50/25 g. This remarkable difference in price has 
lead to the development of a vast number of synthetic strategies for the functionalisation of 
rhodamine dyes, many of which can be found in the review by Martinho et al.4 
 
Figure 2.1: (a) Molecular structure of xanthene; (b) molecular structure and substituent 
numbering pattern of rhodamine dyes; (c) molecular structure of rhodamine B.  
a b c 
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Arguably, one of the most facile functionalisations is reaction at the carboxylic acid group 
of rhodamine B (Figure 2.1 c). The majority of reports for modification at this position, 
however, only began after 2000.4 Many of these modifications react the carboxylic acid group 
with an amine bearing product resulting in an amide bond. This leads to the formation of a 
spirolactam. This is a colourless, non-fluorescent version of the dye, one that can only be 
activated by certain conditions such as in the presence of metal ions or in acidic media 
(Scheme 2.1) In its ring-opened form, the rhodamine derivative displays strong fluorescence 
and a pink colour forms as the carbonyl group of the spirolactam moiety is activated. Not 
surprisingly, this transformation has been heavily exploited in the design and development of 
chemosensors.6  
 
Spirolactam – non-fluorescent   Ring-opened – fluorescent  
Scheme 2.1: Spirolactam ring-opening of a secondary amide derivative of rhodamine B. 
Rhodamine derivatives have been employed for a number of applications including 
molecular switches7, protein labels8 and thermometers.9 They have become especially popular 
as chemosensors for biologically relevant metal ions both in vitro and in vivo.10 Of particular 
interest to this work are rhodamine derivatives capable of measuring pH, targeting 
mitochondria and malignant cells. Some examples of these derivatives are described in the 
following sections. 
2.1.1.1 Rhodamine derivatives for monitoring intracellular pH 
 Intracellular pH regulation is crucial to the successful function of various biological 
processes. Within cells, different organelles have different pH values, for example, 
mitochondria and the cytosol have slightly basic pH values whilst the interior of lysosomes 
and endosomes are slightly acidic.11 Abnormal cellular pH (e.g. pH 4.5 – 6) is often an 
indication of abnormal cellular functions that are associated with many diseases, including 
cancer12 and Alzheimer’s disease.13 A popular technique for the measurement of intracellular 
pH is fluorescence as the highly sensitivity modality lends itself well to reporting on minor 
variations in cellular environments. A recent review discussing spirocyclic derivatives of 
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rhodamine dyes as chemosensors revealed that efficient fluorescent probes that functioned in 
the pH range of 4.5 – 6 (those useful for studying acidic organelles) were rarely reported in 
the literature.6 The structures of those reported (Figure 2.2, compounds a-d) can be seen to be 
relatively simple secondary amide derivatives of their parent rhodamine base, which all 
function via the same process of spirocyclic ring-opening upon the addition of H+. 
 
 
 
Figure 2.2: Structures of a14, b15 and c, d16 all in their spirolactam forms; examples of 
rhodamine derived pH sensors. 
Post publication of the review vide supra, an interesting example of a fluorescent pH 
probe was synthesised that was composed of both rhodamine and fluorescein units, displaying 
a ratiometric fluorescence response in pathogenic cells (Scheme 2.2).11 Both fluorophore 
counterparts can ‘switch on’ their fluorescence by the ring-opening of their respective 
spirolactam groups but each does so at different pH values; at basic or neutral pH conditions, 
fluorescein gives strong green fluorescence (512 nm) whilst at acidic pH, fluorescence from 
the rhodamine moiety is observed (580 nm). Kim et al. were able to label both acidic and 
basic organelles in HeLa cells using one probe.11 
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   λex = 480 nm     λex = 480 nm 
   λem = 580 nm     λem = 512 nm 
Scheme 2.2: Proposed mechanism for fluorescence emission upon pH variation 
2.1.1.2 Rhodamine derivatives as mitochondrial stains 
Mitochondria are organelles found in the cytoplasm of all eukaryotic cells. Their primary 
function is to produce ATP (adenosine triphosphate), the cell’s source of energy, which is 
paramount for the performance of a vast range of cellular functions.17 This energy is produced 
via the electron transport chain (ETC), which involves the transfer of protons and electrons 
between mitochondrial membranes with the use of four protein complexes. The end result of 
these processes is a build up of protons outside the inner membrane of the mitochondria, 
which in turn generates a pH gradient. A fifth complex then uses this gradient to produce 
ATP.18 This proton gradient, or mitochondrial potential, has been monitored with the use of 
fluorescent probes.  
It is well known that delocalised lipophilic cations (DLCs) preferentially accumulate in 
mitochondria, and this is a result of the negative mitochondrial potential.19 The most common 
examples of DLCs are phosphonium and rhodamine cation derivatives. They are able to 
penetrate the hydrophobic layer of plasma and mitochondria membranes because their charge 
is dispersed over a large surface area. The potential gradient is what drives their accumulation 
into the mitochondrial matrix.20 
Rhodamine 123, TMRM (tetramethylrhodamine methyl ester) and TMRE 
(tetramethylrhodamine ethyl ester) are all examples of rhodamine derivatives that have been 
used in a number of investigations to estimate mitochondrial membrane potential (Δψm).21 
More recently though, rhodamine derivatives are being exploited for their ability to be 
transported into the mitochondrial matrix by conjugating them to other molecules of interest. 
For example, rhodamine B was conjugated to a docetaxel derivative (a chemotherapeutic 
agent) via a biodegradable ester bond.22 This prodrug derivative was delivered to 
mitochondria whereby it was activated by cleavage of the ester bond, releasing the active 
form of the chemotherapeutic agent. Rhodamine B played two roles in this case, firstly it 
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acted as a targeting domain and secondly as an imaging reporter, which allowed for in vitro 
image studies to assess the morphological changes of human liver cancer cells HepG2 to 
determine the efficacy of the therapeutic agent. 
Another example is found where rhodamine B was conjugated to a tetraphenyl porphyrin 
(TPP) derivative for the synthesis of a photosensitizer for photodynamic therapy.23 Both the 
TPP derivative and rhodamine B separately showed phototoxicity (both IC50 > 20 mM) but 
combined displayed a much higher level (IC50 = 3.95 mM). This improved photodynamic 
activity was attributed to the greater cellular uptake and localisation in the mitochondria as a 
result of the rhodamine B moiety. 
2.1.1.3 Rhodamine derivatives as cancer targeting probes 
The distribution of a dye across a membrane has been shown to follow the Nernst 
equation.21 According to this equation every 60 mV difference in membrane potential could 
lead to a 10-fold increase in the accumulation of compounds bearing a positive charge.24 A 
change in mitochondrial potential is an important characteristic of cancer, caused by the 
mitochondria not functioning correctly due to oxidative stress and DNA mutation.25 The 
mitochondrial potential in tumour cells is in fact significantly higher than that in normal cells 
(-163 mV in tumour cells vs. -104 mV in normal cells).24 The ability to detect mitochondrial 
dysfunction by targeting this change in mitochondrial potential could aid in the early 
detection of cancer.26 As such, DLCs have been used extensively for the imaging of 
carcinoma mitochondria. 
A recent example using a rhodamine derivative was reported where a lissamine 
rhodamine B (LRB) moiety was conjugated to a 64Cu-DOTA complex to yield a PET 
radiotracer to image tumours in athymic nude mice bearing U87MG human glioma 
xenografts (Figure 2.3).27 It was found that the probe had the highest tumour uptake among 
many 64Cu labelled organic cations evaluated in the same model, and that the probe did 
localise in the mitochondria as a result of the enhanced mitochondrial potential. 
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Figure 2.3: Structure of 64Cu(DOTA-LRB). Lissamine rhodamine B is used as the 
mitochondrion-targeting moiety to transport 64Cu into tumour cells. 
2.1.2 Dual-modal MR/optical imaging probes 
As previously discussed in chapter one, the combination of two imaging modalities such 
as MRI and optical imaging offers synergistic advantages over using either modality alone. 
There are many examples of dual-modal MRI/optical imaging agents but the majority of these 
are of nanoparticle nature.28 However, other examples include heterobimetallic complexes 
where the fluorescence originates from a transition metal ion such as rhenium.29 In the context 
of this work, only examples of gadolinium chelates conjugated to organic fluorophores are 
discussed, and these have been reviewed in chapter 1, section 1.5.  
2.2 Aims 
The aim of the work in this chapter is to conjugate a derivative of the organic 
chromophore rhodamine B to [GdDO3A] and to study the properties of the resulting molecule 
as a dual-modal MRI/optical probe. Although reports of similar compounds exist in the 
literature, close comparison of their properties reveal that even small changes in structure can 
lead to significant changes in function. Due to the intrinsic properties of the rhodamine 
moiety, cellular uptake is expected allowing the probe’s localisation to be monitored via 
fluorescence microscopy and enhancement in MR signal given by the paramagnetic Gd3+ 
metal ion centre. Alternatively, the use of luminescent lanthanide metals such as Eu3+ and 
Tb3+ may lead to a complex displaying improved luminescence properties such as defined 
emission wavelengths and long-lived luminescence. The rhodamine dye is expected to act as a 
sensitiser for the luminescent lanthanide centre. 
When designing and evaluating the resulting compounds, a number of criteria must be 
met: 
• The probe must be water soluble for it to be viable in vivo. 
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• The probe must be sensitive to the pH of tumour cells (ranging from pH 5.7 – 
7.635) so pKa of probe must lie approximately in this range. 
• A spectral change should be observed upon localisation i.e. a significant increase 
in fluorescence intensity. 
• The probe must display a similar or greater relaxivity value to complexes of a 
similar nature (i.e. Dotarem®) currently used clinically. 
• The probe must exhibit selective and well-defined localisation. 
2.2.1 Target lanthanide compounds 
Two synthetic routes (Scheme 2.3) were developed to conjugate a rhodamine derivative to a 
lanthanide chelate. Starting with the commercially available rhodamine B hydrochloride, the 
seven coordinate ligand, L1 and the eight coordinate ligand, L2 were synthesised.  
2.3 Synthesis 
2.3.1 Synthesis of L1 
Reaction of rhodamine B hydrochloride with phosphorus oxychloride yields the acid 
chloride rhodamine derivative 1, and reaction of this crude acid chloride with 2-
bromoethylamine hydrobromide in the presence of triethylamine affords compound 2. This 
procedure was reported by Shiraishi et al., the bromoethylamine derivative being later 
conjugated to cyclen.36 The resulting macrocyclic compound behaved as a highly sensitive 
and selective fluorescent chemosensor for Hg2+. This literature preparation reported an overall 
yield for these reactions of 21%; however, upon reproducing the procedure in this work, 
yields of up to 63% were obtained. Additionally, the original synthesis required an overnight 
reflux in neat phosphorus oxychloride to yield the acid chloride derivative. Upon reviewing 
other preparations for rhodamine, it was revealed that such harsh conditions were not in fact 
necessary and a new procedure was followed whereby only 10 molar equivalents of POCl3 
were used in dichloroethane solvent and heated under reflux for four hours.37 Although more 
moderate yields of ~35% were obtained using this procedure, the reduced reaction time and 
more agreeable reaction conditions resulted in an easier preparation of the desired compound, 
2. 
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Scheme 2.3: Synthesis of [LnL1] and [LnL2]. 
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Tris-t-Bu-DO3A is a compound that is commonly used in the field of MR imaging.38 This 
heptadentate ligand has a secondary amine in the cyclen ring that is available for a number of 
synthetic transformations therefore representing a more than suitable scaffold for the 
preparation of a huge variety of macrocyclic chelates.39 Its preparation is very facile involving 
direct and selective alkylation of the three secondary amine groups on cyclen with t-butyl 
bromoacetate. Separation from the tetra substituted product can be achieved by crystallisation 
upon the addition of diethyl ether.40 The 1H NMR spectrum of tris-t-Bu-DO3A (HBr salt) is 
extremely characteristic (Figure 2.4); the tert-butyl groups display two sharp, closely 
positioned singlets (δ 1.48 ppm) that integrate to 9H and 18H , the acetate methylene protons 
similarly display two singlets at δ 3.31 (2H) and 3.40 (4H), and finally the ring protons 
display three broad signals at δ 2.91 (8H), 3.95 (4H) and 3.11 (4H), their broadness 
originating from the restrained internal motion of the molecule. Characterisation by 1H NMR 
spectroscopy of conjugates with tris-t-Bu-DO3A is facilitated by these distinctive signals. 
 
Figure 2.4: 1H NMR spectrum of Tris-t-Bu-DO3A (HBr salt). 
Functionalisation of the protected DO3A derivative was achieved via direct 
monoalkylation at the remaining secondary amine using the α-halogenated rhodamine 
derivative 2. A 24-hour reflux in acetonitrile using potassium carbonate as base gave 
moderate yields of 3 (37%). The crude product mixture was purified using silica gel 
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chromatography with a graduated solvent system (DCM:MeOH) to give a pale beige powder. 
The 1H NMR spectrum of 3 is shown in Figure 2.5. 
The free ligand L1 was obtained using standard deprotection (i.e. tert-butyl cleavage) 
conditions using trifluoroacetic acid (TFA) in dichloromethane (50/50, v/v). L1 was obtained 
as a bright pink, highly hygroscopic TFA adduct (quantitatively determined by elemental 
analysis). The pronounced change in colour on going from 3 to L1 was a result of the acidic 
conditions used in the ester hydrolysis. The isolation of L1 was evident in the 1H spectrum as 
characteristic signals from the tert-butyl groups at ~ 1.4 ppm were no longer present, and its 
ring-opened nature was elucidated via 13C NMR spectroscopy as the signal in the alkyl region 
of the spectrum (~65 ppm) was no longer present indicating the loss of the quaternary carbon 
of the spirolactam.  
 
 
Figure 2.5: 1H NMR spectrum of 3. Residual solvent peaks (acetone and DCM) have been 
removed for clarity. 
2.3.2 Lanthanide complex formation [LnL1] 
L1 was coordinated to a series of lanthanide metal chloride salts (Ln3+ = Gd3+, Eu3+ and 
Tb3+) in an aqueous, mildly acidic environment (pH = 5.5). It was possible to monitor the 
extent of complexation by observing the formation of a light pink precipitate. After 24 hours 
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stirring at room temperature the resulting precipitate was filtered. It was then taken up in 
DCM, washed with water and dried over MgSO4. Addition of diethyl ether to this solution 
precipitated the lanthanide complexes as pale beige powders in good yields (~80%). 
 
Figure 2.6: Structure of [LnL1] complexes. 
Purification of these complexes was made facile by their precipitation from aqueous 
solution. This property however has consequences for the use of these complexes as 
intracellular contrast agents; a high degree of water solubility is an absolute requirement. It is 
well known that amide functionalities increase water solubility due to their ability to 
participate in hydrogen bonding as a result of their dipolar nature. This was taken into 
consideration when designing L2 with the aim of forming water-soluble lanthanide 
complexes. 
2.3.3 Synthesis of L2 
Rhodamine derivative 4 was obtained via the direct formation of an amide linkage from 
the unactivated carboxylic acid on rhodamine B and ethylenediamine. The direct 
condensation reaction of carboxylic acids and amines to form amides is highly desirable due 
to the abundance of the amide moiety in nature and the relative cleanliness of the reaction – 
its only side product being water.41 This reaction is considered challenging however due to 
the competing acid-base reaction (see Figure 2.7 (a)) which generates a high activation barrier 
that in turn can only be overcome using forcing reaction conditions.42 To bypass this problem 
the carboxylic acid is commonly activated by either a coupling agent or by transforming the 
acid into the corresponding acid chloride (as seen in the synthesis of 2). This is not the case 
however for the formation of the rhodamine amide derivative 4. It can be argued then that this 
synthetic pathway is more environmentally benign than that for the synthesis of 2 due to its 
high yield (yields of up to 96% have been obtained) with high atom efficiency and hence, a 
reduced E-factor (kg waste/kg product).43 Closer examination of the synthesis procedure 
however reveals that the reaction is not atom efficient as ethylenediamine is used in ~7 
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stoichiometric excess. The mechanistic aspects of direct amide formation were recently 
discussed in a review by Whiting et al.44 One method highlighted for the preparation of 
amides was using microwave irradiation. Although the reaction conditions do not mirror those 
used for the preparation of 4, some explanations for the observations could be applicable, and 
additionally, particularly high yields of amide were obtained when using benzoic acid, a 
substrate not too dissimilar from the rhodamine B carboxylic acid. It was argued that excess 
amine in a reaction could complex to the carboxylic acid by hydrogen bonding to the carbonyl 
group.45 This would result in electronic assistance to nucleophilic attack by the amine 
nitrogen atom (Figure 2.7 (b)). It was also argued that a protonated amine could assist in a 
similar manner (Figure 2.7 (c)). Finally, it was theorised that the addition of excess amine 
could help drive the reaction towards product formation according to Le Chatelier’s Principle. 
No mechanistic insight into the reaction between rhodamine B and ethylenediamine was 
provided by Shiraishi et al. in their reported preparation of 4.46 It can however be concluded 
that this is a facile, high yielding method which provides rhodamine amide derivative 4 in 
high purity through the use of simple liquid-liquid extraction purification techniques, negating 
the need for column chromatography as required for the preparation of 3.  
 
Figure 2.7: (a) Preparation of amides from amines and carboxylic acids under microwave 
irradiation; (b), (c) electrophilic assistance to nucleophilic attack. 
Chloroacetyl chloride is an extremely versatile reagent that has been used extensively in 
organic synthesis, most frequently for the acylation of nitrogen groups. Primary and 
secondary amines react readily with it to form amides via a standard nucleophilic 
addition/elimination mechanism.47 Reaction of 4 with chloroacetyl chloride in the presence of 
triethylamine gave compound 5 in high yields and after purification using silica gel 
RCO2H + R'NH2 RCO2-, +NH3R'
H2O
RCONHR' (a)
R OH
O
H
NR H
R OH
O
H2
NR H
NH2R' NH2R'
(b) (c)
 Chapter 2 
80 
chromatography the spirocyclic nature of the compound was confirmed by 13C spectroscopy 
similarly to compound 2 (i.e. signal present at ~65 ppm resulting from the quaternary 
spirocyclic carbon). Functionalisation of the protected DO3A derivative was achieved via 
direct monoalkylation at the remaining secondary amine using the α-halogenated rhodamine 
derivative 5. A 24-hour reflux in acetonitrile using potassium carbonate as base gave yields of 
~50% of 6. The crude product mixture was purified using silica gel chromatography with a 
graduated solvent system (DCM:MeOH) to give a pale off-white powder. The 1H NMR 
spectrum of 6 showed well-defined signals for the aromatic protons of the xanthene core of 
the rhodamine. First order coupling was observed between protons Ha, Hb and Hc, and a 
doublet of doublets resulted from the coupling of Hb to both the meta Ha (4JHH  = 2.6 Hz) and 
the ortho Hc (3JHH = 8.8 Hz) (Figure 2.8 (a)). This coupling pattern was also observed in the 
1H spectrum of 3. The ring-closed structure was confirmed by the presence of a signal in the 
13C NMR spectrum at ~65 ppm arising from the quaternary carbon of the spirolactam. 
The free ligand L2 was obtained using standard deprotection (i.e. tert-butyl cleavage) 
conditions using trifluoroacetic acid (TFA) in dichloromethane (50/50, v/v). L2 was obtained 
as a bright pink, highly hygroscopic TFA adduct (quantitatively determined by elemental 
analysis). Similarly to L1 a pronounced change in colour on going from 6 to L2 was a result 
of the acidic conditions used in the ester hydrolysis. The isolation of L2 in the ring-opened 
form was again evidenced by both 1H and 13C spectroscopy, loss of signals arising from the 
tert-butyl protons at ~1.4 ppm and loss of a signal in the alkyl region of the carbon spectrum 
(~65 ppm) indicating the loss of the quaternary carbon of the spirolactam. 
2.3.4 Lanthanide complex formation [LnL2] 
L2 was coordinated to a series of lanthanide metal chloride salts (Ln3+ = Gd3+, Eu3+, Tb3+, 
Nd3+ and Yb3+) in an aqueous, mildly acidic environment (pH = 5.5). After 24 hours stirring 
at room temperature the complexes were purified. Excess lanthanide salts were removed by 
increasing the pH of the solution to 10 with 2M NaOH solution, at which point the lanthanide 
salts precipitated as Ln(OH)3. Care was taken to ensure that the pH was not increased above 
this as this would result in decomplexation of the lanthanide from the macrocycle. Lanthanide 
hydroxide was removed by centrifugation and the supernatant was collected, adjusted to 
neutral pH and tested for the presence of free lanthanide ions using acetate buffered solution 
of xylenol orange at pH 5.8.48 The xylenol orange assay is a colorimetric assay whereby a 
colour change from orange to purple indicates the presence of free lanthanide. 
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Figure 2.8: The 1H NMR (a, 400 MHz, CDCl3) and 13C NMR spectra (b, 100 MHz, CDCl3) 
of 6, residual solvent signal in 1H NMR spectrum removed for clarity. All aromatic protons of 
the rhodamine fragments have been assigned (a-f) and quaternary carbon labelled with *. 
 
Due to L2 being isolated as a TFA adduct further purification was required to remove salts 
from the complexes and this was achieved using gel filtration. Gel filtration is a technique 
that is effective in separating molecules in solution according to difference in molecular 
weight. Sephadex G-10 is a cross-linked dextran gel that is commonly used for this purpose, 
the G-10 grade being well suited for the separation of biomolecules with MW>700 from 
smaller molecules with MW<100, such as salts. Sephadex G-10 chromatography using water 
as the eluent afforded complexes [LnL2] as pale beige solids in yields of ~30%. The reduced 
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yields compared to [LnL1] are a result of the purification process used; only fractions that 
tested negative to xylenol orange test were collected. The additional amide moiety that was 
introduced did indeed impart water solubility into the [LnL2] complexes as hypothesised. 
 
Figure 2.9: Structure of [LnL2] complexes. 
2.4 Characterisation of [LnL1] and [LnL2] 
The primary objective of this project was to synthesise novel dual-modal MRI contrast 
agents by conjugation of an organic chromophore to a gadolinium(III) chelate. Analogous 
complexes with europium(III) and terbium(III) allowed for insightful luminescence and NMR 
experiments to be carried out that aided in the elucidation of the gadolinium(III) complexes’ 
solution behaviour. 
2.4.1 NMR studies of [EuL1] and [EuL2] 
It is well known that the long electronic relaxation time of the gadolinium(III) ion results 
in severe induced line broadening of resonances, which prevents its use in acquiring high 
resolution spectra of its complexes. Europium complexes are highly suited for analysis by 
NMR as they combine the large chemical shift range typical of paramagnetic species with 
limited line broadening. This aids in the interpretation of spectra as all the resonances are well 
separated. The 1H NMR spectra of europium(III) complexes of DOTA have been previously 
studied and reported, and this data is routinely used to aid in the assignment of resonances in 
the 1H NMR spectra of structurally related complexes. For the parent DOTA complex it was 
reported that two diastereomeric structures could be adopted: the square antiprismatic (SAP or 
M) and the twisted square antiprismatic (TSAP or m).49 Their structures differ in the layout of 
the coordinating arms thus causing a pronounced difference in the relative orientation of the 
two square planes formed by the four nitrogens and the four oxygens. In SAP-type structures 
the two planes make an angle of about 40° whereas the same angle is reduced to 30° (and 
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reversed) in TSAP-type derivatives.50 The preference to which isomer is adopted can be 
elucidated by 1H NMR spectroscopy. 
The application of proton NMR spectroscopy to the well-defined complexes of DOTA 
ligands has become increasingly well understood. The complexes of ligands derived from 
DO3A however have received much less attention. In contrast to the well-defined 
coordination geometries adopted by DOTA complexes, the coordination geometries adopted 
by seven-coordinate complexes are less established. Three coordination geometries may exist 
in DO3A complexes; a pseudo-square antiprism, a pseudo twisted square antiprism, and what 
is considered either as a bi-capped trigonal bipyramid or a mono-capped octahedron (Figure 
2.10).51 These three structures are difficult to distinguish from one another due to their 
similarities and complexes of this type are expected to interconvert freely between these 
geometries by means of ring inversion and arm rotation. 
 
Figure 2.10: Three coordination geometries of [LnDO3A] based complexes; (a) pseudo-
square antiprism, (b) pseudo-twisted square antiprism and (c) mono-capped octahedron. 
Analysis of the 1H NMR spectrum of [EuL1] (278 K, 500 MHz) revealed broad peaks, 
which characterises a system that is in intermediate exchange on the NMR timescale (Figure 
2.11). Although tentative assignments of selected peaks in the spectrum could be made, in 
particular those between 35 and 45 ppm (pseudo-axial protons in a pseudo-square 
antiprismatic arrangement), in general the spectrum was too broad and complex for a 
complete assignment to be performed. It was noted however that the shift patterns observed 
were reminiscent of those in spectra of other N-alkylated complexes of DO3A.52 2-
Dimensional exchange spectroscopy (EXSY) was used to gain insight into the solution 
dynamics (Figure 2.12).  
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Figure 2.11: 1H NMR spectrum of [EuL1] showing the pseudo-axial protons of the SAP and 
TSAP isomers (500 MHz, CD3OD, 278 K). 
 
Figure 2.12: 1H EXSY spectrum of [EuL1] (500 MHz, CD3OD, 278 K). 
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The spectrum displays a large number of cross peaks, and although an assignment of proton 
resonances in the 1H NMR spectrum was not possible, it can be reasoned that the 2D 
spectrum still illustrates that both ring inversion and arm rotation are occurring on the NMR 
time-scale (multiple cross peaks of the pseudo-axial protons at ~30-45 ppm).  
The proton NMR spectrum of [EuL2] is pictured (Figure 2.13). The signals can be found 
between -25 and +40 ppm, which is within the expected range for europium(III) complexes of 
DOTA derivatives. Further examination of the shifted pseudo-axial proton resonances 
between 20 and 50 ppm indicate the number of species (SAP and TSAP) in solution. L2 is an 
asymmetrical derivative of DOTA and as such does not form complexes of C4 symmetry. 
Proton spectra of C4 symmetry DOTA complexes are relatively simple in that they show 12 
peaks that can be divided into two groups of six assigned to the SAP and TSAP isomers.53 
Replacement of one acetic group of DOTA for another moiety leads to the loss of C4 
symmetry and as such removes the equivalence among the protons of the ligand. As a 
consequence, the spectrum of [EuL2] is highly crowded and more difficult to analyse. The 
pseudo-axial ring protons (ax1) gave two sets of four resonances, well separated from all other 
peaks corresponding to the SAP and TSAP isomers (Figure 2.13). The peaks observed at 
higher frequency (δ 37-42 ppm) corresponded to the four pseudo-axial ring protons for the 
SAP geometry, while for the TSAP isomer, signals for the pseudo-axial protons were 
observed at lower frequencies (δ 15-17 ppm). Integration of these resonances gave the isomer 
ratio SAP:TSAP of 1:0.22, majority SAP isomer. This NMR experiment was carried out at 
278 K; when the experiment was performed at elevated temperatures the signals were 
somewhat broadened, and this can be attributed to SAP-TSAP isomeric exchange (Figure 
2.14).54  
It has long been recognised that the water exchange kinetics and thus the relaxivity values 
of the TSAP isomer are considerably greater than those of the SAP isomer.55 [Gd(DOTA)]- 
itself is found to be predominantly in the SAP isomer structure (~85%).54 Appropriate 
substitution of the cyclen ligand frameworks have been shown to ‘freeze out’ exchange 
between isomers, and careful consideration of the stereochemistry enables one coordination 
isomer to be selected over the other.56 Woods and Botta have researched this area greatly and 
have discussed how the design of a chelate ligand can influence the properties of a 
gadolinium(III) contrast agent.57 Considering the work presented here, although loss of 
symmetry has occurred from [Gd(DOTA)]- to [GdL2], substitution of the cyclen ligand 
framework has not occurred and thus it is perhaps not surprising then that the isomer 
preference has not changed significantly ([GdL2] = 78% SAP isomer). 
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Figure 2.13: 1H NMR spectrum of [EuL2] showing the pseudo-axial protons of the SAP and 
TSAP isomers (500 MHz, CD3OD, 273 K).  
Figure 2.14: Pseudo-axial proton region of the 1H NMR spectra of [EuL2] (500 MHz, 
CD3OD) at temperatures from 278 to 328 K. 

	
	
























SAP TSAP 
	
	
	
	

278 K 
288 K 
298 K 
308 K 
318 K 
328 K 
 Chapter 2 
87 
An initial assignment of the 1H NMR spectrum of [EuL2] was performed on the basis of a 
1H-1H 2D COSY spectrum (Figure 2.15) as well as with comparison to the relative shifts to 
[Eu(HPDO3A)]53. This allowed for the assignment of the resonances of the SAP isomer in the 
rhodamine conjugate [EuL2] (see Table 2.1). As discussed previously, generally, the most 
downfield-shifted resonances of the macrocyclic ligand in DOTA-type complexes of 
europium are the pseudo-axial protons located on the carbon at the side of the macrocycle, 
labelled ax1. These protons exhibit characteristic coupling patterns with the other protons of 
the ethylene group on which they reside.58 In the COSY spectrum, for the geminal coupling 
with the pseudo-equatorial proton on the same carbon (eq1), an intense cross peak is observed. 
As a result of the Karplus relationship, the two vicinal protons show different coupling 
intensities.59 Thus, the next strongest coupling is observed between the pseudo-axial proton 
(ax1) and the pseudo-axial proton on the adjacent carbon (ax2). Finally, the weakest coupling 
is between the pseudo-axial protons and the pseudo-equatorial protons on adjacent carbons, 
i.e. ax1 and eq2. In the COSY spectra, this coupling is often too weak to be observed. For 
[EuL2], all but one of the eq2 protons could be assigned. The remaining cross peaks in the 
upfield region were assigned to the three acetate and one acetamide methylene protons.  
 
Figure 2.15: The 1H-1H 2D COSY spectrum of [EuL2] (500 MHz, 298 K, CD3OD). 
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M (SAP) isomer [EuL2] (ppm) 
ax1 38.44; 35.87; 34.54; 33.67 
eq1 2.54; -1.54; -2.71; 0.52 
ax2 -0.96; -13.88; -13.44; -5.06 
eq2 -3.36; -6.68; no signal observed; -6.68 
ac 
-12.82, -17.55; -11.02, -17.81; -6.41, -13.46; -
6.69, -13.92  
 
Table 2.1: 1H NMR peak assignments of [EuL2] (500 MHz, CD3OD, 298 K). 
2.4.2 NMR studies of [YbL2] 
An emerging trend in the field of optical imaging is near-infrared (NIR) imaging. The 
technique allows for the exploration of deeper tissues, with light penetration extending from a 
few millimetres up to 20 cm.60 As well as causing less damage to biological samples, high 
tissue autofluorescence derived from indigenous biomolecules is avoided as they have very 
low absorption coefficients above 700 nm.61 Unfortunately, due to instrument limitations 
(maximum wavelength of fluorimeter at 900 nm), no fluorescence data was acquired for 
[YbL2]. Similarly to europium however, ytterbium is commonly used in the structural 
analysis of DOTA coordination compounds as it combines the large chemical shift range 
typical of paramagnetic species with limited line broadening allowing for interpretation of 
spectra. The 1H NMR spectrum of [YbL2] is shown in Figure 2.16. The chemical shifts 
observed are similar to those reported for other DOTA-monoamide complexes; the spectrum 
of [YbL6] is dominated by a single set of resonances corresponding to the dominant SAP 
isomer, with only traces of the diastereomeric TSAP form (signals at ~ 80 ppm).62 
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Figure 2.16: 1H NMR spectrum of [YbL2] (400 MHz, CD3OD, 300 K). 
2.4.3 T1 relaxation studies 
The gadolinium complexes [GdL1] and [GdL2] were investigated for their relaxometric 
properties. An important characteristic of gadolinium-chelate based contrast agents is the 
number of bound water molecules per Gd(III) (hydration number, q). Considering the 
equation for longitudinal inner-sphere relaxation rate (chapter one), it is easy to recognise that 
doubling q (two inner-sphere water molecules instead of one) will double the inner-sphere 
relaxivity.63 L1 is a seven-coordinate ligand and so is expected to form a complex of q = 2 
when bound to gadolinium(III), which preferentially forms nine coordinate species. The 
additional amide functionality which was incorporated into L2 for water solubility leads to an 
eight coordinate ligand, and thus a q = 1 species (Figure 2.17). A greater relaxivity value is 
therefore expected for [GdL1]. 
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Figure 2.17: Structures of [GdL1] and [GdL2]. 
Inversion recovery experiments were performed on a 400 MHz NMR spectrometer. For 
solubility reasons, the experiment for [GdL1] was carried out in a 50:50, v/v MeOH:H2O mix. 
The relaxivity values, r1, for the complexes were calculated to be 8.5 and 3.8 mM-1s-1 for 
complexes [GdL1] and [GdL2] respectively. These values were within range for Gd(III) 
chelates with hydration states of two and one respectively. The hydration states were 
confirmed by the lifetime measurements of the europium and terbium analogues (vide infra). 
2.4.3.1 Relaxivity vs. HSA 
Human serum albumin (HSA) is the most abundant protein in blood, and binding of a 
contrast agent to it results in an increase in intravascular retention and relaxivity (due to 
decrease in τR of the complex).64 It is well documented that the presence of hydrophobic 
moieties within a probe is one of the basic structural requirements for ligand binding to 
HSA.65 This is exemplified by the clinically approved, blood vessel imaging probe MS-325; 
albumin binding is promoted by a hydrophobic 4,4’-diphenylcyclohexyl moiety appended to 
the DTPA backbone via a phosphodiester linkage.66 In view of the fact that the rhodamine 
moiety has extended aromatic rings and hence hydrophobicity, a study was carried out to 
investigate possible interactions between [GdL2] and HSA. [GdL1] was not considered for 
this study due to its poor water solubility.  
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The relaxation rates of a series of solutions of [GdL2] with increasing concentrations of 
HSA were measured. The relaxation rate was found to remain constant across the series 
indicating insignificant binding of the probe to the protein (Figure 2.18). The binding 
mechanisms of the fluorophore, rhodamine B, with bovine serum albumin (BSA) were 
previously investigated, and site-selective binding was observed. These results however, were 
obtained using high molar ratios of rhodamine B to BSA (>50).67 Such high concentrations 
are not practical for use in MRI probes in vivo, and in any case, large changes in relaxivity 
have been observed in cases where the molar ratio of probe to serum albumin have been much 
lower.68 It is hypothesised that the steric bulk of the complex, [GdL2], is unsuitable for 
selective binding to HSA. 
Figure 2.18: Relaxivity titration of [GdL2] with HSA. 
2.4.3.2 NMRD profiles for [GdL2] 
Nuclear magnetic resonance dispersion (NMRD) profiles were measured in order to gain 
insight into the molecular parameters governing the relaxivity behaviour of [GdL2]. Owing to 
its lack of water-solubility, this experiment was not carried out on [GdL1]. The measurements 
were carried out at three temperatures, 32°C, 37°C and 42°C in the proton Larmor frequency 
range 0.01-10 MHz, corresponding to 0.00023 and 0.24 T (Figure 2.19). The NMRD profiles 
recorded for [GdL2] show a plateau at low field (0.01 – 0.1 MHz). In this magnetic region, 
relaxivity is significantly controlled by the electron relaxation time. Above about 0.1 MHz the 
NMRD profiles show a slight decrease of r1 reaching a maximal at ~ 2 MHz, followed by a 
rapid and pronounced increase in r1 at higher frequencies. Above about 3 MHz the inner 
sphere contribution to relaxivity is determined largely by the residence lifetime of the inner-
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sphere water molecule (τM) and the rotational correlation time (τR). This increase in relaxivity 
at higher fields is characteristic of slowly tumbling systems with τR values in the order of ns.69 
A repeat experiment would be required to fully realise the trend occurring at higher fields, 
with measurements to be acquired up to 100 MHz. Long rotational correlation times are most 
commonly achieved by increasing the size of the agent or by coupling the molecular motion 
of a complex to that of a large structure such as a protein. In the case of [GdL2] no such 
secondary structure has been introduced to induce the resulting NMRD profile. Other 
gadolinium chelates incorporating large aromatic substituents and long hydrocarbon chains 
have been shown to display similar NMRD profiles.70,71,57 Comparing to those systems, it can 
be hypothesised that the increase in relaxivity at high fields can be attributed to the formation 
of micelles, in which the rotation of gadolinium is slowed at higher concentrations. In all the 
literature examples given, the critical micelle concentrations (cmc) of the gadolinium 
complexes were all below 1 mM (mostly around 0.5 mM), so it is reasonable to suggest that 
[GdL2] may be forming micellar aggregates at the concentration of 1.5 mM at which the 
experiments were carried out.  
 
Figure 2.19: NMRD profile of [GdL2] at 32°C (circle), 37°C (triangle) and 42°C (square); 
(1.5 mM, H2O, pH 7.4). 
To fully understand this system, further experiments would be needed, following the 
works of Woods and co-workers.57 They demonstrate that the formation of micelles can 
unambiguously be determined by recording the NMRD profiles of the chelate at 
concentrations above and below the critical micelle concentration (cmc). The NMRD profile 
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at low concentrations (0.2 mM) should be characteristic of small molecule gadolinium 
chelates in which relaxivity is limited by τR. The NMRD profile at high concentration, above 
the cmc (3.98 mM) are characteristic of more slowly tumbling chelates showing a classic high 
field hump, indicating the formation of a slowly rotating species, micelles, at high 
concentration. 
2.4.4 Luminescence Studies 
The excitation and emission spectra were recorded for the lanthanide complexes of the 
rhodamine-DO3A chelators L1 and L2.  
2.4.4.1 Photophysical properties of [GdL1] and [GdL2] 
 
Figure 2.20: Excitation (....) and emission (__) spectra of [GdL2] (H2O), 298 K, pH 7.4. 
Although gadolinium(III) is known to possess very high luminescence quantum yields in 
solution, it emits far into the UV range (315 nm) making it impractical in the field of 
biological imaging where high energy radiation is damaging to tissue. Consequently, only 
fluorescence derived from the organic rhodamine moiety was observed for both [GdL1] and 
[GdL2]. The excitation and emission properties of both complexes were found to be, not 
surprisingly, very similar, both exhibiting fluorescence emission at 580 nm upon excitation at 
560 nm (Figure 2.20). These fluorescence properties, including the short Stokes shift, were 
expected as rhodamine and its derivatives have been extensively studied; modification of the 
carboxylic acid moiety of rhodamine B leads to insignificant changes in the photophysical 
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properties of the chromophore as neither electronic nor structural changes occur to the 
xanthene core (rhodamine B: λex = 553 nm, λem = 572 nm in ethanol).  
It must be highlighted though that the fluorescence intensities observed in the spectra of 
[GdL1] and [GdL2] were relatively low when compared to that of rhodamine B, and this is a 
result of the thermal equilibrium that exists between the fluorescent open form and the non-
fluorescent spirocyclic form of rhodamine derivatives bearing an intramolecular nucleophile. 
Excitation and emission at 560 and 580 nm respectively were observed due to a low 
percentage of the complexes being in the ring-opened form. The majority, however, existed as 
the spirocyclic form as observed by the greater emission intensity at ~ 500 nm giving a blue-
green fluorescence. A 3D Excitation-Emission Matrix (EEM) plot was generated. In order to 
generate these EEM spectra, several scans of emission wavelengths at fixed excitation 
wavelengths were collected and then combined. Twelve spectra were obtained using 325 – 
380 nm excitation, monitoring emission at 400 – 625 nm with a step-increase of excitation 
between emission scans of 5 nm. Both the 3D and contour plots of [GdL1] are seen in Figure 
2.21. The plots show that [GdL1] in the ring-closed form emits at two wavelengths, namely λ 
= 480 and 540 nm, when excited at λ = 380 and 335 nm respectively. There are two distinct 
components of the rhodamine fragment that could give rise to these emission properties, the 
isoindolinone fragment that forms the spirolactam and the diethylalinine fragments that 
constitute the xanthene core. It is difficult to assign these fragments to the emission and 
excitation peaks observed. A similar 3D profile was observed for [GdL2]. 
 
Figure 2.21: 3D (left) and contour (right) plots of excitation-emission matrix spectra (EEMs) 
of [GdL1] (MeOH, 100 µM, 298 K). 
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2.4.4.2 [GdL2] pH titration 
To investigate this equilibrium between the open and closed forms, the pKa of [GdL2] 
was determined. Only this complex was investigated due to its complete solubility in water. 
The pKa of these rhodamine derivatives can also be termed the pKcycl, as described by Urano 
et al. It can be determined from the pH titration curve as the pH value at which the 
absorbance of the open form in the visible range is reduced to half of the maximum value as a 
result of intramolecular spirocyclization.72 The pH sensitivity of [GdL2] was investigated; a 
1.49 mM solution of [GdL2] in 0.1 M NaCl was prepared and the solution pH was altered by 
the addition of 1M HCl and NaOH solutions (Figure 2.22). A titration curve was then 
produced by plotting the fluorescence emission intensity at λ = 580 nm vs. pH (Figure 2.23). 
 
Figure 2.22: Fluorescence emission spectra of [GdL2] with lowering pH (λex = 560 nm, 1.49 
mM, H2O, 0.1 M NaCl). 
Only very weak fluorescence emission was observed in alkaline solution between 450 and 
650 nm. With a decrease in pH however, the fluorescence intensity of [GdL2] gradually 
increased. The fluorescence intensity at low pH (3.12) was ca. 125-fold larger than that at 
high pH (8.62). This fluorescence change was also shown to be reversible. Fluorometric 
titration as a function of pH yielded a sigmoidal curve which was fitted using the Henderson-
Hasslebach-type mass action equation (Figure 2.23).73 The fitting yielded a pKa of 5.11, 
which is valuable for studying acidic organelles.14 
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Figure 2.23: Fluorescence intensity (580 nm) of [GdL2] vs. pH, excitation at 560 nm (1.49 
mM, H2O, 0.1 M NaCl). 
2.4.4.3 Luminescence studies of europium(III) and terbium(III) complexes of L1 and L2 
The luminescence properties of both europium(III) complexes ([EuL1 and [EuL2]) were 
investigated. Europium is well known for its strong luminescence in the red spectral region 
and a distinctive emission profile resulting from the various 5D0 to 7FJ transitions. The 
phosphorescence excitation and emission spectra of [EuL1] are shown in Figure 2.24. The 
emission profile is clearly not one typically observed for europium complexes. The spectrum 
is actually a mixture of terbium and europium emission, the emission peaks at λ = 490 and 
545 nm are clearly derived from a terbium metal centre (5D4 ! 7F6 and 7F5) whilst peaks at λ 
= 585 and 615 nm are a mixture from both the luminescent lanthanides. Small peaks at λ = 
650 and 690 are a result of solely europium emission (5D0 ! 7F3 and 7F4). For [EuL2] a 
mixture of both europium and terbium fluorescence is again observed, with the europium 
fluorescence being the most dominant. The complexations were repeated multiple times and 
similar spectra were always observed. Contamination of the europium chloride hexahydrate 
within the lab was ruled out by purchasing a new bottle of the lanthanide starting material. 
This bottle was of greater purity (99.99% compared to 99.9%) and yet terbium fluorescence 
could still be observed.  
As expected from the results above, the terbium complexes displayed strong fluorescence 
with emission observed for the expected transitions, 5D4 to 7FJ (ΔJ = 6 - 3). The emission 
profiles were the same for both [TbL1] and [TbL2] whereas the excitation profiles were found 
to change (Figure 2.25). [TbL1] displayed an excitation maximum at λ = 315 nm compared to 
λ = 215 nm [TbL2]. As the rhodamine fragment itself has not differed between the 
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complexes, this change in excitation maximum must arise from the additional amide group 
that was introduced resulting in the organic sensitiser (rhodamine moiety) being slightly 
further away from the terbium metal centre.  
 
Figure 2.24: Phosphorescence excitation (…) and emission (__) spectra of [EuL1], λex = 350 
nm (MeOH, 100 µM, 298 K, 0.1 ms delay) and [EuL2] (H2O, 100 µM, pH 7, 298 K, 0.1 ms 
delay). 
Figure 2.25: Phosphorescence excitation (...) and emission (__) spectra of [TbL1] (MeOH, 100 
µM, 298 K, 0.1 ms delay, λex = 330 nm) and [TbL2] (H2O, 100 µM, pH 7, 298 K, 0.1 ms 
delay, λex = 220 nm). 
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Comparing the spectra of the two sets of complexes, i.e. [EuL1,2] and [TbL1,2], it can be 
seen that there is a clear preference of emission from a terbium metal centre than a europium 
metal centre. In fact, the slightest impurity of terbium within the europium starting material is 
enough to observe terbium emission in the luminescence spectrum of the sample. As 
discussed previously, contamination of the europium starting material within the lab was 
ruled out by purchase of a new sample of higher purity europium chloride and many repeat 
complexations. Therefore, the impurity must be derived from the production source, and this 
is feasible as it is well known that lanthanides (especially ones that are close to each other in 
the periodic table such as europium and terbium) are very difficult to separate. Taking that 
into account, it is still interesting to see that such a small impurity of terbium is enough to 
greatly impact the phosphorescence spectrum to the extent that its emission is being observed 
over the europium emission. This leads to the conclusion that the preference for terbium 
emission must be related to the energy levels of the excited states of the lanthanides and the 
excited triplet state of the sensitiser (rhodamine moiety). The spectral overlap for energy 
transfer is different between the two luminescent lanthanides. Pseudo-direct or indirect 
excitation generally occurs over the 17,200 to 25,000 cm-1 frequency range for europium and 
20,500 – 40,000 cm-1 for terbium.74 The fact that emission from both lanthanides can be 
observed at the same time, and that terbium emission dominates means that the antenna triplet 
excited state must lie above 25,000 cm-1, at a level which is slightly too high for efficient 
energy transfer to europium. Triplet state energies in this range are ideal for sensitising 
terbium and thus strong emission is observed from this luminescent lanthanide. 
The spectra seen in Figure 2.24 and Figure 2.25 were carried out using phosphorescence 
settings of a 0.1 ms time delay. The excitation and emission profiles were also investigated 
without the time delay and can be seen in Figure 2.26. Without the use of a 0.1 ms time delay, 
[TbL1] was excited at λ = 310 nm displaying exclusively green emission arising from the 5D4 
– 7FJ transitions of terbium. A very broad and low intensity rhodamine centred emission could 
be observed underneath the terbium emission. Conversely, under excitation at λ = 310 nm, the 
emission spectrum of complex [TbL2] is dominated by rhodamine emission at 580 nm. There 
is no difference between the complexes in terms of the organic sensitiser used, the rhodamine 
moiety remained unchanged, and so the difference in emission properties must be a result of 
the introduced amide moiety and the increased distance between the sensitiser and the 
lanthanide metal centre.  
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Figure 2.26: Fluorescence excitation (…) and emission (__) spectra of [TbL1], λex = 330 nm 
(MeOH, 100 mM, 298 K) and [TbL2] (H2O, 100 mM, pH 7.4, 298 K). 
There are two types of mechanisms for sensitisation of lanthanide luminescence by 
energy transfer from a separate sensitising moiety, Dexter energy transfer and Förster energy 
transfer.75 As the Dexter mechanism requires direct donor-acceptor orbital overlap it is ruled 
out as a mechanism used in these systems as the rhodamine sensitiser is separated from the 
lanthanide metal centre by a saturated alkyl chain. The Förster mechanism is a Coulombic, 
through-space interaction between the donor and acceptor, and has a distance dependence of 
d-6. This dependency on distance is demonstrated in the complexes of [TbL1] and [TbL2] 
where there is a difference of ~ 4.5 Å (the estimated length of the additional methyl amide 
moiety) between the organic antenna and the terbium centre. As predicted by the Förster 
mechanism, the efficiency of energy transfer is reduced in [TbL2], resulting in the 
observation of predominantly rhodamine emission instead of terbium emission. The extra 
amide moiety may also introduce a quenching pathway; this additional N-H bond is close to 
the lanthanide centre and fluorescence deactivation may occur via the N-H vibrational energy 
level oscillator.76 The quantum yields of both complexes were determined, and the results 
were in agreement with the observed spectra confirming the more efficient energy transfer to 
the terbium metal centre in [TbL1] (Φ = 18.6%) and the less efficient energy transfer in 
[TbL2] (Φ = 0.8%). As seen in Figure 2.25 however, using time-gating techniques, terbium 
emission could be induced in both complexes by exciting at 315 nm ([TbL1]) and 215 nm 
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([TbL2]), and without the use of a time delay rhodamine emission could be observed by 
excitation at 560 nm, demonstrating that both complexes behave as dual-luminescent probes.  
3D Excitation and Emission Matrix (EEM) plots were collected for complexes [EuL1,2] 
and [TbL1,2]. Only [TbL1] displayed a plot that differed from that of [GdL1,2]. Both the 3D 
and contour plots can be seen in Figure 2.27. As found in the steady state spectrum of [TbL1], 
terbium emission was observed when exciting at ~325 nm. On shifting to lower energy 
excitation wavelengths the emission shifts to rhodamine centred fluorescence at ~450 nm. 
This indicates that there are two chromophoric components to the rhodamine moiety, only 
one of which sensitises terbium. As discussed for [GdL1] these components must be the 
isoindolinone fragment that forms the spirolactam and the diethylalinine fragments that 
constitute the xanthene core. This was not observed in the 3D EEM plot of [TbL2] due to the 
decreased efficiency of energy transfer resulting from the increased distance between antenna 
and lanthanide. 
Figure 2.27: 3D (left) and contour (right) plots of excitation-emission matrix spectra (EEMs) 
of [TbL1] (MeOH, 100 µM, 298 K). 
2.5 Intracellular localisation of [GdL2] 
2.5.1 In vitro studies 
For a cellular probe to be truly useful, a clear, well-defined localisation profile is 
essential. Rapid and efficient localisation to a single cellular compartment is key. For the 
water-soluble rhodamine-GdDO3A probe [GdL2] discussed here, it is the mitochondria of 
tumour cells that are the target organelle of interest. It was hypothesised that the change in the 
charge (on the organic rhodamine fragment) of [GdL2] going from pH ~ 7.0 to 4.0 could aid 
the probe to localise in the more acidic microenvironment of tumour cells.77 As discussed 
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previously, it is known that tumour cells have a lower pH than healthy cells (Warburg effect). 
As such, upon entering an acidic environment, the probe can undergo rearrangement to its 
fluorescent ring-opened form. This cationic form of the probe is expected to accumulate in the 
mitochondria.78 Localisation was analysed by co-localising with the commercially available 
cellular stain MitoTracker Green. 
To assess the localisation, two cell lines were investigated; human embryonic kidney 
(HEK293) cells and primary mouse islet cells (~70% insulin-containing β cells). This in vitro 
work was carried out by Dr. Florencia Minuzzi of the Department of Medicine at Imperial 
College. After preparation of the cells, both cell lines were incubated with KREBS buffer 
containing 215 mM [GdL2] and 100 nM MitoTracker Green for 30 min and washed twice 
with KREBS buffer before visualisation. Excitation of the rhodamine chromophore was 
achieved using a solid state laser that provided wavelengths of 491 nm to excite MitoTracker 
Green (emission filtered at 525 nm) and 561 nm to excite [GdL2] (emission filtered at 620 
nm). 
 
 
Figure 2.28: (A-C) Confocal microscopy images of HEK cells, (D-F) Confocal microscopy 
images of dissociated mouse islet cells. (A/D) MitoTracker Green signal (100 nM), (B/E) 
[GdL2] signal (215 mM), (C/F) merged signal. Scale bars: 50 µm.5 
Clear accumulation of [GdL2] was observed in both cell types as seen in images B, C and 
E, F in Figure 2.28. Upon studying the merged images however, clear co-localisation of the 
probe and MitoTracker was not evident (Figure 2.28 C, box). Moreover, it was noted that in 
A! B! C!
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cells where significant uptake of [GdL2] was apparent (as seen in the primary cells, images 
E,F), MitoTracker accumulation was lower and more diffuse that in surrounding cells, and 
little co-localisation of red and green signals was evident (Figure 2.28 F). These findings are 
best explained by the fact that [GdL2] fluorescence, which is low at pH > 6.5 (as seen in the 
pH titration in Figure 2.22), is only readily detectable in cells in which mitochondria are 
relatively depolarised, such that the mitochondrial matrix pH falls to levels permissive of 
[GdL2] fluorescence. These mitochondria, however, are expected to be poorly able to retain 
MitoTracker, whose accumulation depends on the inner mitochondrial membrane potential 
and the pH gradient (i.e., high intramitochondrial pH > 7). These results thus do not 
definitively establish the mitochondrial localisation of [GdL2] but are consistent with the 
known properties of both the probe and MitoTracker. 
In hindsight, perhaps another cell line should have also been studied, one that has a 
cellular environment more suited to allow for a higher proportion of [GdL2] to be in its ring-
opened form i.e. more acidic. A cancer cell line such as HeLa cells may have been applicable. 
It is hypothesised that a greater fluorescence signal would be observed in this case. 
Additionally, an alternative mitochondrial stain could have been employed, one that does not 
fail at low mitochondrial pH. MitoTracker Green was primarily chosen because its 
fluorescence emission did not overlap that of [GdL2]. The in vitro studies carried out did 
however positively demonstrate the probe to be cell-permeable, a promising result for these 
preliminary studies. 
2.5.2 In vivo studies 
After performing in vitro studies, imaging agents are routinely assessed by the next stage 
of probe validation: in vivo studies. Evaluation of a probe in small animals can provide 
invaluable information regarding biodistribution and pharmacokinetics and mouse models of 
human cancer have become important tools for the study of human disease. MRI has been an 
especially practical imaging modality on the preclinical setting due to its unique ability to 
combine high resolution anatomical imaging with functional and metabolic analyses.79 
BALB/c nude mice are commonly employed for studies to test new methods of imaging 
and pharmacological treatment of human tumour xenografts.80 A nude mouse is a genetic 
mutant that has a deteriorated or removed thymus gland and thus a lack of body hair and an 
inhibited immune system due to a greatly reduced number of T cells (type of white blood 
cell). This reduced number of T cells leads to successful implantation of xenografts as no 
rejection response is initiated.81 
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Human melanoma cells that are intradermally injected into immune-deficient mice, such 
as BALB/c nude mice, initiate angiogenesis (process through which new blood vessels form 
from pre-existing vessels) and lead to solid tumours. These tumours are similar to the donor 
patients’ tumours with respect to histological appearance and molecular pathology, and as 
such these types of xenografts have been shown to be suitable experimental models for the 
study of malignant melanoma.82 
In vivo studies with [GdL2] were performed by Dr. Juan Gallo at Hammersmith Hospital. 
BALB/c nude mice with neck M21 (human melanoma cell) xenograft implantations were 
injected intravenously with 0.1 mmol kg-1 [GdL2]. The mice were imaged in a 4.7 T MRI 
instrument at three different times (pre-injection, 30 min post-injection and 60 min post-
injection) to evaluate the effect of the contrast agent.  
 
Figure 2.29: Parametric T1 maps of a BALB/c nude mouse tumour: (a) pre-injection, (b) 30 
min post-injection with [GdL2]; (c) 60 min post-injection with [GdL2]. Scale bars in ms. 
30 minutes after injection of [GdL2], a 36.5% decrease in tumour average T1 was 
observed compared with the baseline of the pre-injection image (Figure 2.29 a, b). This 
decrease in longitudinal relaxation time was retained at least up to 60 minutes (31.3% 
decrease; Figure 2.29 c). These preliminary images demonstrate that [GdL2] functions 
successfully in vivo by shortening the T1 of protons in the tumour sufficiently so as to give a 
more detailed image. The observed accumulation of [GdL2] in the tumour area is consistent 
with the predicted effect of a lower pH environment on the probe; the rearrangement of the 
lactam ring at acidic pH introduces a positive charge in the molecule that can promote the 
intracellular uptake of the molecule responsible for the average T1 decrease observed in the 
tumour. 
The mice were euthanized after each MRI experiment, the main organs (liver, lower 
intestine, spleen, muscle and kidney) and the tumour were collected, weighed and frozen until 
further analysis. The gadolinium(III) content was determined by inductively coupled plasma 
mass spectrometry (ICP-MS) by Dr. Stanislav Strekopytov at the Natural History Museum, 
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London. ICP-MS is a highly sensitive technique for elemental determination and analysis of 
the gadolinium(III) content in tissue samples, and it has been used extensively in the tracking 
of gadolinium(III)-based small chelates ex-vivo.83 The gadolinium(III) content in the main 
organs and the tumour were determined; they are presented in Figure 2.30. All small 
gadolinium-chelate based MRI agents show renal clearance by glomerular filtration into the 
urine, however a large proportion of gadolinium content was found in the liver, spleen and 
kidney.84 This is an indication of retention of [GdL2] in the reticule-endothelial system 
(RES). The high liver uptake compared to the kidney could be due to the lipophilic nature of 
the probe, benzylic moieties are known to aid in the targeting if hepatocytes.85 The tumour 
had a similar level of gadolinium to both the spleen and the kidney, showing significant 
uptake in the carcinoma. This result is probably best explained by the fact that [GdL2] 
undergoes a ring-opening process upon entering the more acidic environment of the tumour, 
and as discussed vide infra, results in its localisation in the mitochondrial matrix due the 
abnormally high mitochondrial potential. So although the probe is not in fact targeted to the 
tumour itself, the ability of the probe to ring-open into its cationic form aids the probe to be 
retained within the tumour. 
Figure 2.30: Gd(III) concentrations in various organs and tumour as measured by ICP-MS 
post MRI scans. 
2.6  ‘Always on’ rhodamine derivative – [GdL3] 
As already discussed, secondary amides of rhodamines are predominantly found as non-
fluorescent spirolactams, and are ‘activated’ only under acidic conditions or in the presence of 
metal cations. Demonstrated by [GdL2], this can at times be diagnostically useful, as the 
fluorescent probe will only be switched on in the presence of such stimuli. It is also of 
interest, however to design dual modal probes where the fluorescence moiety displays a 
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signal that is ‘always on’, i.e. a fluorescence signal that is not greatly affected by cellular pH 
for example. To achieve this with rhodamine derivatives that have been modified via the 
carboxylic acid moiety, reaction with a secondary amine must be carried out to afford a 
tertiary amide. This structure will be prohibited from an intramolecular cyclisation process, 
and should thus maintain its fluorescence, analogous to other rhodamine derivatives that bear 
a tertiary amide or an ester functionality at the Z position (Figure 2.1 B), such as the 
commercially available rhodamine 6G. 
 
 
Figure 2.31:  Examples of tertiary amide derivatives of Rhodamine B 
In 2003 Nguyen and Francis reported novel synthetic routes for the preparation of Z-
amide derivatives.86 This is the first example for the preparation of tertiary amide derivatives 
of rhodamine dyes. They synthesised a piperazine amide derivative (Figure 2.31) from 
Rhodamine B through exposure of the lactone form to four equivalents of piperazine and two 
equivalents of AlMe3 in refluxing DCM, obtaining the tertiary amide in 70% yield. Upon 
reviewing the literature for additional examples of tertiary amide rhodamine derivatives, it 
can be noted that the majority are further derivatives of this piperazine conjugate; the 
secondary amine of the piperazine moiety was converted into several other functional groups 
through alkylation of the amine (Figure 2.31). For example, it was used for surface 
modification of tobacco mosaic virus87, for dye-labelling of polymers88 and dye-labelling of a 
chain transfer agent in radical addition-fragmentation chain transfer (RAFT) polymerisation.89 
More recently a chloroacetyl piperazine amide derivative was synthesised that formed 
covalent bioconjugates with intra-mitochondrial protein sulfhydryls90, an azido derivative was 
coupled to dieckol (an anti-inflammatory) via a click reaction91, and a coumarin-rhodamine 
FRET was synthesised as a dual-excitation ratiometric pH probe.92 In these more recent 
reports, the synthesis of the piperazine was improved by the use of coupling agents such as 
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HATU and HBTU. These peptide coupling agents allowed for milder conditions (reflux vs. 
room temperature), shorter reaction times (24 h vs. 3 h) and simplified work-up procedures. 
Non-piperazine derivatives can also be found in the literature such as Årstad et al.’s 
rhodamine-alkyne derivative, which was then transformed into an [125I]iodo triazole 
derivative to give a dual-modal optical/SPECT probe.93 The intramolecular cyclisation 
process is prevented by introduction of a methyl moiety to give the tertiary amide. This 
methodology was taken into consideration for the synthesis of a novel rhodamine derivative 
for the use in a dual-modal MRI/optical probe.  
2.6.1 Synthesis of L3 
Alongside Sarah Stevely-Taylor, a Master’s student undertaking her final year project in 
the Long group, an ‘always on’ derivative of [LnL2] was designed and synthesised.  
N-methylethylenediamine was first transformed to the mono-Boc protected derivative 7 
(see Scheme 2.4) using a methodology reported in the patent literature.94 Its synthesis and 
purification was relatively straightforward, involving silica gel column chromatography using 
a chloroform:methanol solvent mixture (30:1, v:v). It was synthesised in high yields (> 90%) 
and as such a large quantity was synthesised for a number of subsequent reactions and at a 
greatly reduced cost. The peptide coupling reagent HBTU was then used to couple the 
secondary amine 7 to rhodamine B. The reaction conditions were mild; a two-hour, room 
temperature stir in the presence of triethylamine base were sufficient to form 8 in 78% yield 
(after purification on silica column). This novel rhodamine derivative was isolated in its ring-
opened form as anticipated, and this was confirmed by its dark purple colour and orange 
fluorescence in both solid and solution forms. The 1H NMR spectrum displayed the typical 
rhodamine proton resonances as well as additional resonances from the boc-
methylethylenediamine moiety in the form of singlets at 1.38 and 2.70 ppm, and two triplets 
at 2.95 and 3.23 ppm (Figure 2.32). The confirmation of the ring-opened nature of the 
compound was corroborated by the lack of signal at ~65 ppm in the 13C NMR spectrum, as 
observed for the related ring-closed rhodamine compounds.  
Removal of the Boc protecting group was achieved using trifluoroacetic acid (TFA) in 
dichloromethane (50/50, v/v), liberating the NH2 moiety (9). Following the same 
methodology as used in the synthesis of 5, reaction of 9 with chloroacetyl chloride in the 
presence of triethylamine gave compound 10 in high yields. This α-halogenated rhodamine 
derivative 10 was then conjugated to tris-t-Bu-DO3A. Reaction conditions involved a 48-hour 
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reflux in acetonitrile using potassium carbonate as base followed by purification using silica 
gel chromatography (graduated solvent system, DCM:MeOH), giving 11 in 56% yield.  
 
 
Scheme 2.4: Synthesis of [LnL3]. 
 
N
H
NH2 N
H
H
N O
O
O NN
N
O H
N O
O
O NN
N
O
NH2
O NN
N
O H
N
O
Cl
O NN
N
O H
N
O
N N
NN
O
O
O
O
O
O
O NN
N
O H
N
O
N N
NN
O
OH
O
OH
O
HO
O NN
N
O H
N
O
N N
NN
O
O
O
O
O
O
Ln
N-methylethylene-
diamine
7 8
910
11 L3
[LnL3]
Boc2O
TFA, DCM
rt, 24 h
Et3N, EtOH
rt, 24 h
Et3N, DCM
rt, 2 h
Chloroacetyl
chloride
Et3N, DCM
rt, 2 h
Tris-t-Bu-DO3A, 
K2CO3, CH3CN,
reflux, 24 h
TFA, DCM
rt, 24 h
LnCl3.6H2O, H2O, NaOH(aq)
pH 5.5, rt, 24 h
+
++
+ +
+
Rhodamine B,
HBTU
 Chapter 2 
108 
 
Figure 2.32: 1H NMR of 8 (400 MHz, CDCl3, 298 K). 
The free ligand L3 was obtained using standard deprotection (i.e. tert-butyl cleavage) 
conditions using trifluoroacetic acid (TFA) in dichloromethane (v/v, 50/50). L3 was obtained 
as a bright pink, highly hygroscopic TFA adduct (quantitatively determined by elemental 
analysis). 
 
2.6.2 Lanthanide complex formation [LnL3] 
L3 was coordinated to a series of lanthanide metal chloride salts (Ln3+ = Gd3+, Eu3+, Tb3+) 
in an aqueous, mildly acidic environment (pH = 5.5). After 24 hours stirring at 50 °C the 
complexes were purified. A precipitate had formed which was isolated by centrifugation. The 
precipitate and the filtrate were both analysed by mass spectrometry to determine which 
portion contained product. The desired complexes were found in the water layer as predicted. 
Due to L3 being isolated as a TFA adduct purification was required to remove salts from the 
complexes and this was achieved using gel filtration. Sephadex G-10 chromatography using 
water as the eluent afforded complexes [LnL3] as bright pink solids in yields of ~20%. Due to 
the bright pink colour of the complexes in solution, confirmation of removal of free 
lanthanides could not be carried out i.e. the colour change of xylenol orange to purple in the 
presence of free metal would not be detected. As this purification method was successful for 
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[LnL2] however, complexes [LnL3] were assumed pure. Their purities were confirmed by 
elemental analysis and high resolution mass spectrometry.  
 
Figure 2.33: Structure of [LnL3] complexes. 
2.7 Characterisation of [LnL3] 
2.7.1 NMR studies of [EuL3] 
The 1H NMR spectrum of [EuL3] is shown in Figure 2.34. As anticipated, the signals 
were found between -25 and +40 ppm, within the expected range of europium complexes of 
DOTA derivatives. The pseudo-axial ring protons gave two sets of resonances well separated 
from all other peaks corresponding to the SAP and TSAP isomers. The peaks observed at 
higher frequency (δ 34 – 40 ppm) corresponded to the four pseudo-axial ring protons of the 
SAP geometry, while for the TSAP isomer, signals for the pseudo-axial protons were 
observed at lower frequencies (δ 14 - 18 ppm). Integration of these resonances gave the 
isomer ratio SAP:TSAP of 1:0.21; majority SAP isomer and almost identical isomer ratio to 
that of [EuL2].  
Although the ratio between isomers was comparable to [EuL2], the proton spectrum of 
[EuL3] displayed more than four resonances in the downfield region (> 30 ppm). There are in 
fact 8 resonances indicating the presence of two coordination isomers in the SAP 
conformation. Variable temperature experiments may have helped in the resolution of these 
signals but due to time constraints this was not attempted. With this proton spectrum being 
more complex than [EuL2], the corresponding COSY spectrum was even harder to interpret 
and as such an assignment of the peaks in the spectra was not carried out.  
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Figure 2.34: 1H NMR spectrum of [EuL3] (400 MHz, CD3OD, 298 K). 
2.7.2 T1 relaxation studies of [GdL3] 
Just like L2, L3 is an eight coordinate ligand and so is expected to form a complex of q = 
1 when bound to gadolinium. Inversion recovery experiments were performed on a 400 MHz 
NMR spectrometer. The relaxivity value, r1, was calculated to be 4.09 mM-1s-1, which is 
within range for a gadolinium chelate with a hydration state of one. This hydration state was 
corroborated by the lifetime measurements of the europium and terbium analogues.  
The relaxation rate was also measured in the presence of BSA to compare with the results 
of [GdL2] HSA relaxivity titration. The r1 value was calculated to be 4.06 mM-1s-1 indicating 
that no significant binding to protein occured. This was the expected result as the structure of 
the probe has not changed dramatically. 
2.7.3  Luminescence Studies 
2.7.3.1 Photophysical properties of [GdL3] 
[GdL3] was designed to behave as a dual-modal probe whereby both modalities are ‘always 
on’. The fluorescence properties of [GdL3] were studied in order to directly compare to those 
of [GdL2]. [GdL3] displayed very similar fluorescence properties in terms of excitation and 
emission wavelengths (560 and 580 nm respectively) but with a much greater fluorescence 
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intensity as anticipated. In its ring closed form, [GdL2] was found to emit a blue-green 
fluorescence at ~ 500 nm. When [GdL3] was excited at 380 nm only a very low intensity 
emission at 480 nm was observed (Figure 2.35 (c)), but when an excitation wavelength of 300 
nm was used, emission was observed at 330 nm and at 580 nm (Figure 2.35 (b)). Both these 
higher energy emissions (λem = 330, 480 nm) are of very low intensity when compared to 
emission at 580 nm (after excitation at 560 nm, Figure 2.35 (a)) indicating that the ring-
opened structure is the main form of [GdL3]. 
Figure 2.35: Fluorescence excitation and emission spectra of [GdL3]; (a) λex = 560 nm; (b) 
λex = 300 nm; (c) λex = 380 nm (H2O, 100 µM, pH 7, 298 K).  
Figure 2.36: Fluorescence excitation and emission of [GdL3] as a function of pH (100 mM, 
H2O, adjusted to appropriate pH with HCl or NaOH). 
The effect of pH on the fluorescence excitation and emission of [GdL3] was studied by 
collecting data at pH 2, 7 and 10. The probe was found to retain its fluorescence emission 
properties under a range of pH conditions showing that the spirocyclisation mechanism has 
been successfully obstructed by the introduction of the methyl group (Figure 2.36). 
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2.7.3.2 Photophysical properties of [EuL3] and [TbL3]. 
The phosphorescence spectra of [EuL3] and [TbL3] were very similar to the luminescent 
complexes of L2, displaying matching excitation and emission properties. As before, the 
europium spectrum is corrupted by terbium emission with the 5D4 ! 7F5 band at 545 nm. 
Incomparison to [EuL1] and [EuL2] however, a much greater emission intensity was 
observed for [EuL3] (all fluorescence experiments carried out at same concentration). This 
means that the energy transfer in the latter system is more efficient and this must be related to 
the triplet state energy level of the rhodamine moiety. The ring-opened form of the probe 
must have a lower triplet state energy level that is more suited to the ideal frequency range for 
europium excitation. The terbium complex displayed a very strong excitation band at 215 nm 
as observed in [TbL2], but could also be excited at 245 nm to give the characteristic terbium 
emission bands observed. 
 
Figure 2.37: Phosphorescence emission spectra of [EuL3] and [TbL3] (H2O, 100 µM, pH 7, 
298 K). 
The complex hydration states, q, were estimated by measuring the decay of intensity of 
the lanthanide emissions in H2O and D2O. Values of q of 0.7 [EuL3] and 0.6 for [TbL3] were 
obtained, and the rate constants and lifetimes can be seen in Table 2.2. Non integer values of 
q are not uncommon when using Horrocks’ method for determining the number of 
coordinated water molecules, as a result of the strong distance dependence of energy 
transfer.95 
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Complex kH2O / ms-1 τ / ms kD2O / ms-1 τ / ms q 
[EuL3] 1.59 0.62 0.71 1.41 0.7 
[TbL3] 1.03 0.97 0.84 1.19 0.6 
 
Table 2.2: Rate constants, k, and lifetimes (τ), observing radiative decay of the lanthanide 
excited state (616 nm for Eu(III), 545 nm for Tb(III)) (100 µM, pH 7, 298 K) and derived 
hydration numbers, q. 
2.8 Intracellular localisation of [GdL3] 
2.8.1 In vitro studies 
The cellular localisation of [GdL3] was investigated to compare with the results obtained 
for [GdL2]. Improved fluorescence signal and localisation in the mitochondria was 
anticipated due to the ring-opened form of the compound being dominant and its positively 
charged structure being well known to accumulate in this target organelle. As with the 
previous cellular study, localisation was analysed by co-localising with the commercially 
available cellular stain MitoTracker Green. 
 
 
Figure 2.38: (A-C) Confocal microscopy images of HEK cells. (A) MitoTracker Green signal 
(1.5 µM), (B) [GdL3] signal (2.5 mM), (C) merged signal. Scale bars: 15 µm. 
To assess the localisation, a human embryonic kidney (HEK293) cell line was 
investigated. This in vitro work was carried out by Dr. Pauline Chabosseau of the department 
of medicine at Imperial College (Hammersmith hospital campus). After preparation of the 
cells, the cell line was incubated with [GdL3] (2.5 mM) and MitoTracker Green (1.5 µM) for 
A B C 
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30 minutes and washed twice with KREBS buffer before acquisition. Globally, the probe 
showed good staining of the cells displaying excellent cell-permeability (Figure 2.38). Very 
good co-localisation with MitoTracker Green was observed confirming the probe to localise 
in the mitochondria. These results are much more conclusive than those obtained for [GdL2] 
and this must be a consequence of the cationic form of [GdL3] being better suited to 
accumulation in the mitochondria as observed in related rhodamine-based fluorophores used 
in cell imaging.96 Additionally, a much smaller amount of the probe was required to obtain 
satisfactory images (215 mM of [GdL2] vs. 2.5 mM [GdL3]) again demonstrating the 
improved fluorescence emission properties of [GdL3]. 
2.9 Conclusions 
A novel series of dual-modal MR/optical probes have been synthesised. Complexes of L1 
and L2, rhodamine-DO3A derivatives, behaved as pH sensitive probes displaying strong 
fluorescence at low pHs. Complexes of L3 behaved as ‘always on’ probes, being specifically 
designed to not be able to ring-close into their non-fluorescent forms by the addition of a 
methyl group to the secondary amide responsible for spirocyclisation in L1 and L2. 
Coordination of these ligands to gadolinium(III) gave paramagnetic compounds that 
successfully decreased the longitudinal relaxation time of water protons, whereas 
complexation with terbium(III) gave dual-luminescent probes that functioned on two different 
time scales. The photophysical data collected showed the impact of distance between the 
sensitiser (rhodamine) and the lanthanide metal centre on the efficiency of energy transfer. 
Europium(III) complexes were synthesised that displayed terbium emission as well as 
europium, and this gave some insight into the triplet state energy level of the spirolactam 
rhodamine antenna. 
Being water soluble, both [GdL2] and [GdL3] were viable for in vitro studies. As the 
rhodamine fragment in [GdL2] was pH sensitive, the probe was applied to targeting 
mitochondria in tumour cells. Colocalisation with MitoTracker Green demonstrated [GdL2]’s 
ability to enter cells (HEK 293 and primary mouse islet cells), with compartmentalisation 
believed to be in the mitochondria. Probe [GdL3] was no longer pH sensitive but its cationic 
structure meant that it would behave as a much better mitochondrial stain. This was 
confirmed by excellent co-localisation of the probe with MitoTracker Green when applied to 
HEK293 cells. [GdL2] was also evaluated as an MR probe for imaging of tumours in BALB/c 
nude mice bearing M21 xenografts. A 36.5 % decrease in T1 within the tumour was observed 
post injection. These in vitro and in vivo studies showed how [GdL2] behaved successfully as 
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a dual-modal probe displaying an off-on pH switch upon its preferential uptake within the 
more acidic microenvironment of tumour cells. 
These complexes were primarily designed to allow for the understanding of a solely dual-
modal, MR/optical probe. These systems are often complex enough on their own before 
further functionalities such as metal sensing moieties are included. Their synthesis and design 
were therefore very important in determining the mechanisms by which they behave in terms 
of relaxivity and fluorescence. From the outset, it seemed that these systems would be fairly 
simple yet upon detailed examination some interesting properties were discovered. Now that 
these systems are better understood they can be further functionalised to include zinc sensing 
moieties with the aim of selective sensing of intracellular zinc. 
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3.1 Introduction 
3.1.1 Biological importance of zinc 
After iron, zinc is the second most abundant transition metal ion in the body; the total 
mass of zinc in an average adult human is estimated at between 2 and 4 g.1 The majority of 
this zinc is chelated and protein bound playing an important role both catalytically and 
structurally. The remaining zinc (approximately 10%)2 serves as a ‘free pool’ for newly 
synthesised proteins or potential signalling functions.3 These free zinc pools exist in specific 
tissues such as the brain, intestine, pancreas and retina and it is thought that the presence of 
zinc is an essential factor in many biological processes such as brain function, immune 
function and reproduction4 as well as some pathological processes such as Alzheimer’s 
disease, diabetes and epilepsy.5 
3.1.1.1 Zinc and diabetes 
Diabetes mellitus is a disease characterised by high blood glucose concentrations as a 
consequence of decreased secretion or action of insulin. Insulin is stored in secretory vesicles 
in pancreatic β-cells as a solid hexamer bound with two Zn2+ ions per hexamer. During 
exocytosis the zinc-insulin complex dissolves and dissociates to release free zinc and insulin.6 
Destruction of pancreatic β-cells is one of the major immunological processes that cause the 
onset of diabetes and as such changes in the total mass and functional activity of β-cells have 
been adopted as indexes of the disease.7,8 The loss of β-cells and the underlying mechanisms 
of type 2 diabetes are less well established than for type 1 despite the fact that the former 
compromises approximately 90% of the cases of diabetes mellitus. Obesity is a significant 
risk factor for type 2 diabetes, which is increasing as a consequence of the Western lifestyle. 
This disease is expected to become an even greater health problem in the future (currently 
affecting >340 million individuals worldwide, projected to increase by ~100% by 2030)9 and 
there is currently an absence of robust approaches to track changes in β-cell mass in vivo. 
3.1.2 Coordination chemistry of zinc 
The fundamental properties of zinc are responsible for its multifaceted role in biology; its 
Lewis acidic nature is critical to its enzymatic activity10, its lack of ligand field stabilisation 
energy (LFSE) confers flexibility in its coordination geometry allowing for a variety of 
structural motifs11 and its kinetic lability of coordinated ligands means it can undergo ligand 
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exchange reactions relatively rapidly. These properties are a result of the closed d shell (d10) 
configuration of zinc. An important consequence of this closed shell configuration is that zinc 
is spectroscopically silent and thus difficult to detect. Despite this, zinc sensors constitute the 
largest family of chemosensors for transition metals, and this is owing to the growing 
evidence of zinc’s importance in biology, as well as the need to study and track zinc 
homeostasis and correlate variations in zinc levels with disease.12 
When designing or selecting a chemical probe for the detection of zinc, it is important to 
understand the metal ion’s chemical properties and hence its coordination preference. Simple 
factors such as ligand donor atoms can be considered, but since zinc is classified as a 
borderline Lewis acid it should tolerate both hard and soft Lewis bases. The Irving-Williams 
series13 shows the general stability sequence of high spin complexes of the divalent ions of 
first-row transition metals, with the stability constant for the formation of a complex 
following the order: 
 
Mn(II) < Fe(II) < Co(II) < Ni(II) < Cu(II) > Zn(II) 
 
This order is related to the decrease in ionic radii across the series leading to stronger 
metal to ligand bonds. To change this order of ligand binding preference, a ligand that only 
binds to a desired metal ion in a preferred geometry can often lead to greater selectivity. For 
example, copper(II) prefers to bind in a Jahn-Teller distorted or square planar geometry due to 
its LFSE being maximised. Zinc(II) on the other hand, having no LFSE due to its d10 
configuration, tetrahedrally arranges its ligands so as to minimise repulsion between donor 
groups.14 Finally, increased stability of the complex can be achieved by the coordination of 
two or more donor atoms from a single ligand to a central metal ion i.e. the chelate effect.  
Over the last fifteen years, research into contrast agents which respond to different 
concentrations of biologically relevant ions, such as Ca(II), Fe(II)/(III) and Zn(II) has become 
a key area of interest. The assessment and understanding of metal distribution in living 
systems has shed light on diseased states and their treatment.15 Although fluorescent 
chemosensors have been the most widely studied (especially for zinc) their use is limited to 
cell cultures, tissues near the skin surface or in vivo surface analysis.16 Imaging techniques 
that have no limitation on the depth of the sample to be examined are particularly beneficial 
for monitoring molecular events in human subjects.12 MRI is a technique that fulfils this 
requirement.  
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3.1.3 MRI zinc sensors 
Current clinically approved contrast agents are nonspecific. In order to create responsive 
contrast agents (often termed ‘smart’) the relaxivity has to be selectively influenced by the 
particular metal that one wishes to detect. The mechanism of relaxation behaviour has been 
discussed previously in chapter 1, but a few important factors that affect relaxivity will be 
reiterated here; they are: 
• Hydration number (q) i.e. the number of water molecules directly coordinated to 
the gadolinium centre; 
• The exchange rate of these water molecules with the surrounding bulk water (kex); 
• The reorientational correlation time (tumbling) of the probe (τR); 
• The residence lifetime of inner-sphere water molecules (τM). 
These inner-sphere relaxivity factors all contribute to the overall relaxivity value and in 
principle any of them could be modulated by the presence of a biomarker/metal.17 Some 
parameters however, are much more readily modified by interactions between a target metal 
cation with a gadolinium based probe, i.e. q and τR. At any magnetic field, the inner-sphere 
relaxivity is linearly proportional to the hydration number and so an increase in q will lead to 
an increase in r1. In general terms, the slower a probe tumbles in space the higher the 
relaxivity, and this can be affected by larger probe sizes and reduced flexibility. This effect 
however is strongly dependent on the magnetic field and attenuates at fields above ~4T. 
Common routes to detecting metal ions using MRI contrast agents are depicted in Figure 3.1. 
The first two MR-based zinc sensors were reported by Nagano’s group in 2001, both 
relying on a Gd-DTPA scaffold (Figure 3.2 (a)).18,19 Both probes rely on a change in q to alter 
r1 via method B in Figure 3.1. Their first iteration probe utilised two dipicolylamine (DPA) 
moieties for selective zinc binding.18 Upon addition of one equivalent of zinc a 33% decrease 
in relaxivity was observed (r1 = 6.06 to 3.98 mM-1s-1). However, when two equivalents of 
zinc were added, the relaxivity increased back up to its original value. This behaviour was 
explained by the cooperative binding of both DPA units to zinc in the presence of one 
equivalent, whilst when more than one was added, each DPA unit bound one Zn2+ and the 
gadolinium centre was no longer shielded, restoring the original relaxivity value. Issues arose 
from this behaviour, as the signals from 0.5 and 1.5 equivalents of added zinc were 
comparable. As such, a second iteration probe was designed in which two of the picolyl 
moieties were replaced with carboxylic acid groups.19 In this case, when one equivalent of 
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zinc was added, the relaxivity decreased from 4.8 to 3.4 mM-1s-1 and additional equivalents of 
zinc did not elicit a change in the final relaxivity value. 
 
Figure 3.1: MRI-based metal ion sensing via changes in q (A/B) or τR (C). 
Example of probes that function via mechanism A (Figure 3.1) are represented by two 
Gd-DO3A based contrast agents reported by Meade et al. (Figure 3.2 (b)) The first example, 
Gd-daa3, uses an iminodiacetate group for zinc binding which in the presence of one 
equivalent of zinc causes a 122% increase in relaxivity (r1 = 2.3 to 5.1 mM-1s-1). The zinc 
associated increase in relaxivity is attributed to an increase in q, and this was corroborated by 
luminescence lifetimes with Tb-daa3 and NMR spectroscopic experiments using a 13C-
labelled Eu-daa3 complex.20 A second iteration probe, Gd-apa3, containing one pyridine and 
one acetate arm for zinc binding, displays a 103% increase in relaxivity in response to the 
binding of zinc.21 Both sensors were found to be selective for zinc over other biologically 
relevant ions Na+, K+, Mg2+ and Ca2+. 
More recently, Gd-DOTA-diBPEN (Figure 3.2 (c)) was synthesised by De León-
Rodríguez et al. which displayed a modest increase in r1 in response to zinc in Tris buffer (r1 
= 5.0 to 6.0 mM-1s-1, a 20% increase).22 In the presence of human serum albumin (HSA) 
however, a much larger relaxivity response was observed upon addition of zinc (r1 = 6.6 to 
17.4 mM-1s-1, a 165% increase). This result was suggested to be a cause of longer τR value 
due to interaction with HSA. 
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Figure 3.2: Examples of some zinc-activated contrast agents. 
Finally, a dansyl-DO3A-trisamide (DO3ATA) gadolinium complex was synthesised 
within the Long group (Figure 3.2 (d)).23 Relaxivity studies showed insignificant changes in 
r1 in the presence of zinc (3.8 to 3.2 mM-1s-1). The initial relaxivity in the absence of zinc was 
unexpected as the coordinating ligands suggested that two water ligands should bind to the 
gadolinium centre (q = 2). The low value of 3.8 mM-1s-1 (more akin to values observed in q = 
1 complexes) was hypothesised to be a result of large steric hindrance derived from the dansyl 
and pyridine arms, thus blocking extra water ligands from binding to the lanthanide metal 
centre. Additionally, the three amide coordinating arms are thought to slow water exchange 
rates. In the presence of zinc, a small shift in emission wavelength of 10 nm from 500 to 490 
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nm and a 5% increase in intensity were observed. The probe displayed a high affinity for zinc 
but its fluorescence and water proton relaxation properties do not change significantly upon 
its binding.  
3.1.4 Dipicolylamine (DPA) zinc receptor 
The zinc binding selective chelate unit dipicolylamine (DPA) has been the most popular 
receptor for constructing zinc binding domains,24 having had particular success within the 
field of fluorescent zinc chemosensors.25 It is a derivative of N,N,N’,N’-tetrakis(2-
pyridylmethyl)-ethylenediamine (TPEN, Figure 3.3), a classic membrane-permeable zinc 
chelator that displays high selectivity for zinc over group one and two metal ions, which 
occur in much higher concentrations in biological samples. Increased zinc affinity, zinc 
complex formation rate and zinc complex stability can be achieved by addition of a fourth 
coordination site on DPA to give N,N-bis(2-pyridyl-methyl)ethylenediamine (BPEN, Figure 
3.3). These DPA derivative chelators show excellent selectivity for zinc over metal ions such 
as Ca2+, Mg2+, K+ and Na+ but display little or no selectivity over divalent ions of similar size 
and coordination chemistry, such as Cu2+. Serum copper concentrations however are 
relatively low in comparison to zinc.26 
 
Figure 3.3: Structures of zinc chelators DPA, BPEN and TPEN. 
3.2 Aims 
The aim of the research reported in this chapter was to firstly synthesise an MRI zinc 
sensor and study its response to zinc by both relaxometry and luminescence methods. The 
study of its europium(III) and terbium(III) analogues was hoped to aid in the understanding of 
the lanthanide complexes’ solution behaviour. Once a response mechanism had been 
understood, the probe was then to be functionalised with the rhodamine derivative applied in 
[LnL2] to produce a dual-modal MR/optical zinc sensor. Relaxometry and luminescence 
studies would inform on any changes arising from the inclusion of the organic chromophore. 
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Cellular studies were found to be viable for [LnL2] as a result of its cell-permeability and as 
such the novel dual-modal zinc sensor was expected to behave in a similar fashion. Cellular 
localisation was to be explored and compared to [LnL2]. 
In addition to criteria outlined in chapter 2 regarding the design and synthesis of MRI 
contrast agents, when developing imaging probes responsive to metal ions, one must keep in 
mind the following two points: 
• The probe must be responsive (either by MR or optical techniques, or both) to the 
metal ion of interest in the physiologically relevant concentration range; 
• It must show good selectivity for the metal ion. 
3.3 Mono-modal MR zinc sensor – [LnL4] 
As the DPA derivative BPEN is well known to have a high selectivity for Zn2+ ions over 
other biologically relevant metal ions such as Ca2+ or Mg2+, [LnL4] was developed as a zinc 
binding MR probe.27 The synthetic route is outlined in Scheme 3.1. 
 
Scheme 3.1: Synthesis of [LnL4]. 
3.3.1 Synthesis of L4 
Synthetically the first step was to prepare BPEN following a previously reported 
procedure involving a protection-derivatisation-deprotection method.28 BPEN was then 
coupled to chloroacetyl chloride in the presence of triethylamine to yield BPEN-
chloroacetamide, 12. Purification of 12 by alumina (I) chromatography (DCM:MeOH, 99:1) 
was necessary to remove chloroacetic acid that was not removed by liquid/liquid extraction 
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with DCM/water. The presence of this impurity was first detected in the 1H NMR spectrum 
where additional signals (with respect to signals expected for 12 alone) at 4.10 (singlet) and 
5.62 (broad singlet) were observed (Figure 3.4). Two additional signals were also observed in 
the 13C NMR spectrum at 42.1 and 170.6 ppm. 2D-NMR spectroscopy (HSQC) confirmed 
these signals from both the 1H and 13C NMR spectra to be associated with one another and 
literature research validated the presence of chloroacetic acid. 12 was then further reacted 
with tris-t-Bu-DO3A to yield the protected ligand prescursor, 13, as the potassium complex in 
moderate yields (~50%) after purification by alumina (I) chromatography (DCM:MeOH, 1-
10% MeOH). The elemental analysis results of this species revealed 13 to be a potassium 
complex (K2CO3 used as base) whilst ES+ mass spectrometry analysis shows only {M}+ ion at 
m/z 797 as the parent ion peak (i.e. loss of potassium ion). 
 
Figure 3.4: 1H NMR spectrum of 12 before purification on alumina column. Signals arising 
from chloroacetic acid marked with ! and residual solvent peaks marked with asterisks 
(CDCl3, 400 MHz ,298 K). 
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Figure 3.5: 1H NMR spectrum of L4 (D2O, 400 MHz, 298 K). 
Cleavage of the butyl groups using trifluoroacetic acid (TFA) in DCM for 24 h yielded 
the free ligand, L4 as a TFA adduct. The presence of TFA was confirmed by 13C{1H} NMR 
spectroscopy revealing quartets at 116.2 and 162.8 and then deduced quantitatively by 
elemental analysis. The 1H NMR spectrum confirmed that the tert-butyl groups had indeed 
been removed as evidenced by the disappearance of the signal at ~1.35 ppm. Broad signals 
were observed for the DO3A protons (both the cyclen and acetate arm protons) whereas sharp 
signals showing detailed coupling patterns were given by the protons residing on the pyridine 
moieties (Figure 3.5). 
3.3.2 Lanthanide complex formation [LnL4] 
L4 was coordinated to a series of lanthanide metal chloride salts (Ln3+ = Gd3+, Eu3+ and 
Tb3+) in an aqueous, mildly acidic environment (pH = 5.5). After 24 hours stirring at room 
temperature the complexes were purified. Purification was carried out using the same 
methods employed in the purification of [LnL2]. Absence of free lanthanide was checked 
with xylenol orange indicator at pH 5.8. The water-soluble complexes were obtained as pale 
beige solids in yields of ~10%. The low yields were attributed to the purification process used 
(Sephadex G-10 gel filtration), only fractions that tested negative to xylenol orange were 
collected.  
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Figure 3.6: Structure of [LnL4] complexes. 
Analytical HPLC was carried out to assess the purity of the complexes before purification 
on a Sephadex G-10 column. Only a single component was observed in the chromatogram 
when detecting at 254 nm (pyridyl absorbance) ([GdL4], Figure 3.7). The compound 
therefore, before further purification, was free of other pyridyl containing molecules (i.e. free 
ligand); only salts were needed to be removed, which was carried out using gel filtration 
methods (Sephadex G-10). 
 
Figure 3.7: HPLC trace (A:B 95:5 to 5:95 over 20 minutes) analysis confirmed the purity of 
[GdL4]. The chromatogram was obtained with detection in terms of absorbance at 254 nm. Rt 
at 12.5 min. 
3.4 Characterisation of [LnL4] 
3.4.1 NMR studies of [EuL4] 
The 1H NMR spectrum of [EuL4] was recorded to assess the ratio of SAP/TSAP isomers 
in solution (Figure 3.8). Similarly to [EuL2], the C1 symmetry of the complex leads to a large 
number of isomers in 1H spectrum, relative to more symmetrical C4-type complexes 
([Eu(DOTA)]-). The pseudo-axial ring protons (ax1) gave two sets of resonances well 
N N
Ln
O
N
O
O
O
N
H
N
O
O
O
N
N
N
[LnL4]
Ln3+ = Gd3+, Eu3+, Tb3+
 Chapter 3 
132 
separated from all other peaks. The peaks observed at higher frequency (31-33 ppm) 
corresponded to the four pseudo-axial ring protons for the SAP geometry. The peaks observed 
at lower frequency (11-13 ppm) were much well less defined and corresponded to the pseudo-
axial protons of the TSAP isomer. Integration of these resonances gave the isomer ratio 
SAP:TSAP of 1:0.14 (86% SAP isomer). This ratio is comparable to the ratio observed in the 
1H NMR of [Eu(DOTA)-].29 Assignment of the ring protons can be seen in Table 3.1. 
 
Figure 3.8: 1H NMR spectrum of [EuL4] showing the pseudo-axial protons of the SAP and 
TSAP isomers (400 MHz, D2O, 298 K). 
M (SAP) isomer [EuL4] (ppm) 
ax1 33.81, 33.08, 32.01, 31.85 
eq1 -0.39, -2.08, -0.50, -3.09 
ax2 -3.95, -10.82, -5.87, -11.51 
eq2 -5.93, -6.93, -7.68, -8.01 
ac -15.11, -16.59; -13.17, -15.44; -12.71, -15.45; 
-6.85, -8.49 
 
Table 3.1: 1H NMR peak assigments of [EuL4] (400 MHz, D2O, 298 K). 
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3.4.2 T1 relaxation studies of [GdL4] 
The gadolinium complex [GdL4] was investigated for its relaxometric properties. L4 is 
an eight coordinate ligand and so is expected to form a q = 1 complex when bound to 
gadolinium. In the absence of zinc, the relaxivity of [GdL4] was determined to be 4.97      
mM-1s-1, a value within range for a gadolinium chelate with hydration state of one. 
 
Figure 3.9: Structure of [GdL4]. 
3.4.2.1 Relaxivity vs. Zn2+ 
 
Figure 3.10: Water proton relaxivity of [GdL4] (400 MHz, 9.4 T, 25°C, pH 7.4, 5 mM) in the 
presence of increasing concentrations (0 to 5 eq) of zinc. Inset, hypothesised ordering second 
sphere of water.  
The relaxivity of [GdL4] was measured in 0.1 M HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) buffer at pH 7.4 in the presence of increasing zinc 
concentration (400 MHz, 9.4 T, 25°C). The relaxivity of the probe increased with addition of 
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zinc, increasing by approximately 10% and levelling at 5.39 mM-1s-1 at equivalents of one and 
above (Figure 3.10). This result is indicative of only one binding event occurring and thus one 
zinc bound species being formed in solution, the 1:1 [GdL4]:Zn2+. At high equivalents of 
zinc, i.e. > 3 a reduction in relaxivity observed and this is attributed to transmetallation of the 
Gd3+ complex with Zn2+. The small yet significant change in relaxivity upon introduction to 
zinc is hypothesised to be a consequence of the binding of the metal ion increasing second 
sphere water ordering, with possible hydrogen bonding to a solvated zinc to the outer sphere, 
as well as the increase in the overall mass of the molecule. 
3.4.2.2 Relaxivity vs. HSA 
 
 
 
 
 
 
 
Figure 3.11: Relaxivity titration of [GdL4] with HSA. 
Given that [GdL4] has two aromatic rings on the BPEN unit, a study of the possible 
interactions between the probe and human serum albumin (HSA) was undertaken. The 
affinity of hydrophobic compounds with HSA is a topic often studied in the field of MRI 
research since noncovalent binding of a probe to the abundant protein can control both 
relaxivity and pharmacokinetics.30 The relaxation rates of a series of solutions of [GdL4] with 
increasing concentrations of HSA were measured. The relaxation rate was found to rise 
slowly yet significantly with increasing HSA indicating weak binding (Figure 3.11). A similar 
trend was observed for the related compound GdDOTA-diBPEN (Figure 3.2, c).22 
Surprisingly, when 2 equivalents of zinc were added to GdDOTA-diBPEN prior to addition 
of HSA, strong binding was observed with an increase in relaxivity from 6.6 to 17.4 s-1mM-1. 
Unfortunately due to time constraints, further relaxivity investigations were not carried out to 
determine whether addition of zinc to [GdL4] prior to addition of HSA would increase the 
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binding affinity of the probe to the protein. The similarity between the compounds however 
would lead one to think that [GdL4] would show an improved response to HSA. The trend 
observed in the absence of zinc for [GdL4] is still significant; relaxivity increased from 5.03 
to 27.77 s-1mM-1 (9.4 T, 25°C), likely as a result of slower rotational correlation time (τR) for 
the complex when bound to the protein. 
3.4.3 Luminescence studies 
3.4.3.1 Photophysical properties of [GdL4] 
UV-vis spectroscopy can be used to study the binding of zinc to the BPEN unit; the 
pyridine groups give a characteristic absorption at λmax = 261 nm which can be monitored 
over the addition of metal ions.31 The UV-vis absorption spectra of [GdL4] were recorded in 
0.1 M HEPES buffered aqueous solution (pH 7.4) and are presented in Figure 3.12. The broad 
absorption band between 230 and 300 nm, typical of π-π* transitions centred on the pyridyl 
units, changed linearly with increasing concentrations of Zn2+ up to a 1:1 [GdL4]:Zn2+ molar 
ratio. Isosbestic points at 252 and 264 nm were observed indicating a smooth transition from 
the free compound to the zinc bound complex, and absorbance remained at a plateau with 
further increase of Zn2+. This result is in agreement with the relaxivity results, one inflection 
point in the titration profile of [GdL4] indicates the formation of only the 1:1 [GdL4]:Zn2+ in 
solution. The dissociation constant was determined from the titration profile (zinc 
concentration vs. absorbance at 256 nm) to be 55.7 µM (Figure 3.12). This dissociation 
constant shows that the probe has an appropriate zinc affinity for imaging zinc release in areas 
that contain a high level of the metal ion, such as in pancreatic β-cells32 and in pathological 
brain tissue.33 The effect of biologically relevant ions Mg2+, Ca2+, K+ and Cu2+ on the 
absorption profile was also examined (Figure 3.13). The addition of Mg2+, Ca2+ and K+ 
showed a negligible effect on the absorption spectra of [GdL4] (Kd(Ca) = 246 mM, Kd(Mg, K) 
= unfittable), whilst the addition of Cu2+ provoked a significant increase and shift of the 
absorption maxima toward shorter wavelengths. This result was expected, as it is known that 
DPA derivative chelators show little selectivity between metal ions of similar size and charge. 
As serum copper concentrations are relatively low in comparison to zinc however, this result 
becomes negligible for in vivo applications. Although a greater change in absorption was 
observed with Cu2+ compared to Zn2+, a comparison of dissociation constants (13.8 mM vs. 
55.7 µM) indicates a clear preferential binding for Zn2+ over other biological metal ions 
showing that the BPEN fragment is suitable as a Zn2+-specific chelator. 
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Figure 3.12: UV/vis spectra of [GdL4] (100 µM) in HEPES buffer (0.1 M, pH 7.4) in the 
presence of increasing concentrations of (0 to 3 eq.) of Zn2+. 
 
Figure 3.13: UV/vis spectra of [GdL4] (100 µM) in HEPES buffer (0.1 M, pH 7.4) in the 
presence of increasing concentrations of biologically relevant metal ions. 
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3.4.3.2 Photophysical properties of [EuL4] and [TbL4]. 
Phosphorescence emission spectra for complexes [EuL4] and [TbL4] were recorded (298 
K, H2O) following excitation at 262 nm. Representative spectra are shown in Figure 3.14 with 
their transitions assigned. For both complexes the absorption properties were typical of 
pyridyl containing species with the absorptions at 220 and 259 nm corresponding to the 1ππ* 
transitions.31 
The steady state visible phosphorescence spectrum of [EuL4] shows characteristic 
emission from the Eu3+ centre for the 5D0 " 7FJ (J = 1, 2, 3, 4) transitions. The 5D0 – 7F0 
transition was not observed. This transition is forbidden by electron selection rules but it is 
formally allowed in systems of certain symmetry groups, i.e. Cnv, Cn and Cs. For example, this 
transition was observed Bryden and Reilley in the [EuDOTA]- complex, displaying a very 
sharp, intense peak at 580 nm.34 For Eu3+ complexes in solution, the strongest emissions 
generally arise from 5D0 – 7F1,2 transition at 590 and 620 nm respectively, the relative 
intensities of which are highly sensitive to the ligand environment reflecting the 
hypersensitive nature of the 5D0 – 7F2 transition. A small peak at 540 nm is observed in the 
spectrum that is not consistent with europium emission. It is thought that a small amount of 
terbium is present in the sample therefore giving rise to this anomalous result.  
 
Figure 3.14: Phosphorescence excitation (.....) and emission (––) spectra of [EuL4] and [TbL4] 
(H2O, pH 7.4, 298 K). 
In the case of [TbL4] the steady state visible phosphorescence spectrum displays all 
emission peaks expected. The four intense bands observed arise from transitions from the 
[EuL4] [TbL4] 
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emissive 5D4 state to 7F6,5,4,3 levels of the ground state manifold. Immediately obvious are the 
higher intensities of the transitions compared to the europium emission spectrum. Emission is 
often much weaker for europium complexes compared to terbium complexes due to a 
competitive charge transfer mechanism of energy capture by the europium ion.35 
The effect of zinc binding to both [EuL4] and [TbL4] on their spectral forms and the 
fluorescence lifetimes was investigated by adding up to two equivalents of ZnCl2 to the 
solutions of the complexes. This was carried out to determine whether the pyridyl groups 
were coordinating to the lanthanide metal centres. As discussed previously, europium species 
display subtleties in the 5D0 " 7FJ (J = 0, 2, 3, 4) transitions with the 5D0 " 7F2 transition at 
616 nm demonstrating hypersensitivity and the 5D0 " 7F4 transition at 690 nm also being 
sensitive to changes in ligand environment. Experimentally, there was no significant change 
in the spectral forms of either complex. The intensities were seen to change but not 
consistently with the addition of zinc. This result indicates that the pyridyl groups do not 
coordinate to the lanthanide metal centres in the absence or in the presence of zinc. If one of 
the pyridyl groups had been coordinating, upon the addition of zinc a conformational change 
would occur whereby the pyridyl groups would coordinate to the transition metal over the 
lanthanide metal, which would in turn cause significant quenching in the intensity of most of 
the bands due to the increase in solvation of the europium and terbium centres. This was 
observed in a related europium complex by Pope and co-workers.31  
 
Figure 3.15: Phosphorescence emission spectra of [EuL4] and [TbL4] using λex = 260 and 
220 nm respectively (H2O, pH 7.4, 298 K). 
[EuL4] [TbL4] 
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 τ(H2O)/ms τ(D2O)/ms q 
[EuL4] 0.69 1.89 0.7 
[EuL4] + 0.5 eq. Zn2+ 0.71 1.85 0.6 
[EuL4] + 1 eq. Zn2+ 0.73 1.85 0.6 
[EuL4] + 2 eq. Zn2+ 0.74 1.77 0.6 
[TbL4] 1.84 3.02 0.7 
[TbL4] + 0.5 eq. Zn2+ 1.84 2.73 0.5 
[TbL4] + 1 eq. Zn2+ 1.87 2.75 0.5 
[TbL4] + 2 eq. Zn2+ 1.84 2.80 0.6 
 
Table 3.2: Luminescence lifetimes (τ) and inner sphere hydration numbers (q) for the free 
complexes and after addition of zinc (λem = 616 nm for Eu(III),  λem = 545 nm for Tb(III), 100 
µM, pH 7, 298 K). 
Time-resolved luminescence data, shown in Table 3.2, was also obtained for the [EuL4] 
and [TbL4] complexes in deuterated and non-deuterated aqueous environments, in the 
presence and absence of zinc. Typically, the lifetimes were of millisecond order as expected 
for these luminescent lanthanide complexes, [TbL4] showing longer lifetimes due to it being 
less readily quenched by O-H oscillators as a result of a less prominent Frank Condon 
overlap.36 From the lifetime analysis the application of the Horrocks equation for europium 
and terbium allowed an approximation of the degree of solvation at the lanthanide (q). For the 
free probes q = 0.7, and as it is well known that the equation frequently yields non-integer q 
values with a certain degree of inaccuracy, this q value was assumed to indicate the presence 
of one bound water molecule.37 This corroborated the relaxivity results of the [GdL4]. The 
form of the decays in both deuterated and non-deuterated water did not change significantly in 
the presence of zinc. A slight lowering of q is observed, which could result from the increased 
rigidity of the zinc bound complex perhaps hindering water access to the lanthanide metal 
centre. This reduction of q however is not mirrored in the relaxivity values of [GdL4] in the 
presence of zinc, and this is attributed to the slowing of rotational tumbling due to a slightly 
larger mass. 
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3.5 Dual-modal MR/optical zinc sensor – [GdL5] 
As the response mechanism of [GdL4] had been explored, [GdL5] was designed and 
synthesised as a dual-modal MR/optical zinc sensor. This involved functionalisation with the 
rhodamine derivative applied in [LnL2]. 
 
 
Scheme 3.2: Synthesis of [GdL5] 
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3.5.1 Synthesis of L5 
The non-trivial synthesis of L5 began with the conjugation of rhodamine derivative 5 
(Scheme 3.2) to 1,7-bis-tert-butyl-DO2A. DO2A itself is a hexadentate ligand that has 
received particular attention in the field of radiopharmaceuticals with coordination to PET 
active elements such as 68Ga.38 Examples can also be found in the field of MRI as seen in the 
works of Toth et al. with their crown ether appended gadolinium complexes and Angelovski 
et al.’s biotinylated contrast agents.39,40 It is synthesised by regioselective acylation of cyclen 
with benzyl chloroformate followed by alkylation with tert-butyl bromoacetate and 
hydrogenolysis.41 This cyclen derivative is invaluable in the synthesis of bifunctional chelates 
of the type described here as the two functionalities, i.e. fluorophore and zinc chelator, can be 
conjugated to the lanthanide chelate in a step-wise fashion. 
Figure 3.16: 1H NMR spectrum of 14 (400 MHz, CDCl3, 298 K). 
L5 was obtained using the synthetic route outlined in Scheme 3.2, and it commenced with 
the preparation of the two side arms 5 and 12, the syntheses of which were described earlier. 
This multi-step synthesis involved 12 steps in total, the first 6 steps being previously reported 
methods. The key reaction of the synthesis of L5 was the selective mono-alkylation of bis-
tert-butyl DO2A with the rhodamine derivative 5 to obtain the tris-alkylated cyclen derivative 
14, which was achieved under high dilution in acetonitrile, using potassium carbonate. 
Purification was carried out using alumina (I) chromatography (DCM:MeOH, 1-3% MeOH) 
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resulting in appreciable yields of ~55%. Purity was confirmed by 1H and 13C NMR 
spectroscopy, high-resolution electrospray mass spectrometry and elemental analysis. The 
proton spectrum (Figure 3.16) displayed sharp and well-defined signals for the rhodamine 
fragment as well as broad resonances for the cyclen based protons (δ 2.40, 2.56, 2.72, 2.79 
ppm), as is observed tri-alkylated cyclen derivatives.42 Mono-alkylation was confirmed by 
analysis of the proton integrations. Finally, the ring-closed nature of the compound was 
confirmed by the resonance at 64.90 ppm in the 13C NMR spectrum (quaternary spirolactam 
carbon).   
 
Figure 3.17: 1H NMR spectrum of 15 and close up of aromatic region with all signals from 
both rhodamine and BPEN moieties assigned (400 MHz, CDCl3, 298 K). 
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The final alkylation of 14 was achieved using the BPEN derivative 12 under similar 
conditions as the previous alkylation, acetonitrile in the presence of potassium carbonate. 
Purification using alumina (I) chromatography gave 15 in a 34% yield at best but often lower 
yields were obtained. It must be noted that this compound was extremely difficult to purify 
and that multiple columns were commonly used to purify the same sample resulting in very 
low yields. Once purified, the pale brown solid was fully characterised by 1H and 13C NMR 
spectroscopy and high-resolution mass spectrometry. All signals resulting from the aromatic 
protons were sharp and well defined, and were assigned with the help of 2D COSY 
(correlation spectroscopy) and HSQC (heteronuclear single quantum coherence) experiments 
(Figure 3.17). Sharp resonances were also observed for the BPEN methylene (NCH2Py), tert-
butyl and rhodamine ethylene protons whilst a large range of broad resonances was observed 
for the remaining methylene protons (δ 2.14 – 3.39 ppm). This broadness is characteristic of a 
tetra-substituted cyclen derivative and is a result of increased restrain in the internal motion of 
the molecule. A resonance at 65.6 ppm in the 13C NMR spectrum confirmed the ring-closed 
form of the compound. 
 
Figure 3.18: 1H NMR spectra of 15 (above) and L5 (below) showing how the aromatic 
resonances shifted after deprotection. Inset is the structure of L5 (400 MHz, CDCl3, 298 K). 
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The free ligand L5 was obtained using standard tert-butyl cleavage deprotection 
conditions (TFA:DCM, 50:50, v/v). L5 was isolated as a bright pink, highly hygroscopic TFA 
adduct. The presence of TFA was confirmed by 13C NMR spectroscopy revealing quartets at 
119 and 162.7 ppm. The successful cleavage was evidenced by the loss of signals arising 
from the tert-butyl protons at 1.28 ppm in the 1H NMR spectrum and the ring-opened nature 
was confirmed by the loss of signal in the alkyl region of the carbon spectrum (~65 ppm). In 
comparison to the 1H NMR spectrum of 15, the aromatic resonances are not as well defined 
yet a full assignment was achieved using 2D COSY and HSQC experiments. Significant 
downfield shifts were observed for protons 1-3 and B-D (Figure 3.18). Such shifts have been 
observed in other compounds in the presence of trifluoroacetic acid.43,44 They were attributed 
to hydrogen bonding between the acid and oxygen- and nitrogen-containing substituent 
groups. 
3.5.2 Gadolinium complex formation [GdL5] 
L5 was coordinated to the gadolinium chloride salt in an aqueous, mildly acidic 
environment (pH = 5.5). Upon reaching this pH a pale brown precipitate formed. After 24 
hours stirring at 60°C the resulting precipitate was filtered and dried to give [GdL5] as a pale 
brown powder in ~30% yield. Using a water:methanol (50:50) solvent mixture the absence of 
free lanthanide metal was confirmed by xylenol orange indicator. Product formation was 
confirmed by high resolution electrospray mass spectrometry. 
Figure 3.19: Structure of [GdL5]. 
Unfortunately, due to difficulty in purification of compound 15 and thus very low product 
yields, insufficient amounts of L5 were synthesised to allow for complexation to the 
luminescent lanthanides europium and terbium. These complexes would have given insight 
into the conformational properties of probe [GdL5] through NMR and luminescence studies. 
The data obtained for complexes [LnL2] and [LnL4] could shed insight on the resulting 
properties of the merged dual-modal zinc sensor [GdL5]. 
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3.6 Characterisation of [GdL5] 
3.6.1 T1 relaxation studies 
The lack of water solubility of [GdL5] meant that relaxivity experiments had to be carried 
out in a methanol:water (HEPES buffer), 50:50 solvent mixture. T1 measurements were 
performed at 400 MHz (9.4 T, 25°C) and the r1 value of [GdL5] was assessed over a range of 
zinc concentrations (Figure 3.20).  
 
Figure 3.20: Water proton relaxivity of [GdL5] (400 MHz, 298 K, pH 7.4, 5mM) in the 
presence of increasing concentrations (0 to 5 eq.) of zinc. 
The observed relaxation rate in the absence of zinc was 2.94 mM-1s-1. Of the complexes 
studied so far, one would expect a higher relaxivity value as [GdL5] is a larger molecule and 
so should experience slower rotational tumbling in solution. Unlike the previous complexes 
however, there is increased steric bulk around the gadolinium centre in [GdL5] which could 
prevent access from the surrounding water molecules. Additionally, the presence of two 
coordinating amides could reduce the water exchange rate. Complex charge has previously 
been thought to be a factor, with positively charged systems displaying much slower water 
exchange than negatively charged systems.45 Aime et al. have however reported differences in 
water exchange rates between the SAP and TSAP isomers of identically charged lanthanide 
tetraamide complexes.29 The water exchange of the TSAP isomer was reported to be 50 times 
faster. If [GdL5] is predominantly in the SAP isomer as both [GdL2] and [GdL4] were, then 
this could also be contributing to the observed reduction in relaxivity of the complex. 
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In the presence of zinc the relaxivity value of [GdL5] was seen to increase to a maximum 
of 3.88 mM-1s-1. It is unfortunate that this increase does not even surpass the relaxivity value 
of [GdL4] in the absence of zinc (4.97 mM-1s-1), but it clearly displays an improved response 
to the transition metal (31% increase in r1) when compared to the relaxivity response of 
[GdL4] (10% increase). This increase is most probably attributed to the increased molecular 
weight of the molecule and thus a slowing of the rotational tumbling rate, as well as an 
increase in the second sphere water ordering as was discussed for [GdL4]. 
3.6.2 Luminescence studies 
3.6.2.1 Photophysical properties of [GdL5] 
The UV-vis absorption spectra of [GdL5] were monitored upon addition of zinc as well as 
the biologically relevant cations copper, magnesium and calcium. In comparison to [GdL4] 
metal binding processes at the pyridyl moieties could no longer be directly followed by UV-
vis spectroscopy as the absorption bands of the rhodamine fluorophore from 220 to 340 nm 
dominated the spectra obscuring the characteristic pyridyl absorptions. This was similarly 
observed in the fluorescence spectra. Very weak, broad fluorescence emission bands can 
sometimes be observed from pyridine containing compounds (1ππ* state, 325 nm) and 
addition of zinc can cause an increase in the emission intensity.46 This was not observed the 
fluorescence spectra of [GdL5] as again, the rhodamine fluorophore fluorescence dominated. 
 
Figure 3.21: (Left) Representative UV-vis spectrum of [GdL5] which did not change 
upon zinc addition. (Right) Fluorescence emission spectra of [GdL5] upon increasing 
concentrations of zinc (0 to 10 eq., λex = 260 nm, MeOH, pH 7.4). 
Eq. Zn2+ 
 Chapter 3 
147 
3.6.2.2 [GdL5] pH titration 
To determine whether [GdL5] could function as a dual-modal agent, the fluorescence 
properties of the rhodamine fluorophore were studied. Characteristic rhodamine emission was 
observed at 580 nm when an excitation wavelength of 560 nm was applied. At pH 7.4 the 
emission intensity was very weak resulting from the spirolactam form being the dominant 
species, as was observed for [GdL2]. Under acidic conditions however, the rhodamine 
fragment ring-opened to regenerate the strong fluorescence emission at λ = 580 nm (Scheme 
3.3). 
 
Scheme 3.3: pH-mediated ring opening of the intramolecular spirolactam of [GdL5] to give a 
highly fluorescent species. 
The pH titration seen in Figure 3.22 was performed by monitoring emission between 330 
and 700 nm upon decreasing of pH using an excitation wavelength of 260 nm. At high pH 
only fluorescence from the spirolactam form of [GdL5] was observed, centred at 370 nm. As 
the pH was lowered, emission intensity at 580 nm gradually increased reaching a maximum at 
the lowest pH used for this titration, 2.21. This then allowed for a titration curve to be plotted 
using the ratio of fluorescence emission at 580 nm to fluorescence emission at 370 nm vs. pH. 
The sigmoidal curve was fitted to yield a pKa of 4.25. This value is slightly lower than that 
calculated for [GdL2] (pKa = 5.11).  
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Figure 3.22: Fluorescence spectra of [GdL5] showing an increase in rhodamine fluorescence 
at λ = 580 nm upon lowering of pH (λex = 260 nm, 100 µM, MeOH:water, 50:50). Inset: ratio 
of emission intensity at λ = 580 nm over λ = 377 nm vs. pH.  
3.7 Intracellular localisation 
3.7.1 In vitro studies 
Efficient cell penetration is key for the use of imaging probes to investigate free levels of 
biological zinc. Zinc-responsive luminescence imaging of [GdL5] was carried out by 
Matthew Nicholas alongside Linsay Malcolm, Dr. Cordula Kemp and Dr. Graeme Stasiuk at 
The University of Hull. A human ovarian carcinoma cell line (A2780) was investigated 
through confocal luminescence and fluorescence microscopy.  
Firstly, an initial co-localisation experiment was carried out whereby the probe was 
compared to other well known stains such as DAPI (4’,6-diamidino-2-phenylindole, nuclear 
stain), concanavalin a fluorescein (membrane stain). This involved the incubation of A2780 
cells with 20 µM [GdL5] in PBS buffer for 20 min at 37 °C, followed by incubation with the 
DAPI, and then the fluorescein dyes. The images obtained (Figure 3.25) demonstrated a 
positive result in that there was no co-localisation of the dyes and the probe meaning that 
[GdL5] does not localise in either the nucleus or the membrane. The red staining of the cells 
with [GdL5] is thought to be localised in the cytosol. The cells were then incubated with zinc 
 Chapter 3 
149 
to study whether the probe’s localisation changed. Upon addition of zinc the [GdL5] dye was 
found to move more towards the edge of the cells indicating the possibility of movement to 
the vesicles within the cells (Figure 3.23 (B)). The changes were however rather insignificant 
and as such it was difficult to confirm whether the addition of zinc did indeed alter the 
localisation behaviour. Positively however, the probe did not seem to be localising in the 
mitochondria as [GdL2] did, making [GdL5] more useful as fluorescent zinc sensing probe. 
 
Figure 3.23: Fluorescence microscopy co-localisation of A2780 cells with [GdL5] (red), 
DAPI (blue) and fluorescein (green), (A) without zinc, (B) with incubation of zinc. The size 
bar is equal to 20 µm. 
The next cellular imaging experiment used confocal microscopy to view co-localisation 
of A2780 cells at a higher magnification (Figure 3.24). This allowed for a more accurate 
identification of where [GdL5] localised within the cell. Again, the images show that the 
probe does not bind to the cell membrane or the nucleus, however the images do not confirm 
that the probe resides in the cytosol. Instead, the image shows the probe to be seemingly 
rejected from the cell through exocytosis via vesicles.47 This was thought to be a result of the 
incubation period; in this experiment an incubation period of 5 hours was used whereas an 
incubation period of 1 hour was used previously in the microscopy experiments. An argument 
against probe rejection was however suggested: as vesicles are made up of the cell membrane 
the outer part of the vesicle should have been stained with fluorescein.47 This was not fully 
evident and so it was thought that the morphology of the A2780 cells was perhaps different 
from that expected. The cells are assumed spherical in shape but there is evidence to suggest 
that what is being seen in the images is actually a result of a different cell morphology, one 
that would possible be mistaken as rejection of the probe from the cell.48 Further testing was 
A B 
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suggested to conclude on this issue as it was possible that there was simply not enough dye 
present within the membrane to show in the image and make the vesicles clearly discernible. 
  
Figure 3.24: Co-localisation confocal images of A2780 cells, [GdL5] = red, fluorescein = 
green. The size bar is equal to 20 µm. 
Finally, an experiment was undertaken to incubate the A2780 cells with both [GdL5] and 
the mitochondrial stain, MitoTracker Green. The image displayed in Figure 3.25 shows the 
probe to not be localising in the mitochondria, confirming the original co-localisation results 
in Figure 3.23. As with the preceding experiments further experiments are required to fully 
confirm and verify the results but from first assessment it seems that the probe remains within 
the cytosol of cell. 
 
Figure 3.25: Co-localisation of [GdL5] and MitoTracker Green in an A2780 cell. [GdL5] = 
red, fluorescein = green. The size bar is equal to 20 µm. 
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To summarise, the in vitro cellular experiments the probe was shown to successfully enter 
cells. It was demonstrated that the probe does not bind to the membrane, mitochondria or the 
nucleus, and remains in the cytosol. The affect of zinc within the cell was not fully 
understood and requires further experimentation for elucidation. 
3.8 Conclusions 
Two first generation MR active zinc selective probes, one of which is dual-modal, based 
on the cyclen motif have been synthesised. [GdL4] was developed in order to probe the 
effectiveness of the zinc-chelating moiety BPEN (Kd(Zn) = 256 nM vs. Kd(Ca) = 246 mM), 
determining whether it was selective enough for zinc to be continued with the the synthesis of 
a dual-modal analogue. An increase in relaxation rate with increased zinc concentration was 
observed (10% increase) along with high selectivity over a range of biologically relevant 
cations. [GdL5] was then designed to behave as a dual-modal zinc sensing probe by 
combining the BPEN zinc chelator with the rhodamine fluorophore both conjugated to a 
central bis-t-Bu-DO2A moiety. The probe showed an improved relaxivity response to zinc 
(2.94 to 3.88 mM-1s-1, a 31% increase) although the values themselves were lower than 
anticipated. The rhodamine fluorophore was shown to give no response to the presence of 
zinc, but did however display a strong increase in fluorescence upon lowering of pH as 
observed for the lanthanide complexes of L1 and L2. To note, the design and synthesis of 
[GdL3] was carried out at a much later date than that of [GdL5]. In hindsight, it would have 
been better to use the ‘always on’ rhodamine derivative used in [GdL3] as the fluorophore in 
[GdL5] as although the probe would still not show a fluorescence response to zinc, a greater 
fluorescence signal would be observed which would be better suited to cellular imaging 
applications. Although [GdL5] was not fully water soluble and mostly in the spirolactam form 
(small percentage in ring-opened form due to equilibrium state), in vitro experiments were 
successfully carried out that determined the intracellular localisation to be in the cytosol. This 
meant that the addition of the BPEN moiety on going from [GdL2] to [GdL5] altered the 
localisation behaviour such that the probe should perform as a better cellular zinc sensing 
probe by not localising in the mitochondria. Although it is evident that [GdL5] is not an ideal 
zinc sensing probe in terms of its poor relaxation rates and poor fluorescence response, its 
synthesis was not futile as important aspects concerning the design of a probe have been 
better understood. These results have aided greatly in the design of next iteration compounds 
discussed in the following chapter. 
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4.1 Introduction 
The fluorescent detection of metal ions represents a field of chemistry that continues to 
expand, with applications ranging from analytical to biomedical. Due to its simplicity, 
fluorescence is an extremely powerful tool and thanks to readily available instrumentation and 
ease of use it has become one of the most versatile modalities available.1 Analytically, 
fluorescence techniques are very popular due to their high sensitivity and selectivity, and 
when an analyte is fluorescent, such as aromatic hydrocarbons, selected proteins, chlorophylls 
etc., direct fluorometric detection can be achieved. However, the majority of ions and 
molecules of interest are not fluorescent and thus require carefully designed fluorescent 
chemosensors (containing a receptor linked to a fluorophore) that translates a recognition 
event into a fluorescence signal.2 In the biomedical arena, the non-invasive visualisation of 
analytes in live samples requires even greater careful design to ensure high selectivity for a 
specific analyte in such a dynamic, diverse environment. 
Metals play key roles in all forms of life, and although they contribute a much smaller 
proportion to the human body elemental composition compared to carbon, nitrogen, hydrogen 
and oxygen, their presence is absolutely vital. Group I and II metals (i.e. sodium, potassium, 
calcium and magnesium) represent the most abundant metals in biological organisms and they 
aid in the storing of potential energy, osmotic regulation and signalling.3 The transition metals 
(copper, manganese, cobalt, nickel, molybdenum, tungsten, chromium and vanadium) are 
often referred to as trace elements as when compared to the group I and II metals, they are 
present at much lower levels. The transition metals zinc and iron however are found in 
substantial amounts. 
There are an extremely large number of fluorescent sensors designed to detect transition 
metals found in biological systems. As mentioned previously, fluorescent sensors for metals 
contain two features which are essential for their function: a metal binding moiety and at least 
one fluorophore. The binding of the metal analyte must induce a change in the electronic or 
molecular structure of the sensor for it to function as a chemosensor. 
4.1.1 Fluorescent chemosensors for zinc 
As discussed in chapter three, zinc’s biological significance has lead to its intense study 
and its involvement in various diseases means that it is becoming increasingly important to 
determine free zinc pool levels and how they affect biological processes. Due to its d10 
electronic configuration, zinc is a spectroscopically silent transition metal. This has lead to the 
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design and synthesis of a large number of zinc chemosensors, a field which has been 
reviewed many times.4,5,6 There are a number of ways in which metal binding can alter a 
fluorescence signal, the most applied in zinc chemosensors being photoinduced electron 
transfer (PeT), internal charge transfer (ICT) and spirocyclisation:7,8 
 
• Chemosensors that use a PeT mechanism usually consist of a fluorophore that is 
connected to a metal chelator via a spacer containing a non-bonding electron pair 
(usually nitrogen) (Figure 4.1 (1)). An electron from the HOMO of this electron rich 
heteroatom is transferred to the ‘hole’ left in the HOMO of the excited fluorophore 
and thus fluorescence is quenched. When the electron pair is bound by coordination to 
zinc, the HOMO of the chelator becomes lower in energy than that of the fluorophore 
and thus fluorescence is restored. 
• The ICT mechanism involves a fluorophore that is directly connected to a metal 
chelator (most commonly an amino group) to form a π-electron conjugated system 
that contains both electron rich and electron poor terminals (Figure 4.1 (2)). ICT from 
the electron rich donor to the acceptor results in a change of the dipole moment and 
thus a change in the Stokes’ shift. When the chelator acts as the electron donor, 
binding to zinc will cause a reduction in its electron donating ability resulting in a blue 
shift of the emission. A red shift is observed when the chelator acts as the acceptor. 
• Xanthene dyes such as rhodamine and fluorescein can be derivatised to form 
spirolactams or spirolactones. These spirocyclic forms are colourless and non-
fluorescent due to separation of the π-conjugation of the original fluorophore.9 Ring 
opening by zinc can give rise to strong fluorescence emission and colour by retrieving 
the large π-conjugated system (Figure 4.1 (3)). Rhodamine derivatives display a red 
colour change by activation of a carbonyl group in a spirolactam or spirolactone 
moiety. The precise modulation of the equilibrium between the two forms of the 
fluorophore represents an ideal strategy for chemosensing of zinc. 
 
As can be deduced from the many reviews on the subject of fluorescent zinc sensors 
there are a multitude of probes that report on zinc levels via fluorescence changes. For this 
work only the probes that function via the spirocyclisation method will be considered. 
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Figure 4.1: Fluorescence mechanisms of PET zinc sensors (1), ICT zinc sensors (2), and 
rhodamine based zinc sensors that utilise the spirocyclisation mechanism (3). 
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4.1.1.1 Rhodamine based fluorescent zinc sensors 
Fluorescence probes based on rhodamine spirolactams were pioneered by Czarnik et al. 
in 1997 when he reported the first example of a probe of this type as a Cu2+ fluorescent 
sensor.10 Since then, there has been a surge of reports of similar probes used for sensing 
applications, mainly for metal ions but also for oxidative species and glutathione.11 Despite 
the numerous reports of metal sensing spirolactam derivatives, only a handful have been 
reported that were developed specifically for sensing zinc. Mashraqui et al. reported the first 
example of these in 2009 (Figure 4.2 (e)).12 Rhodamine 6G was functionalised with 2-
picolylamine to give the final compound. The probe could detect micromolar concentrations 
of zinc displaying a change in absorption maximum from 302 to 528 nm, and was shown to 
be selective for zinc over other competitive ions. There properties however were investigated 
only in organic solvents and no information regarding applicability for cell imaging was 
discussed. 
The next probe developed utilised both spirocyclisation and FRET fluorescence 
mechanisms to report on zinc levels by conjugating rhodamine B thiohydrazone to fluorescein 
(Figure 4.2 (a)).13 When bound to zinc via the sulphur and nitrogen atoms in the rhodamine 
moiety and the oxygen atom in the fluorescein moiety the thiospirolactam was ring opened. 
This form of the rhodamine was then able to act as the energy acceptor for the FRET system 
with fluorescein being excited at 490 nm to give emission at 520 nm, and rhodamine 
absorption (560 nm) matching well with this emission. This ratiometric probe showed high 
selectivity for zinc and a reversible response as well as a large wavelength shift (~ 105 nm) 
between the donor excitation peak and the acceptor emission peak. 
Other reports include an asymmetric rhodamine 6G/110 derivative incorporating an 
iminodiacetic acid chelator by Nagano et al.14 (Figure 4.2 (f)), a 4-N,N-
diethylaminosalicylaldehyde hydrazone rhodamine derivative by Li et al.15 (Figure 4.2 (b)), 
and a rhodamine 6G, N-(2-hydroxyethyl)ethylenediamine condensate synthesised by 
Sivaraman et al. (Figure 4.2 (g)).16 
The remaining two reports on zinc sensing probes based on the spirocyclic ring opening 
of rhodamine dyes are the most relevant to this work as they both contain the dipicolylamine 
zinc chelator. The first was reported in 2005 by Yoon et al. as a fluorescence sensor for lead 
ions (Figure 4.2 (d)).17 Although not primarily a zinc sensor, the probe was found to respond 
to zinc at a quarter of the emission intensity observed for lead. When tested against various  
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Figure 4.2: Structures of rhodamine derivative zinc sensors as represented in their respective 
literature reports: (a)13, (e)12, (f)14 and (d)17 in the ring opened form when bound to zinc, (b)15, 
(c)18 and (g)16 in their spirolactam forms. 
 
other mono- and divalent cations, no other increase in emission intensities (at 580 nm) was 
observed. Finally, Lippard et al. reported a rhodamine B, 2-[bis(2-pyridyl-
methyl)aminomethyl]aniline conjugate that displayed a ~220 fold increase in fluorescence 
quantum yield upon binding zinc (Figure 4.2 (c)).19 It displayed excellent selectivity against 
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other cations, including copper and cadmium, cations that are often difficult to distinguish 
from zinc.  
Rhodamines in their spirolactam forms have neither absorbance nor fluorescence in the 
visible region. When applied to cellular imaging therefore, improved signal-to-noise ratio can 
be achieved with ring-opening by cellular zinc when compared to other fluorescence 
mechanisms. Their application to zinc sensing has been relatively unexplored as noted by the 
few reports. These reports do however, show how powerful the spirocyclisation technique can 
be for the sensing of this metal cation. 
4.1.2 Dual-modal MR/optical zinc sensors 
The development of dual-modal MR/optical zinc sensing probes is a relatively new area 
of research and even less examples than rhodamine based fluorescent zinc sensors can be 
found in the literature. MRI for the detection of biomarkers as a single modality is 
challenging as the local concentration of contrast agent is unknown and the sensitivity of the 
technique is relatively low compared to other modalities.20 Incorporation of a fluorescent 
moiety to an MRI probe offers a potentially powerful approach for the quantitative integration 
of molecular processes on a cellular level, since the modality of optical imaging boasts 
excellent sensitivity.21 
Figure 4.3: Examples of dual-modal MRI/optical zinc sensors.22,23,24,25 
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In 2012, Luo et al. reported the synthesis of an 8-sulfonamidoquinoline-DOTA conjugate 
that upon zinc binding (0.5 equivalent) displayed a 55% enhancement in relaxivity (r1 = 3.8 to 
5.9 mM-1s-1) and a 7-fold enhancement increase in fluorescence intensity (Figure 4.3 (a)).22 At 
a stoichiometry of 1:1, the dianionic 8-sulfonamidoquinoline unit acted as a terdentate ligand 
resulting in a red-shift in fluorescence to 520 nm due to increased π conjugation. A slight 
lowering of r1 to 5.2 mM-1s-1 was observed. The overall increase in relaxivity was attributed 
to the increased molecular weight of the zinc complexes and improved molecular rigidity. 
This report is one of the only prominent examples of a probe of this type. 
Other related works include Nagano et al.’s DTPA quinoline DPA conjugate23 (Figure 4.3 
(b)) and Pope’s DOTA aminoquinoline/anthraquinone DPA conjugates (Figure 4.3 (c)).24 
These works however focus on the luminescent lanthanide europium complexes to form dual-
luminescent complexes. Nagano et al.’s probe was coordinated to paramagnetic gadolinium 
but relaxivity studies in the absence and in the presence of zinc showed similar values (r1 = 
6.05 and 5.81 mM-1s-1 respectively). 
A dual-modal zinc sensing probe was developed and reported within the Long research 
group. The second generation probe was designed whereby the fluorescent zinc sensor 8-
aminoquinoline was conjugated to DO3A (Figure 4.3 (d)).25 The probe displayed similar 
relaxivity properties as that observed with Luo et al.’s probe; the presence of 0.5 equivalents 
in zinc gives the largest r1 value (4.2 to 6.6 mM-1s-1) as a result of a ‘metallostar’ compound 
forming, where two gadolinium complexes coordinate to one zinc moiety. An increase in zinc 
concentration leads to a decrease in r1 to 4.9 mM-1s-1 corresponding to the 1:1 complex. The 
probe displayed ratiometric fluorescence changes with a large Stokes shift from λem = 410 nm 
to λem = 500 nm upon zinc binding. In vitro and in vivo studies showed the probe to 
efficiently accumulate in the secretory granules of β-cell derived lines and to reduce T1 in the 
pancreas. This was the first reported example of a dual-modal ratiometric zinc sensor. 
4.2 Aims 
The aim of the work in this chapter was to synthesise a dual-modal MR/optical zinc 
sensor. This probe would differ from [LnL5] in that zinc binding would induce both a turn on 
in fluorescence as well as an increase in relaxivity. The probe would still be based on the 
three components used previously, i.e. rhodamine fluorophore, cyclen based lanthanide 
chelator and BPEN based zinc chelator, the novelty being how these components are 
conjugated to each other to give the desired properties. Relaxometry and luminescence studies 
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would inform on the ability of this probe to function as a cellular zinc sensing agent. Cellular 
localisation was to be explored and compared to previously synthesised probes. 
4.3 Fluorescent zinc sensor – 16 
4.3.1 Synthesis of 16 
A fluorescent zinc sensor was first synthesised using compounds already applied in this 
work, the rhodamine derivative 2 and the zinc chelator BPEN (Scheme 4.1). Nucleophilic 
aliphatic substitution of the brominated rhodamine derivative with BPEN in the presence of 
triethylamine and refluxing overnight gave 16 in ~ 20 % yield. Purification was achieved 
using silica gel chromatography (DCM:MeOH, 99.5:0.5 to DCM:MeOH:NEt3, 94:5:1) to give 
a pale brown solid. The low yield was attributed to the difficulty in separation on the column. 
Alumina chromatography was attempted but no separation could be achieved. On repeating 
this synthesis in the future, a Boc-protected BPEN would be used to avoid possible side 
reactions such as disubstitution of the amine. It is thought that the Boc-protected version of 16 
would also be easier to purify by column chromatography as no secondary amines would be 
present in the molecule (which gives rise to streaking). Removing the Boc protecting group 
using trifluoroacetic acid would give quantitative yields of 16 and so even though an extra 
synthetic step had been introduced a much higher yield would perhaps be achieved.  
 
Scheme 4.1: Synthesis of fluorescent zinc sensor 16. 
 
Mono substitution was confirmed by high-resolution electrospray mass spectrometry as 
well as analysis of the proton integrations on the 1H NMR spectrum (Figure 4.4). A broad 
singlet centred at 1.72 ppm was identified as the secondary amide proton. All proton and 
carbon nuclei were assigned using COSY and HSQC 2D NMR spectra. An additional 
ROESY NMR experiment was required to accurately assign the ethylene protons (Figure 4.5). 
ROESY NMR experiments are useful for determining which signals arise from protons that 
are close to each other in space even if they are not bonded, yielding through-space 
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Figure 4.4: 1H NMR spectrum of 16 (400 MHz, CDCl3, 298 K). 
 
Figure 4.5: ROESY NMR spectrum of 16. Highlighted are the cross peaks associated with 
the ethylene protons. Inset, structure of 16 with ethylene protons assigned (400 MHz, CDCl3, 
298 K). 
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correlations via spin-spin relaxation. A cross peak was expected as a result of correlation 
between the methylene protons of the dipicolylamine moiety at 4.03 ppm and a methylene 
group on one of the ethyl chains. This methylene group was found to be at 3.08 ppm. Two 
cross peaks were also observed for the ethylene protons closest to the xanthene ring protons at 
6.53 ppm. Using all these correlations alongside the COSY spectrum data, the ethylene 
protons were successfully assigned. Finally, the ring-closed form of the compound was 
confirmed by the resonance at 66.26 ppm in the 13C NMR spectrum. 
4.3.2 Coordination of zinc to 16 
Scheme 4.2: Synthesis of 16.Zn. 
An NMR scale reaction was set up to study the effect of zinc binding on the structure of 
16 in solution. To 16 in a methanolic solution was added one equivalent of zinc as its chloride 
salt upon which the solution turned instantly from colourless to bright pink. The fluorescence 
was also observed to change from a blue/green to a bright orange. The sample tube was then 
stirred using a vortex stirrer for 5 minutes. The structure of 16.Zn seen in Scheme 4.2 shows 
how 16 is expected to coordinate to the zinc ion. It is in accordance with similar complexes 
discussed earlier whereby the oxygen atom is directly involved with coordination (Figure 
4.2). Figure 4.6 shows the 1H NMR spectra of 16 before and after addition of ZnCl2. 
Significant changes in the NMR spectrum of 16 were observed upon addition of ZnCl2 
(Figure 4.6). Firstly, broadening and downfield shifts of the majority of the pyridine protons 
reflected the presence of a zinc coordination compound. Proton D of the pyridine protons 
displayed broadening and an upfield shift upon coordination. This was also observed in a 
europium complex bearing two dipicolylamine moieties synthesized by Meade et al.26 The 
aromatic rhodamine protons displayed only small downfield shifts. Broadening and downfield 
shifts were also observed for the methylene protons of both ethyl linkers (protons 7, 8, G, F). 
The most significant changes were found for the methylene protons of the dipicolylamine 
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Figure 4.6: 1H NMR spectra of 16 before (above) and after (below) addition of ZnCl2. Inset, 
colour and fluorescence changes upon addition of zinc (400 MHz, CDCl3, 298 K). 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Methylene region of the variable temperature 1H NMR spectra of 16.Zn (400 
MHz, CDCl3). 
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moiety (protons E). A sharp singlet at 3.99 ppm was transformed into what appeared to be a 
broad doublet at 4.52 ppm on coordination to zinc. Additional variable temperature NMR 
experiments were carried out to further investigate this feature (Figure 4.7). At low 
temperature (~ 0 °C), the two pyridine rings are inequivalent and each methylene proton is 
coupled to its diastereotopic partner to give the doublets observed. Coalescence occurs at high 
temperatures (~ 40 °C) and the averaged signals can be seen at ~60 °C. Diastereotopic 
methylene protons, as observed in 16.Zn, have been previously reported for dipicolylamine 
(DPA) complexes.27,28 This splitting pattern is confirmation of metal binding at the dpa site. 
At lower temperatures the sharp doublet splitting pattern is lost and it is hypothesised to be a 
solvent effect. To verify this, the NMR experiment would have to be repeated using a solvent 
with differing properties i.e. DCM, a non-hydrogen bonding solvent.  
Analysis of the 13C NMR spectrum of 16.Zn shows the disappearance of the quaternary 
carbon signal at 66 ppm. Although the distinct colour change observed upon synthesis of this 
complex is evidence enough of the ring-opened form of the rhodamine fluorophore, the lack 
of this quaternary carbon signal further corroborates this structure.  
Finally, mass spectrometry data was used to characterise the zinc complex and confirm 
that complexation had taken place. A comparison of the observed profile to the calculated 
isotopic distribution of complex 16.Zn (Figure 4.8) was found to be in good agreement, 
indicating complexation had occurred. 
 
Figure 4.8: Calculate (left) and observed (right), accurate mass spectral data for 16.Zn. 
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Needles of 16.Zn were obtained by both vapor diffusion and liquid/liquid diffusion. 
Unfortunately, no crystals were found suitable for analysis by X-ray crystallography. This 
structural insight would have been invaluable in confirming the how 16 coordinated to zinc. 
16 was synthesised in order to determine whether, as predicted, it could successfully bind 
zinc and intramolecularly ring open to give a fluorescent molecule. The selectivity of 16 to 
zinc in comparison to other biologically relevant cations was unfortunately unexplored due to 
time constraints, but its similarity to other rhodamine-dpa conjugates would lead one to 
believe that the probe would show high selectivity. The experiments carried out and discussed 
above show the probe to be successful in sensing zinc; addition of metal cation results in an 
instantaneous ring-opening reaction that switches on fluorescence emission at 580 nm. 
4.4 Dual-modal MR/optical zinc sensor – [GdL6] 
As the fluorescence response of 16 in the presence of zinc had been explored, [GdL6] was 
designed and synthesised as a dual-modal MR/optical zinc sensor. This involved the 
incorporation of the fluorescent zinc sensor 16 with a gadolinium chelate. Four synthetic 
methodologies were attempted for the synthesis of [GdL6], three being unsuccessful. They 
are outlined and described below. 
 
Figure 4.9: Structure of [GdL6]. 
4.4.1 Synthetic strategy 1 
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fluorescent zinc probe was thought to be impractical. Only yields of up to 300 mg were 
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gadolinium chelate which could be directly conjugated to 16, an OH functionalized DOTA-
monoamide (Scheme 4.3). 
Compound 18, a DO3A derivative bearing a free alcohol functionality was prepared using 
an adapted procedure reported by Cravotto et al.29 Ethanolamine was reacted with 
chloroacetyl chloride in water at pH 10 to prevent ester formation. A large quantity of 17 was 
isolated as a viscous colourless oil in 70 % yield. Tris-t-Bu-DO3A free base was then further 
alkylated with 17 in the presence of triethylamine to give 18 in 45 % yield. The literature 
reported procedure called for purification on a XAD 1600 chromatographic column but it was 
found that this was not necessary as the differences in solubilities between the starting 
materials and the product could be used to successfully purify 18. Firstly, after removing the 
reaction solvent, the residue was dissolved in DCM and washed with water. This removed 
any residual 17 and triethylamine. The organic layer was then reduced to a small volume and 
diethyl ether added to precipitate unreacted tris-t-Bu-DO3A. The filtrate was then evaporated 
to dryness to give a fluffy white solid which when analysed by 1H NMR spectroscopy and 
mass spectrometry matched the data reported in the literature method. The unreacted tris-t-
Bu-DO3A was of satisfactory purity to be used again.  
 
Scheme 4.3: Synthetic strategy 1. 
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The final reaction needed to synthesise a DO3A derivative that could be conjugated to 16 
involved the conversion of the free alcohol into a suitable leaving group thus enabling the 
substitution reaction. There are several methods to choose from, the most popular two being 
conversion of the alcohol into an alkyl chloride using thionyl chloride or into a sulfonic ester 
using para-toluene sulfonyl chloride to give a tosylate. Both methods are routinely used and 
consequently a large number or reports can be found detailing reaction conditions. The 
tosylation reaction was attempted using standard reaction conditions such as pyridine base 
and addition of para-toluene sulfonyl chloride at 0°C. This reaction was attempted three 
times, once at reflux and for all attempts analysis of the reaction mixture by TLC showed a 
new spot on both silica and alumina plates. Purification by both alumina and silica 
chromatography gave fractions that by NMR appeared to be product 20 as evidenced by the 
distinctive aromatic doublets of the tosyl group integrating well with the tert-butyl groups of 
the DO3A. Analysis of these fractions by mass spectrometry however only showed peaks for 
the starting material 18 at m/z 616 (product m/z = 770). It is possible that the tosyl moiety was 
simply very easily removed in the mass spectrometry experiment, but due to having only a 
small amount of 16 to use in the subsequent conjugation reaction, a test reaction with ‘20’ 
was not carried out. Attempts at chlorination using thionyl chloride were even less successful, 
analysis of the resulting products of these reactions by 1H NMR spectroscopy were messy and 
evidence of starting material 18 was lacking in mass spectrometry spectra. 
As the tosylation reaction was the most promising in terms of converting the alcohol into 
a suitable leaving group, many more reactions using alternate reaction conditions could have 
been carried out. Owing to time constraints however this synthetic strategy was relinquished. 
4.4.2 Synthetic strategy 2 
This second synthetic strategy involved the synthesis of another gadolinium chelate that 
could be conjugated to 16, an NH2 functionalised DOTA monoamide (Scheme 4.4). 
Compound 25 was prepared following an adapted procedure again from previously reported 
literature by Cravotto et al.29 N-Boc ethylenediamine was converted to the orthogonally di-
protected amine 21 using benzyl chloroformate and triethylamine. Having these orthogonal 
protecting groups allowed for selective removal of each group when required. Illustratively, 
cleavage of the tert-butyloxycarbonyl (Boc) group was achieved using trifluoroacetic acid to 
give 22 in quantitative yields without removal of the benzyloxy carbamate (Cbz) group.  
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Scheme 4.4: Synthetic strategy 2. 
22 was then converted to the chloroacetamide derivative 23 using chloroacetyl chloride in 
the presence of triethylamine. As no alcohol was present in this molecule there was no need to 
use a high pH aqueous solution as used for the synthesis of 17. Compounds 21 to 23 were 
prepared in high yields (greater than 90%) and on large scale. Compound 23 was then used 
for the N-alkylation of tris-t-Bu-DO3A. After purification using silica gel chromatography 
small yields of 24 were acquired, but as the N-alkylation reaction could be carried out on a 
large scale thanks to the success of previous reactions, an appreciable quantity of 24 was 
obtained that did not prohibit further reactions. After alkylation, the Cbz protecting group was 
removed by hydrogenation. The removal of this protecting group is commonly carried out 
under standard conditions of vigorous stirring of a methanolic solution in the presence of 
Pd/C catalyst, such as that used for the synthesis of bis-t-Bu-DO2A reported in chapter three. 
When carried out under these conditions, the cleavage of 24 was unsuccessful even after 48 
hours and under 1 bar hydrogen pressure. Further analysis of the literature revealed that 
ultrasound conditions were used. Indeed, cleavage of 24 was achieved using sonochemical 
conditions after only 2 hours. The final synthetic step was to convert 24 into a 
chloroacetamide derivative, 25, for conjugation to the secondary amine of 16. The reaction 
was carried out using conditions routinely used but unfortunately the synthesis of 26 was 
unsuccessful. Analysis by 1H NMR spectroscopy showed the reaction may have been 
successful as an additional signal that was expected as a sharp singlet at ~ 4 ppm was present. 
The rest of the spectrum was not definitive of change as all the methylene protons gave a very 
broad set of signals from 2.1 – 3.5 ppm, as seen in many DOTA derivatives, and the tert-butyl 
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groups gave a sharp singlet at 1.5 ppm that was of course unchanged. Mass spectrometry 
analysis however confirmed the failure of the reaction as no molecular ion peak was observed 
(m/z = 690). An ion peak was not observed for the starting material (m/z = 614); the major ion 
peak was found at m/z 755. The structure of this reaction product could not be interpreted 
from these analyses alone but due to time restrictions, no further analysis was carried out. 
4.4.3 Synthetic strategy 3 
 
Scheme 4.5: Synthetic strategy 3. 
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reported for this compound (Scheme 4.5), but surprisingly, only one method proved 
successful.  
Method one involved the slow addition of chloroacetyl chloride in chloroform and 
potassium carbonate in water to a stirred solution of ethylenediamine in chloroform.30 After 
four hours stirring at room temperature the organic layer was separated and purified to give 
the desired bisacetamide. Upon reproducing this reaction, a white, extremely viscous solid 
was formed upon addition of the reagents to the ethylenediamine solution. The organic layer 
was treated as specified in the reported procedure to give ~60 mg of 27 (theoretical yield was 
4.7 g). An attempt at washing the viscous solid was made using aqueous base and acid and 
then an extraction into DCM was attempted. Again, no product was found in the organic 
layer. Finally, the solid mass was dissolved in hot sodium hydroxide and extraction with 
chloroform was attempted, which was again unsuccessful. 
For method two, the literature experimental instructed the dropwise addition of the 
diamine to a solution of methyl chloroacetate at room temperature, followed by 10 hour 
agitation.31 Further examination of the reported method revealed that good yields were only 
obtained by setting a suitable temperature (<10 °C), using vigorous stirring for a reduced time 
(6 hr vs. 10 hr) and using an optimal reactant ratio (2.4 eq. of methyl chloroformate to 
diamine). Following these improved methods, ~0.5 g of a white precipitate was isolated from 
the reaction mixture (theoretical yield = 3.15 g). Unfortunately, analysis by 1H NMR 
spectroscopy and electrospray mass spectrometry informed that this isolated solid was not the 
desired bisacetamide.  
The third method was not a literature procedure but one that has been used extensively in 
this work, for example in the synthesis of 5, 10 and 12. Similar to the other methods it 
involved the dropwise addition of ethylenediamine to chloroacetyl chloride in 
dichloromethane (at 0 °C) , using triethylamine as base. Salt formation occurred during the 
course of the reaction indicating it was working, however the solution continued to turn 
darker until a black solution was obtained after 2 hours. As with previous reactions of this 
type, the salts and DCM were removed and the residue was loaded on an alumina(II) column. 
The resulting fractions did not contain the desired product. 
Finally, a procedure by Kankare et al. was followed which instructed the addition of 
chloroacetyl chloride (in diethyl ether) to a solution of ethylenediamine and potassium 
carbonate in diethyl ether (at 0 °C).32 After stirring at room temperature overnight water was 
added and the resulting mixture was filtered. 27 was isolated as a white solid in 55 % yield 
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(4.6 g). Both the proton NMR spectrum and the electrospray mass spectrum agreed with the 
reported method.  
One would consider 27 to be a fairly simple molecule, one that would be easily 
synthesised. It was surprising that several literature methods failed, but perhaps precise 
conditions and reagent ratios were vital so as to prevent the possible formation of polymeric 
compounds. The bisacetamide compound itself is unexpectedly extremely insoluble in most 
solvents, only being soluble in DMSO and hot methanol. This perhaps had an impact on the 
failure of the subsequent reactions. 
The conjugation of 27 to tris-t-Bu-DO3A was then attempted. Using potassium carbonate 
as base (as used throughout this work for the alkylation of the DOTA derivative ) the reagents 
were refluxed in methanol overnight. After removal of the solid base and solvent, a white 
fluffy solid was obtained which was reminiscent of other DO3A based compounds 
synthesised in this work. Proton NMR spectroscopy of this crude product confirmed the need 
for further purification. This was attempted using both silica and alumina(II) chromatography 
but with no success. Fractions of the silica column produced ~140 mg of sample that looked 
promising by proton NMR spectroscopy, but analysis by mass spectrometry exposed the 
sample not to be the desired compound, 28. An m/z value of 917 was observed for the 
molecular ion peak, a value which is too large for the value expected for 28 (m/z 691) and too 
small for the dimer that may have formed (m/z 1169). 
As 28 was proving difficult to synthesise, the conjugation of 27 to 16 was next attempted. 
It was thought that 29 may be easier to purify using chromatography methods because of its 
coloured nature. The conjugation was carried out following similar reaction conditions and 
reagents used by Pope et al. in the conjugation of bischloroacetamides to pre-formed cyclen 
units.33 The reaction was monitored by thin layer chromatography (DCM:MeOH, 9:1). After 
24 h reflux, a number of new spots were observed in the TLC plate that ran higher than all 
other reagents. These spots were pink indicating the compounds contained the rhodamine 
derivative. Silica gel chromatography (DCM:MeOH, 0-30 % MeOH) resulted in the 
separation of five fraction composites that matched the TLC plate of the crude sample. 
Unfortunately, none of these fractions contained the desired product and in fact, a large 
proportion of the crude residue could not be removed from the column (~80%). All of 16 that 
was synthesised was used in this reaction and so no repeat reactions could be carried out. 
As 27 proved very difficult to work with in terms of its synthesis and solubility, this 
synthetic strategy was not continued with or reattempted. 
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4.4.4 Synthetic strategy 4 – synthesis of L6 
 
Scheme 4.6: Synthetic strategy 4. 
This final synthetic strategy was used to successfully synthesise L6 in a 6-step process 
(Scheme 4.6). The first step involved the conjugation of the zinc-sensing moiety BPEN to 2-
(Boc-amino)ethyl bromide (to later act as a bridging unit). Nucleophilic aliphatic substitution 
of the halide using potassium carbonate as base and purification on silica gel 
(MeOH:NEt3:DCM, 1:1:100) gave 30 in 36% yield. A significant amount of the di-substituted 
product was also synthesised which explains the fairly low yield of 30. These two products 
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were however very easily separated by column chromatography, with the di-substituted 
product eluting very quickly, closely followed by 30. If the reaction were to be repeated, Boc-
protected BPEN would be used to prevent the formation of the di-substituted product. 
Next, the rhodamine derivative 2 was introduced. It was covalently attached to 30 
following reflux in the presence of potassium iodide and triethylamine base. The reaction was 
followed by TLC, and after 48 h the reaction mixture was purified using silica gel 
chromatography (MeOH:DCM, graduated solvent system). The desired compound eluted 
when a 5:95 MeOH:DCM solvent system was used and was isolated as a light brown solid in 
22% yield. Again, this was a low yield and longer reaction times could perhaps have been 
used, since a significant amount of the rhodamine starting material 2 was recovered after 
column chromatography.  
31 was fully characterised by 1H and 13C NMR spectroscopy as well as electrospray mass 
spectrometry. Interestingly, in the proton NMR spectrum some resonances appeared sharp 
(rhodamine ethyl arms, pyridine) while others were broad (all methylene protons). This 
spectral line broadening is believed to be a result of the reduced tumbling rates of the 
molecule, caused by the tethering of three moieties around a central tertiary nitrogen. All  
 
 
Figure 4.10: 1H NMR spectrum of 31 with all signals assigned (400 MHz, CDCl3, 298 K). 
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signals in the proton NMR spectrum (Figure 4.10) were assigned with the help of 2D COSY 
and HSQC spectra as well as spectra of related compounds synthesised in this work . 
The Boc protecting group of 31 was then removed using trifluoroacetic acid to give 32 
followed by acylation with chloroacetyl chloride to give 33. Both these reactions were carried 
out in 2 hours each with minimal purification required (water wash only) and were high 
yielding (>80 %). The signals of the methylene protons in the NMR spectra were more 
defined resulting from the loss of the bulky Boc group. 
Tris-t-Bu-DO3A free base was then alkylated with 33 using potassium carbonate as base. 
The reaction was followed by TLC, and after 48 hours reflux, purified. Chromatography 
using alumina(I) was attempted but the product mixture eluted too rapidly. It was therefore 
purified by silica gel chromatography (MeOH;DCM, graduated solvent system). Pure product 
was found to elute when 10% MeOH was used in the solvent system, and was isolated as a 
brown solid in 26% yield. Again, this yield was low, but this can partly be attributed to the 
fact that this was a novel reaction and the purification methods were untested. If this reaction 
were to be repeated, as well as the previous low yielding reactions in this synthetic strategy, it 
is predicted that higher yields could be achieved by improved purification methods. 
 
Figure 4.11: 1H NMR spectrum of 34 with protons assigned (tris-t-Bu-DO3A protons not 
assigned) (400 MHz, CDCl3, 298 K). 
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The protons in 34 were fully assigned using 1H (Figure 4.11), 13C and 2D NMR 
experiments and the structure was confirmed by high resolution electrospray mass 
spectrometry. Interestingly, the methylene protons of the ethyl chains reverted to broad 
resonances as observed in the proton spectrum of 31. This indicates that the tumbling rate of 
the molecule in solution has reduced compared to 32 and 33. This could have positive 
consequences on the relaxivity properties of the gadolinium complex. To note, all compounds 
31-34 were confirmed to be in the ring-closed form as corroborated by the resonance signal at 
~ 65 ppm in their 13C NMR spectra. 
The free ligand L6 was obtained in quantitative yields by cleavage of the tert-butyl 
groups on the DO3A fragment using trifluoroacetic acid (TFA;DCM, 50:50). L6 was isolated 
as a bright pink, highly hygroscopic TFA adduct. As with all the rhodamine derivative ligands 
synthesised in this work, the ring-opened form was confirmed by loss of signal (~65 ppm) in 
the carbon spectrum. 
4.4.5 Lanthanide complex formation [LnL6] 
L6 was coordinated to the paramagnetic gadolinium and the luminescent europium (in 
their chloride hexahydrate forms) in an aqueous, mildly acidic environment (pH = 5.5). Upon 
reaching this pH a pale brown precipitate formed. After 24 hours stirring at 60°C the resulting 
precipitate was filtered. The filtrate was basified to precipitate any unreacted lanthanide but 
before reaching the pH at which this occurs, a large quantity of pale brown precipitate 
formed. Electrospray mass spectrometry confirmed the two precipitates to be the desired 
complexes ([GdL6] and [EuL6]). Although the complexes precipitated from their aqueous 
complexation solvent, they displayed a much greater solubility in water compared to [LnL1] 
requiring only 1% MeOH to become soluble. This therefore meant that further studies of the 
complexes were not greatly prohibited. The complexes were obtained as pale beige solids in 
yields of ~20%. 
 
 
Figure 4.12: Structure of [LnL6]. 
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4.5 Characterisation of [LnL6] 
4.5.1 NMR studies of [EuL6] 
The 1H NMR spectrum of [EuL6] was recorded to assess the ratio of SAP/TSAP isomers 
in solution (Figure 4.13). Compared to the spectra observed for the europium complexes of 
L2 and L4, the spectrum of [EuL6] is much simpler. The only discernible signals arise from 
the SAP isomer with the characteristic resonances at low field (35 – 40 ppm) resulting from 
the SAP pseudo-axial protons. No real signals could be observed for the TSAP isomer and as 
such no isomer ratio could be determined (i.e. ~100 % SAP isomer). It is noted that the 
spectrum is broader than those obtained for [EuL2] and [EuL4] and this could be a result of 
the decreased rotational tumbling of the molecule, as noticed in the 1H NMR spectra of 31 
and 34. The 1H NMR spectrum of [EuL6] was reassessed after the addition of one equivalent 
of zinc chloride. Addition of the transition metal only resulted in the broadening of the whole 
spectrum, with no new resonances found in the TSAP pseudo-axial proton region between 12 
and 15 ppm. This confirms that no change in structure between SAP and TSAP occurred. 
 
Figure 4.13: 1H NMR spectrum of [EuL6], highlighting the pseudo-axial protons of the SAP 
isomer (400 MHz, MeOD, 298 K). 
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4.5.2 T1 relaxation studies of [GdL6] 
The paramagnetic gadolinium complex [GdL6] was investigated for its relaxometric 
properties. The result of this measurement would lend insight into whether the pyridine 
moieties played any part in coordination to the gadolinium metal centre; if they did, a low 
relaxivity would be expected, if not a relaxivity similar to other q = 1 complexes would be 
anticipated. In the absence of zinc, the relaxivity of [GdL6] was determined to be 4.99       
mM-1s-1. As well as being in the correct range for a complex of hydration state one, and thus 
inferring that the pyridine moieties do not coordinate to the lanthanide, this value is larger 
than that observed for [GdL2] (3.8 mM-1s-1) and [GdL5] (2.94 mM-1s-1). This is thought to be 
a consequence of both the increased mass of the complex compared to the two previous 
complexes and of the tethering approach used for the synthesis of [GdL6]. As observed in the 
proton NMR spectra of L6 precursors, a reduction in the tumbling rate of the molecule caused 
the signals of the methylene protons to broaden. This phenomenon could also lead to an 
increase in the water proton relaxivity.34 
 
Figure 4.14: Structure of [GdL6]. 
4.5.2.1 Relaxivity vs. Zn2+ 
The relaxivity of [GdL6] in the presence of increasing concentrations of zinc was then 
measured (Figure 4.15). The water proton relaxivity was found to increase with the addition 
of zinc, with an approximate increase of 50 % and leveling at ~ 7 mM-1s-1. This is a much 
improved response compared to previous zinc sensing MR probes synthesised in this work; 
[GdL4] (10% increase), [GdL5] (31% increase).  
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Figure 4.15: Relaxivity titration of [GdL6] with increasing concentrations of zinc (0-5 eq) 
(400 MHz, 9.4 T, 298 K, pH 7.4, 5 mM). 
Although the trend observed in Figure 4.15 is not as definitive as that seen for [GdL4] 
and [GdL5], it is still hypothesised that only one single binding event is occurring, i.e. one 
zinc bound species being formed. An increase in relaxivity at 0.5 equivalents of zinc followed 
by a reduction at 1 equivalent would indicate the formation of 2:1 complex:Zn species as seen 
in some zinc responsive MR probes.25,22 It was hoped that a pyridine moiety would bind to the 
gadolinium centre, thus forming a q = 0 complex, then in the presence of zinc the pyridine 
would preferentially bind to zinc resulting in an open coordination space on the gadolinium 
for a water molecule. This would have resulted in an ‘off-on’ MR probe which is a highly 
desirable response as greater contrast between unbound and zinc bound species can be 
determined. Nevertheless, an increase of 50% in relaxivity in the presence of zinc is a 
significant response and is a great improvement on the responses observed in the zinc sensing 
probes previously synthesised in this work. 
Unfortunately, due to the small quantity of [GdL6] produced (~ 15 mg), further relaxivity 
measurements could not be acquired. A titration with HSA would have been carried out to 
compare with the titrations previously performed on [GdL2,3,4]. All those complexes 
displayed an increase in relaxivity in the presence of the protein, it is expected therefore that 
[GdL6] would follow a similar trend. 
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4.5.2.2 NMRD profiles for [GdL6] 
In a similar fashion to that of [GdL2], NMRD profiles were carried out however the 
measurements were additionally performed in the absence or the presence of zinc. They were 
measured at three temperatures, 32°C, 37°C and 42°C, in the proton Larmor frequency range 
0.01-10 MHz, corresponding to 0.00023 and 0.24 T (Figure 4.16). 
The shapes of the NMRD plots in the absence of zinc were very similar to those observed 
for [GdL2], a plateau at low field (0.01 – 0.1 MHz) followed by a decrease in r1 until ~ 2 
MHz and then a pronounced increase back up to the original r1 value. As discussed in chapter 
2, this NMRD plot shape is hypothesised to be a result of the formation of micelles as 
observed in other gadolinium chelates incorporating large aromatic substituents.35 As 
remarked previously, further NMRD experiments at different concentrations would need to be 
carried out to test this hypothesis. 
Figure 4.16: NMRD profile of [GdL6] at 32°C (circle), 37°C (triangle) and 42°C (square); 
left in the absence of zinc, right in the presence of 1 eq. of zinc (1.5 mM, H2O, pH 7.4). 
When zinc is introduced to the system, the NMRD profiles change significantly. As well 
as the relaxivity values being slightly higher than the zinc free probe, the relaxivity values at 
higher fields (> 1 MHz) decrease dramatically. This trend is more in accordance with what is 
expected of small molecule gadolinium species.36 This could mean that upon binding to zinc a 
change in structure of the probe prohibits the formation of micelles as observed in [GdL2], 
and the zinc free probe [GdL6]. These experiments would of course have to be repeated with 
data points up to 100 MHz to fully realise this trend, and also at different concentrations as 
for [GdL2]. 
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4.5.3 Luminescence studies 
4.5.3.1 Photophysical properties of [GdL6] 
[GdL6] in the absence of zinc is in the ring-closed form, and this is evidenced by its 
colour (pale brown) and the characteristic carbon signal in the 13C NMR spectrum. In the 
absence of zinc however, a low level of fluorescence emission is observed at λ = 580 nm, 
emission which is typical of the ring-opened form. Although the majority of [GdL6] is in its 
non-fluorescent spirolactam form, a small proportion of the probe exists in the ring-opened 
form; in protic solvents rhodamine derivatives exist as an equilibrium mixture between the 
colourless lactam and the coloured ring-opened structure.37 As the majority of the probe exists 
in the spirocyclic form, fluorescence emission at ~ 500 nm is observed as seen in the related 
rhodamine compounds of this work. A 3D EEM plot was generated to compare to the result 
for [GdL2] and is seen in Figure 4.17. The plots showed that [GdL6] in its ring-closed form 
emits at two different wavelengths, λ = 480 and 520 nm when excited at λ = 380 and 325 nm 
respectively. This is very similar to that observed for [GdL1] and [GdL2].  
 
Figure 4.17: 3D (left) and contour (right) plots of excitation-emission matrix spectra (EEMs) 
of [GdL6] (MeOH, 100 µM, 298 K). 
The absorption and fluorescence properties of [GdL6] were then studied to determine 
whether the probe displayed a fluorescence response in the presence of zinc. According to the 
preliminary results of coordination of 16 with zinc, an increase in fluorescence of [GdL6] at λ 
= 580 nm was anticipated. The fluorescence emission spectra of [GdL6] were recorded in 
HEPES buffered aqueous solution (pH 7.4) and are presented in Figure 4.18. As zinc is 
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introduced to the system, the fluorescence reaches its maximum intensity (~ 3 fold) when 0.5 
equivalents are added. Upon further addition of zinc, the fluorescence intensity plateaus to 
around 2.3 fold the intensity of the fluorescence in the absence of the transition metal. This 
result was mirrored in the UV absorption zinc titration. The two-step emission spectral 
change suggests the formation of two types of zinc bound species, which are dependent on the 
amount of zinc added. This is in contrast to the conclusions derived from the relaxivity 
titration. As fluorescence spectroscopy is a more sensitive technique than NMR/relaxivity 
methods, the fluorescence titration result must be considered more accurate.  
 
Figure 4.18: Fluorescence emission spectra of [GdL6] in the presence of increasing 
concentrations (0 to 5 eq) of zinc (100 µM, aqueous HEPES buffer 0.1 M, pH 7.4); inset, 
emission intensity at λ = 580 nm vs. eq. zinc. 
A structural elucidation of the zinc-enhanced fluorescence is proposed in Figure 4.19, 
showing formation of a heterotrinuclear (metallostar) array [GdL6]2.Zn in the presence of up 
to 0.5 equivalents of zinc, as well as the heterobinuclear array [GdL6].Zn when more than 0.5 
equivalents of zinc are present. The structure of [GdL6].Zn is proposed based on many 
examples of rhodamine derivatives that sense metal cations via ring-opening of the  
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Figure 4.19: Proposed binding mechanism of [GdL6] to zinc. 
spirolactam, such as the related rhodamine-dpa conjugate synthesised by Yoon et al.17 The 
structure of [GdL6]2.Zn however is less defined. There are no literature examples of a bis-
rhodamine zinc complex of this sort and so crystallographic data would be required to shed 
more light on structural detail. What is known however, is that the fluorescence increased 
dramatically and so the structure must contain the ring-opened forms of the rhodamine 
moieties. As to whether the oxygen is binding to the zinc metal as in [GdL6].Zn, this is 
unknown. The rhodamine moieties could have ring-opened because the oxygen was taking 
place in binding to the zinc, or simply because of steric reasons; having the ring-opened form 
would leave more space for the two dipicolylamine chelators to bind to the transition metal to 
give an octahedral coordination geometry as observed in zinc complexes with TPEN and a 2-
anthyltriazolyl-dpa conjugate.38,39 The dissociation constant was determined from the titration 
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profile (zinc concentration vs. absorbance at 580 nm). Two dissociation constants were 
calculated, one taking into account all data points, another not including data points 
hypothesised to be a consequence of the [GdL6]2.Zn complex. They were determined to be 
84 and 121 nM respectively. Both these values are greater than that determined for [GdL4] 
(55.7 µM) showing [GdL6] to be a more sensitive probe for zinc. 
Due to the small quantity of sample isolated and time restrictions, no further spectral 
analysis could be carried out on [GdL6]. This was unfortunate as the mechanism of zinc 
binding was not fully understood and the probes selectivity for zinc over other biologically 
relevant ions was yet to be tested. A repeat of the relaxivity titration with more data points 
would be carried out to see of the results corroborated those of the fluorescence titration. 
Electrospray mass spectrometry studies could also be used to confirm a [GdL6]2.Zn in the 
absence of crystallographic evidence.  
4.5.3.2 Photophysical properties of [EuL6] 
Phosphorescence excitation and emission spectra of [EuL6] were recorded and can be 
seen in Figure 4.20 (MeOH:H2O, 1:99 solvent system used). In the absence of zinc the steady 
state visible phosphorescence spectrum shows characteristic emission from the europium 
centre for the 5D0 ! 7FJ (J = 1, 2, 3, 4) transitions following excitation at 260 nm. Given that 
it is hypothesised the pyridyl units to not be playing a part in coordination to the lanthanide 
metal centre, efficient sensitisation via a Dexter type mechanism can be ruled out. As such, a 
Förster type sensitisation mechanism must be taking place which could have contributions 
from both the pyridyl and rhodamine moieties. The effect of zinc binding was then 
investigated by adding one equivalent of ZnCl2 to the solution of the complex. As discussed 
previously europium complexes display subtleties in the 5D0 ! 7FJ (J = 0, 2, 3, 4) transitions 
with the 616 nm peak (5D0 ! 7F2) in particular demonstrating hypersensitivity and the 5D0 ! 
7F4 peak being very sensitive to changes in ligand environment.40 Experimentally, the first 
observation in the europium emission spectrum was that the relative intensity of the bands 
remained unchanged. The 5D0 ! 7F1 and 5D0 ! 7F2 peaks have merged slightly and the 5D0 
! 7F3 is now observed but this could be a consequence of the increased emission intensity. 
This observation (of the unchanged relative intensity) indicates that there is no change in the 
europium coordination environment upon addition of zinc, i.e. q = 1 for both zinc free and 
zinc bound species. This agrees with the relaxivity results for [GdL6]. The increase in 
phosphorescence emission intensity is a significant change and is hypothesised to be a result 
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of the ring-opening of the rhodamine moiety upon addition of zinc. As discussed in chapter 
two, L2 was found to be a poor sensitiser for europium, displaying weak emission when 
complexed to europium and much improved emission when bound to terbium. This was 
thought to be a result of the triplet state energy of the rhodamine fragment lying above 25,000 
cm-1, at a level too high for efficient energy transfer to europium. These phosphorescence 
measurements were carried out on the ring-closed forms of the complexes. For the [EuL6] 
system, similarly weak europium emission is observed when the probe is in its ring closed 
form. In the presence of zinc however, the rhodamine moiety displays its typical fluorescence 
emission at 580 nm via the spirocyclisation method. This will significantly change the triplet 
state energy of the organic rhodamine moiety. In its ring closed form, emission at ~ 500 nm 
can be achieved by excitation at 325 and 380 nm. This means that the first singlet excited 
states of this structure lie at ~ 30,700 and 26,300 cm-1 respectively. The triplet excited states 
required for sensitisation of a luminescent lanthanide via intersystem crossing will lie a little 
lower than these levels. These levels are rather high for efficient sensitisation of europium 
(17,200 – 25,000 cm-1 being the ideal range frequency range for europium excitation).41 In the 
ring-opened form however, emission at 580 nm is now observed after excitation at 560 nm. 
This gives a much lower singlet excited state of ~ 17,900 cm-1. Again, the triplet excited state 
level will be slightly lower than this value, but it can be observed that it is much better suited 
to the ideal frequency range for europium excitation. Therefore, greater europium emission 
intensity is observed for [EuL6] in the presence of zinc as a result of better spectral overlap 
between the triplet excited state of the ring-opened rhodamine and 5D0 excited state of 
europium. 
 
Figure 4.20: Phosphorescence excitation and emission spectra of [EuL6] in the absence 
(black) and the presence (red) of zinc (MeOH:H2O, 99:1, v/v, pH 7.4, 298 K). 
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Time-resolved data for [EuL6] in deuterated and non-deuterated aqueous environments in 
the presence and absence of zinc was also obtained, the results of which can be seen in Table 
4.1. Typically, the lifetimes were of millisecond order as expected for europium compounds 
of this type. The Horrocks equation for europium, [q = 1.2(kH2O – kD2O – 0.25)], was applied 
to the lifetime analysis allowing for an approximation of the degree of solvation of the 
lanthanide, q. For both the free probe and zinc bound probe the data revealed q = 1.1 
indicating that the coordination environment around the europium metal is not affected by 
zinc coordination, again corroborating that the pyridyl groups do not play any part in 
coordination to the lanthanide. 
 
 τ(H2O) / ms τ(D2O) / ms q 
[EuL6] 0.54 1.73 1.0 
[EuL6] + Zn2+ 0.51 1.40 1.1 
 
Table 4.1: [EuL6] luminescence lifetimes and inner sphere hydration numbers (q) for the free 
complex and after addition of zinc. 
Unfortunately, the terbium analogue of the europium and gadolinium complexes could 
not by synthesised due to the small amount of L6 synthesised, and time constraints 
prohibiting the synthesis of more of the ligand. It would have been interesting to study how 
the zinc binding affected terbium emission in light of the results from [EuL6]. Of course, all 
complexes would be re-synthesised in order to carry out further experiments and fully 
understand the probes, as well as the mechanisms by which they respond to zinc both in terms 
of relaxivity and luminescence.  
4.6 Intracellular localisation 
In vitro cellular luminescence imaging using [GdL6] was carried out by Dr. Pauline 
Chabosseau at Hammersmith hospital, London. Both HEK (human embryonic kidney) and 
INS1 (insulinoma, characteristic of pancreatic β-cells) cells were evaluated. 
Firstly, initial cellular staining experiments were carried out in the absence of zinc. This 
involved the incubation of the both cell lines with 100 mM with [GdL6] in KH (Krebs 
Henseleit) buffer for 30 minutes. The images obtained (Figure 4.21) demonstrated excellent 
staining of both cell types. A co-localisation experiment was also performed to determine the 
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probe’s staining properties within the cellular environment. This involved the incubation of 
the INS1 cells with Yellow/Blue LysoSensor™, a lysosome targeting dye (1 µM). The probe 
displayed excellent co-localisation with the LysoSensor dye (Figure 4.22), with a Pearson 
coefficient of 0.912 (the closer this value is to one, the greater the co-localisation). 
 
 
Figure 4.21: Fluorescence microscopy images of HEK and INS1 cells with [GdL6]. 
 
Figure 4.22: Fluorescence microscopy co-localisation of INS1 cells with [GdL6]. 
Zinc-responsive fluorescence imaging was then assessed in both cell lines. As in the 
preceding in vitro experiments, a 100 mM concentration of [GdL6] was used. This is a 
relatively large concentration of probe when compared to the amount of LysoSensor used 
(100 mM vs. 1 µM), and it was required in order to observe a high fluorescence signal. It was 
however remarked that [GdL6] did not appear to be toxic for the cells at this concentration. 
The average fluorescence was charted for one bright ‘spot’ chosen from each cell line (HEK 
and INS1). The fluorescence signal was slightly reduced by the addition of the zinc chelator 
tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) as expected, and the addition of zinc and 
the zinc ionophore pyrithione caused a slight increase in the fluorescence intensity in both cell 
lines. This response was more pronounced in the HEK cells. Following the increase in 
HEK! INS1!
[GdL6]! LysoSensor! Merge!
 Chapter 4 
190 
fluorescence upon zinc addition, an abrupt decrease in fluorescence was then observed. This 
is hypothesized to be due to the compound leaking from the vesicles under pyrithione 
treatment. These results are promising in that an increase in fluorescence is observed upon 
addition of zinc, however, this response must be greatly enhanced if the probe is to be useful 
in the quantification of zinc levels within pancreatic β-cells.  
4.7 Conclusions 
The design and synthesis of a second iteration dual-modal MR/optical, zinc sensing probe 
was described. The fluorescent zinc sensor 16 was first synthesised to determine whether the 
compound was capable of reporting on zinc levels in solution via a fluorescence response. 16 
did indeed display a ‘turn on’ in fluorescence at λ = 580 nm (as well as a colorimetric change 
going from colourless to bright pink) in the presence of zinc, and this occurred via an 
intramolecular ring-opening mechanism. As well as by eye, the zinc binding event could be 
monitored by 1H NMR spectroscopy (splitting of methylene protons of the dpa unit) and by 
electrospray mass spectrometry. Unfortunately time restrictions prevented the full 
characterisation of this compound in terms of detailed fluorescence and UV-vis analysis, 
including transition metal titrations, but it was deemed worthy of involvement with the 
subsequent syntheses. 
The second-generation dual-modal zinc sensing probe was then designed by incorporating 
the fluorescent zinc sensor 16 with a DO3A lanthanide chelator via an aliphatic linker. Four 
synthetic strategies were tested to synthesise this complex molecule, only one of which was 
employed successfully involving the step-wise addition of components (BPEN, linker, 
rhodamine moiety then DO3A chelator) to result in the desired complex [LnL6]. The 
gadolinium complex displayed the largest r1 value (without zinc) observed throughout this 
work, and in the presence of zinc a ~ 50% increase in relaxivity value was recorded (4.99 – 
7.40 mM-1s-1). This significant increase was attributed to both the increased mass of the 
complex and the tethering approach used in its synthesis, both attributes of which contribute 
to the reduction of the tumbling rate of the molecule. [GdL6] displayed a good fluorescence 
emission response to zinc as predicted from the results of 16. A two-step emission spectral 
change is observed (with maximum emission at 0.5 equivalents) which is in discord with the 
single-step change observed in the relaxivity result. It is therefore not clear whether a dimer is 
first being formed at lower concentrations of zinc as observed in similar systems. A more 
detailed relaxivity titration should be carried out to study this further.  
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In vitro studies showed [GdL6] to enter and stain both HEK and INS1 cells successfully, 
with localisation in INS1 cells determined to be lysosomal. Upon zinc addition to both HEK 
and INS1 cell lines, a slight increase in fluorescence intensity was observed, which was 
followed by an abrupt decrease. This was attributed to compound leakage under pyrithione 
treatment. 
To conclude, the results obtained concerning [LnL6] show that the probe has certain 
potential to be a successful dual-modal zinc sensing agent. It is acknowledged that this 
compound has had significant less analysis than preceding compounds in this work, but this 
has purely been a consequence of little time left during the project. Due to the probe’s 
promising results, it will be investigated further after the conclusion of this PhD.  
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5.1 Conclusions 
This thesis describes the design and synthesis of a family of lanthanide chelates, which 
were all prepared and analysed to contribute to the on going works of the Long research group 
in the field of dual-modal MR/optical probes, with a focus on zinc sensing. The detection of 
zinc intracellularly is becoming increasingly important due to its involvement in a number of 
biological processes and diseases, in particular, diabetes. It is well known that there is a high 
concentration of zinc within insulin granules held in pancreatic β-cells. Changes in pancreatic 
β-cell mass contribute to the development of both type 1 and type 2 diabetes, the underlying 
mechanisms of which are poorly understood. As such, the concept of using MR-active probes 
capable of binding zinc to report on β-cell mass levels in vivo has fast become a field of 
importance. The incorporation of a fluorescent moiety leads to a dual-modal probe that 
potentially offers important advantages. By overlaying images obtained by different 
techniques, better image resolution and co-validation of the accumulated, targeted contrast 
agents can be achieved.  
The overall aim of the project was to make a complex that was capable of doing three 
things: a) giving an MR signal, b) giving a fluorescence signal and c) binding zinc. This third 
requirement not only needed to be selective in terms of other metal cations, but the binding 
event also had to induce a change in either the MR or fluorescence signals, preferably both. 
Without extensive experience in the field of imaging probes, the design and synthesis of a 
molecule of such intricacy is a daunting task. Therefore, in this work a ‘bottom up’ design 
strategy was employed whereby the piecing together of smaller systems gave rise to more 
complex systems. Each component of the assembly performs a simple act, while the entire 
assembly performs a more complex, useful function. 
The first results chapter (chapter two) therefore describes the synthesis of the first 
component, a dual-modal MR/optical probe (Figure 5.1). A rhodamine B derivative was 
employed as the fluorophoric unit to be conjugated to a DO3A chelating unit. The resulting 
ligands were then complexed to selected lanthanide metals to allow for study of relaxation 
properties (Gd3+), fluorescence properties (Eu3+, Tb3+) and structural properties (Eu3+, Yb3+). 
[LnL1] and [LnL2] were very similar in structure only differing by an amide group on the 
linker between the fluorophore and the chelate which imparted water solubility to the latter 
complexes. Fluorescence studies showed that the rhodamine unit exists in its majority as the 
non-fluorescent spirolactam. Upon lowering of pH, a switch on in fluorescence emission is 
observed due to ring-opening of the spirolactam. Studies on the luminescent lanthanide 
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derivatives [EuL1,2] and [TbL1,2] showed that the lanthanide phosphorescence emission was 
much less efficient when L2 was used as the sensitiser and this was hypothesised to be a 
result of both the increased distance between the lanthanide and the organic antenna, as well 
as the additional amide NH introducing a quenching pathway. Only the L2 complexes were 
fully water soluble, therefore further studies on [LnL1] were discontinued. Rhodamine 
derivatives have had particular success as mitochondria targets, and as [GdL2] displayed a 
switch-on in fluorescence at pH < 7, the probe was tested on its ability to accumulate in the 
energised mitochondria of tumour cells (negative mitochondrial potential is greater in tumour 
cells than in normal cells). Co-localisation with MitoTracker Green demonstrated the ability 
of [GdL2] to enter cells, with localisation believed to be in the mitochondria. The probe was 
also evaluated as an MR probe for imaging tumours in BALB/c nude mice bearing M21 
xenografts. A 36.5% decrease in T1 within the tumour was observed 30 min post injection 
showing that [GdL2] is preferentially taken up in the tumour. The ligands L1 and L2 were 
therefore shown to be dual-modal when bound to gadolinium (r1 = 8.5 and 3.8 mM-1s-1 
respectively) and dual luminescent when coordinated to europium and terbium displaying 
luminescence on two different time frames. [GdL2] was the first example of a small-molecule 
MR/optical dual-modal agent to display an off-on pH switch upon its preferential uptake 
within the more acidic microenvironment of tumour cells. 
The final complex described in this chapter was the ‘always on’ derivative of [LnL2], 
[LnL3]. Initially, the rhodamine spirocyclisation mechanism was not well understood and so 
the non-fluorescent form at neutral pH was not anticipated. Fortuitously, this property was 
applicable to the imaging of acidic organelles within tumour cells displaying ‘off-on’ 
fluorescence behaviour, but it is also of use to have a dual-modal MR/optical probe where the 
fluorescence emission is constant. This was achieved by incorporating a methyl group on the 
amide moiety central to the spirocyclisation mechanism, thus prohibiting ring-closing. All 
complexes of L3 (Gd3+, Eu3+, Tb3+) displayed strong fluorescence emission from the 
rhodamine moiety that was pH indepenent, as well as the properties resulting from the 
lanthanides i.e. r1 = 4.09 mM-1s-1 in [GdL3] and the characteristic lanthanide luminescence 
signals from [EuL3] and [TbL3]. Intracellular studies demonstrated the probe to be a much 
better mitochondrial stain than [GdL2] showing excellent co-localisation with MitoTracker 
Green in HEK293 cells. 
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Figure 5.1: Structures of [LnL1,2,3], compounds discussed in chapter two 
These complexes were primarily designed to allow for the understanding of a purely dual-
modal, MR/optical probe. Their synthesis and design were important in determining the 
mechanisms by which they behave in terms of relaxivity and fluorescence. With this 
knowledge, [GdL2] was further derivatised to make the probe applicable to zinc sensing. 
 
Chapter three describes the design and synthesis of two first generation zinc sensing MR 
probes, one of which is dual-modal. [GdL4] was developed in order to examine the 
effectiveness of BPEN (zinc chelator) when conjugated to DO3A, determining whether it was 
selective enough to be taken forward in the synthesis of a dual-modal analogue. Displaying a 
10% increase in relaxation rate in the presence of zinc, alongside a high selectivity for zinc 
over other cations, the chelator was deemed suitable. [GdL5] was then designed to behave as 
a dual-modal zinc sensing probe by combining the BPEN zinc chelator with the rhodamine 
fluorophore from [GdL2], both conjugated to a central DO2A lanthanide chelator. This probe 
displayed an improved relaxivity response to zinc (2.94 to 3.88 mM-1s-1, a 31% increase), 
although the values themselves were much lower than any of the probes synthesised in this 
work. The rhodamine moiety did not give a fluorescence response to zinc, but as with 
[GdL2], it displayed a strong increase in fluorescence by lowering of pH. 
In vitro experiments were performed to assess whether intracellular localisation had 
altered after modification of [GdL2] by introduction of the BPEN moiety. Co-localisation 
experiments with an A2780 cell line and DAPI and fluorescein cell dyes determined the 
localisation to be in the cytosol. This differed notably from the results observed for [GdL2] 
and [GdL3] (mitochondrial targeting) indicating that the structural modification was 
significant enough to result in a change in cellular localisation. It is thought that this 
localisation behaviour is preferable if the probe is to be successful as a zinc sensing agent. 
Although it was clear that [GdL5] was not a successful zinc sensing probe (low relaxivity 
values and no fluorescence response to zinc), its synthesis and analysis contributed to the 
development of a second-generation probe, which was subsequently discussed. 
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Figure 5.2: Structures of [LnL4,5], compounds discussed in chapter three. 
The final results chapter describes the development of the second iteration dual-modal 
zinc sensing probe, [GdL6]. The fluorescent zinc sensor 16 was first synthesised to determine 
whether the compound was capable of reporting on zinc levels in solution via a fluorescence 
response. After establishing that the fluorophore does indeed behave as desired (both a 
fluorescence and colorimetric change), the compound was carried forward in the synthesis of 
the final complex. This final compound was the culmination of the project, combining all 
aspects explored (rhodamine fluorophore, BPEN zinc chelator, DO3A lanthanide chelator) in 
such a way as to arrive at a more complex, functional molecule. The way in which these 
individual components were combined proved critical to the successful functioning of the 
probe, i.e. [GdL5] only showed an MR response in the presence of zinc, the BPEN and 
rhodamine moieties being separated by the macrocyclic chelator. [GdL6] was structured so 
that the BPEN moiety was conjugated to the rhodamine fluorophore, and this unit was then 
conjugated to the macrocycle via an aliphatic linker. The probe displayed the largest r1 value 
(without zinc) observed throughout this work, and in the presence of zinc a ~ 50% increase in 
relaxivity value was recorded (4.99 – 7.40 mM-1s-1). This significant increase was attributed 
to both the increased mass of the complex and the tethering approach used in its synthesis, 
both of which contribute to the reduction of the tumbling rate of the molecule. The probe also 
showed an excellent concentration dependent fluorescence response in the presence of zinc, 
with a maximum 3-fold increase in emission intensity at 0.5 equivalents. The results obtained 
for [LnL6] showed the probe to have great potential as a successful dual-modal zinc sensing 
agent, although it was acknowledged that further detailed are required to fully realise this 
potential. 
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Figure 5.3: Structures of 16 and [GdL6], compounds discussed in chapter four. 
To summarise, a series of compounds were synthesised: three dual-modal MR/optical 
complexes [GdL1], [GdL2] and [GdL3], a zinc sensing MR probe [GdL4], a fluorescent zinc 
sensor 16 and two dual-modal zinc sensing complexes [GdL5] and [GdL6]. By synthesising 
these complexes in a successive manner a greater understanding of the relaxivity and 
fluorescence properties of the final complexes was achieved, with europium and terbium 
analogues contributing to their analysis. The final complex, [GdL6], proved to be the most 
promising candidate as a functioning dual-modal zinc sensor. More analysis is required to 
fully understand the probe’s properties and this will be carried out after the conclusion of this 
PhD. 
5.2 Future work 
The complexes synthesised in this work are untargeted, discrete gadolinium complexes, 
which have been shown to successfully enter a cellular environment. The project has been 
geared towards imaging pancreatic β-cell mass as its deterioration has been linked to type two 
diabetes. MR imaging has the inherent problem in that it has considerably lower sensitivity of 
contrast agent detection compared to other imaging techniques. This has been somewhat 
alleviated in this work by the inclusion of an organic chromophore to the probe to achieve 
better image resolution and co-validation of accumulation. The fundamental problem remains 
however that if the MR contrast agent spreads universally throughout a body, then a strong 
signal enhancement will not be observed. To address this problem, one needs to bind to a 
target that is present in high concentrations in the location of interest. 
As stated previously, β-cells are found in the islets of Langerhans. They are responsible 
for the synthesis and secretion of insulin and their dysfunction is linked to both type one and 
type two diabetes. Currently, the diagnosis of diabetes is only possible via indirect methods 
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such as determination of plasma glucose or HbA1c (detection of glycated haemoglobin). 
These methods are far from optimal as these markers only become detected after more than 
80% of the islets have degraded and thus when the progression of the disease is irreversible.1 
As such, the non-invasive determination of β-cell mass to allow for the earlier discovery of 
the disease is becoming increasingly important. One potential target that is highly expressed 
on β-cells is the glucagon-like peptide receptor-1 (GLP-1R). GLP-1 itself is a metabolically 
unstable endogenous ligand and as such, exendin-4 is commonly used in its place, having 
been successfully used to image insulinoma (tumour of the pancreas derived from β-cells) in 
human patients.2 Exendin-4 is a 39 amino acid peptide that induces the secretion of insulin 
and has glucoreulatory effects. Its characterisation showed that the peptide was related to 
GLP-1 (52% sequence homology) but that it displayed a longer in vivo half life and prolonged 
duration of action.3 
There are three ways that an imaging probe can be introduced to exendin-4: by 
conjugation to the free amine of a C-terminally attached lysine or cysteine residue or by 
conjugation to one of the two naturally occurring lysines at positions 12 and 27 (Figure 5.4).  
 
 
Figure 5.4: Graphical representation of exendin-4 highlighting the three commonly used 
points of conjugation (shown in red).4 
Altering a peptide chain by the introduction of non-native moieties can often have 
negative effects on the binding affinity to the target receptor. There are conflicting reports as 
to whether the conjugation site of a new moiety affects the properties of the peptide. Some 
experiments show that conjugation at positions K12 and K27 does not affect the binding 
affinity, whilst other results show the opposite to be true.5 In terms of compounds that have 
been conjugated to exendin-4 that are similar in structure to complexes in this work, Jodal et 
al. compared three 67/68Ga-NODAGA-labelled exendin-4 derivatives and Weissleder et al. 
compared a series of fluorescent exendin-4 derivatives, both investigating the effects of the 
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conjugation position.4,6 Both conclude that the lysines at postitions 12 and 40 showed the 
most favourable in vitro properties binding to GLP-1R positive tissue. 
The next stage of the project would therefore be to conjugate [GdL6] to exendin-4 via one 
of the two lysine residues specified above. This would involve alteration of the DO3A moiety 
to allow for conjugation on the opposite side of the rhodamine-BPEN moiety. This could 
possibly be achieved by using bis-t-Bu-DO2A as the starting chelate and functionalising each 
of the two secondary amides successively in a similar manner to that used in the synthesis of 
[GdL4]. A structure is proposed in Figure 5.5. The peptide is conjugated to the lanthanide 
chelator via an L-glutamic acid residue and a spacer group. The use of L-glutamic acid 
residues for conjugation of peptides to DOTA derivatives has been well explored in the Long 
research group and so methodologies are already in place to explore this derivatisation route. 
 
 
Figure 5.5: Proposed structure of a possible [GdL6] exendin-4 conjugate. 
A particular challenge faced when imaging β-cells is the limited amount of overall GLP-1 
receptors available. This requires the administration of low amounts of peptide with a high 
specific activity in order to avoid receptor blocking.7 This could be achieved by attaching a 
second chelator to the peptide allowing more relaxivity signal per molecule and as discussed 
previously, exendin-4 has multiple points for conjugation  
To conclude, the functionalisation of [GdL6] to include a targeting moiety is deemed the 
next step in advancing to the goal of targeting pancreatic β-cells. This would contribute to the 
ongoing effort to make contrast agents more specific for particular diseases, in this case type 
II diabetes. 
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6.1 General 
6.1.1 Conditions and materials 
No special precautions were taken to exclude air or moisture during reactions or workups, 
unless otherwise stated. All solvents and reagents were obtained from commercial sources 
and used without further purification. TLC was performed on Kieselgel 60 F254 plates 
(Merck) and the spots were visualized under UV fluorescence (254 and 366 nm) or I2 vapour. 
Silica, neutral alumina of Brockman activity I (0% H2O), activity II (3% H2O) or V (15% 
H2O) and Sephadex G-10 were used for chromatographic separations. Compounds 11, 21, 42, 
tris-t-Bu-DO3A3, 74, BPEN5 and bis-t-Bu-DO2A6, were prepared via literature methods from 
commercially available starting materials. 
6.1.2 Instrumentation 
1H and 13C{1H} NMR spectra were recorded at ambient temperature on a Bruker 400 
MHz spectrometer and internally referenced to the residual solvent peaks of CDCl3 at δ 7.26 
(1H) and 77.16 ppm (13C{1H}); MeOD at δ 3.31 (1H) and 49.15 ppm (13C{1H}); DMSO-d6 at 
δ 2.50 (1H) and 39.52 ppm (13C{1H}); D2O at δ 4.79 (1H).7 13C{1H} spectra were fully 
assigned where possible using 2D correlation spectroscopy. Additional NMR experiments 
were performed by Mr. P. Haycock: when needed, higher resolution 1H and 13C{1H} NMR 
experiments were performed on a Bruker AV 500 spectrometer. Spectra were processed and 
analysed using Mestrenova software. The 1/T1 NMRD profiles were measured on a fast field-
cycling Stelar SmartTracer relaxometer (Stelar s.r.l., Pavia, Italy) over a continuum of 
magnetic field strengths from 0.00024 to 0.25 T (corresponding to 0.01 – 10 MHz protom 
Larmor frequencies). The relaxometer operates under computer control with an absolute 
uncertainty in 1/T1 of ±1%. Mass spectrometry analyses were conducted by the Mass 
Spectrometry Service, Imperial College London. Microanalyses were carried out by Stephen 
Boyer of the Science Centre, London Metropolitan University for all novel compounds 
isolated in sufficient purity and yield. Some compounds did not produce satisfactory analyses, 
despite drying under vacuum for extended periods. ICP-MS analyses were carried out by Dr. 
Stanislav Strekopytov at the Natural History Museum, London. UV-vis absorption spectra 
were recorded on a PerkinElmer 650 UV-vis spectrometer using quartz cuvettes (10 x 4 mm) 
or semi-micro polystyrene disposable cuvettes (10 x 4 mm, BRAND). Fluorescence spectra 
were recorded on a Varian Cary Eclipse fluorescence spectrophotometer using quartz cuvettes 
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(10 x 4 mm). pH measurements were carried out using a Jenway model 3510 
pH/mV/temperature meter, calibrated against ‘NIST’ pH, 10.00, pH 7.00 and pH 4.00 buffers.  
6.2 Measurement of photophysical properties 
6.2.1 Luminescence lifetimes of Ln(III) complexes 
The number of coordinated water molecules was determined from luminescence lifetime 
measurements using Eu(III) and Tb(III) analogues. In brief, 1 mg/mL solutions of a test 
Ln(III) complex were prepared in H2O and the other in D2O. The integrated intensity was 
monitored during a fixed time gate of 0.1 ms, at a delay time later. Delay times were set at 0.1 
ms, covering four or more lifetimes. Excitation and emission slits were set to 10:10 nm 
bandpass respectively. The obtained decay curves were fitted to a simple monoexponential 
first-order decay curve using Microsoft Excel.  
6.2.2 Fluorescence quantum yield measurements 
Fluorescence quantum yields of terbium complexes were determined from the integrated 
fluorescence intensities of the complexes following a previously reported8 method using the 
reference compound9 Na3[Tb(dpa)3] in water or methanol at 279 nm (quantum yield = 26.5% 
or 18.2% respectively).  
6.3 Relaxometric measurements of Gd(III) complexes 
6.3.1 T1 measurement at 400 MHz 
The gadolinium(III) complexes were dissolved in water or methanol/water (v:v, 50:50) 
depending on solubility to give a solution of concentration 5 mM. The resulting solutions 
were placed in 1.7 mm diameter capillaries which were sealed. The 1/T1 measurements were 
performed in a Bruker Avance 400 spectrometer (400 MHz) by Mr. P. Haycock. These 
experiments were carried out a minimum of three times and the relaxivity results given are 
averages of all experiments. The concentration of Gd(III) was checked by the chemical shift 
measurement of HOD induced by magnetic susceptibility.10 
6.3.2 HSA relaxivity titration 
A 1.49 mM solution of [GdL2] in 0.1 M NaCl (pH 7.4) was prepared, from which 10 x 67 
µL aliquots were taken. To each aliquot was added an aliquot of 2 µM solution of HSA (0.1 
M NaCl, pH 7.4) to give 10 different sample concentrations (0, 0.1, 0.25, 0.35, 0.5, 0.65, 0.85, 
 Chapter 6 
206 
1, 1.5 and 2 eq. of HSA). The solutions were then made up to a volume of 100 mL by 
addition of water. The resulting solutions were placed in 1.7 mm diameter capillaries, which 
were sealed. The 1/T1 measurements were performed on a Bruker Avance 400 spectrometer 
(400 MHz) by Mr. P. Haycock. 
6.4 In vitro and in vivo studies from chapter 2 
6.4.1 In vitro cell culture and imaging 
HEK293 cells were cultured in DMEM (Lonza) supplemented with 10% Fetal Bovine 
Serum (FBS, Lonza), 1% Glutamine (Lonza) and 1% penicillin / streptomycin (Gibco). On 
the day of visualization, cells were washed twice with KREBS buffer (140 mM NaCl, 3.6 
mM KCl, 0.5 mM NaH2PO4, 0.2 mM MgSO4, 1.5 mM CaCl2, 10 mM HEPES (pH 7.4), 2 
mM NaHCO3), pre-equilibrated with 95:5 O2:CO2 and containing 25 mM glucose. Cells were 
then incubated with KREBS plus 215 µM [GdL2] and 100 nM of MitoTracker® Green for 30 
minutes and washed twice with KREBS buffer before visualization. Images were captured 
using a Zeiss Axiovert confocal microscope coupled to a Nipkow spinning-disk head 
(Yokogawa CSU-10) using a 63x oil objective.  A solid-state laser (CrystaLaser) controlled 
by a laser-merge module (Spectral Applied Physics) provided wavelengths of 491 nm to 
excite [GdL2], and wavelengths of 561 nm to excite Mitotracker Green. Images were 
captured by a highly sensitive 16-bit, 512 × 512 pixel back-illuminated EM-CCD camera 
(ImageEM 9100-13; Hamamatsu). Volocity software (PerkinElmer) provided the user 
interface.  
HEK cells on coverslips were washed twice in  Krebs-HEPES-bicarbonate (KHB) buffer 
(140mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.2 mM MgSO4, 1.5 mM CaCl2, 10 mM 
HEPES, 25 mM NaHCO3), which was warmed, bubbled with 95:5 O2/CO2, set to pH 7.4, and 
contained 3 mM glucose. Cells were then loaded with compounds for 30 minutes in KHB 
buffer (2.5 mM for [GdL3]). Cells were maintained at 37 °C throughout with a heating stage 
(MC60, LINKAM, Scientific Instruments). Images were captured at 550 nm monochromatic 
excitation wavelength (Polychrome IV, Till photonics) using an Olympus IX-70 wide-field 
microscope with a 40×/1.35NA oil immersion objective and a zyla sCMOS camera (Andor 
Technology) controlled by Micromanager software. Emitted light was filtered using a T570lp 
dichroic mirror and ET620/60m emission filter (Chroma Technology). For co-localisation 
experiments, cells were loaded with compounds as described above and with MitoTracker 
Green (Life Technologies) at 1.5 µM. Images were captured on a Nikon Eclipse Ti 
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microscope equipped with a Crest X-Light spinning disc system and Orca Flash4.0 camera 
(Hamamatsu). [GdL3] compounds was excited with a 561 nm laser line and emitted light was 
filtered with a ET630/75m emission filter, Mitotracker was excited with a 488 nm laser line 
and emitted light was filtered with a ET535/50m emission filter. 
6.4.2 In vivo tissue isolation and imaging 
Islet isolation was carried out as shown in (PMID= 20204627). In short, a female CD1 
mouse (8-12 weeks old) was sacrificed by cervical dislocation. The pancreas was injected 
with 1 mg/ml collagenase solution through the bile duct and excised. The pancreas was 
digested by heating with collagenase solution, and islets were isolated through the use of 
ficoll gradient centrifugation. Islets were hand-picked and kept at 37⁰C in Islet media (RPMI 
supplemented with 10% FBS and 1% penicillin/streptomycin). Islets were dispersed into 
clusters and single cells according to Ravier and Rutter, 2010. Briefly, islets were incubated 
with Hank’s based enzyme-free dissociation buffer (Invitrogen, Paisley, UK) and centrifuged. 
All but 1 ml of the supernatant was removed, and the pellet re-suspended vigorously via 
pipetting. The cells were washed and re-suspended with RPMI 1640, then loaded onto a Poly-
L-lysine treated coverslip. On the day of visualization, cells were washed twice with KREBS 
buffer (140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.2 mM MgSO4, 1.5 mM CaCl2, 10 
mM HEPES (pH 7.4), 2 mM NaHCO3), pre-equilibrated with 95:5 O2:CO2 and containing 25 
mM glucose. Cells were then incubated with KREBS plus 215 µM [GdL2]  and 100 nM of 
MitoTracker® Green for 30 minutes and washed twice with KREBS buffer before 
visualization. Images were captured using a Zeiss Axiovert confocal microscope coupled to a 
Nipkow spinning-disk head (Yokogawa CSU-10) using a 63x oil objective.  A solid-state 
laser (CrystaLaser) controlled by a laser-merge module (Spectral Applied Physics) provided 
wavelengths of 491 nm to excite GdL2, and wavelengths of 561 nm to excite Mitotracker 
Green. Images were captured by a highly sensitive 16-bit, 512 × 512 pixel back-illuminated 
EM-CCD camera (ImageEM 9100-13; Hamamatsu). Volocity software (PerkinElmer) 
provided the user interface.  
6.4.3 In vivo tumour models 
All animal experiments were performed by licensed investigators in accordance with the 
United Kingdom Home Office Guidance on the Operation of the Animal (Scientific 
Procedures) Act 1986 and in keeping with the newly-published guidelines for the welfare and 
use of animals in cancer research.66 Female BALB/c nude mice (aged 6 - 8 weeks; Harlan) 
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were used. M21 cells were injected subcutaneously on the back of mice (5 x 106 cells in 100 
µl sterile PBS). Animals were used when the xenografts reached ~ 100 mm3. Tumor 
dimensions were measured continuously using a caliper and tumor volumes were calculated 
by the equation: volume = (π / 6) × a × b × c, where a, b, and c represent three orthogonal 
axes of the tumor. 
6.4.4 In vivo MRI 
In vivo MRI was performed in a 4.7T horizontal bore Direct Drive Varian MRI system 
(Palo Alto, CA) equipped with 40 G/cm actively-shielded gradients (VnmrJ 3.1). For imaging 
the tumours and generating the T1 parametric maps, a 45-mm diameter saddle coil was used in 
transmit mode and a separate, 20-mm diameter stripline resonator was used as a surface coil 
to accommodate the tumours.67 Imaging was performed with an inversion recovery (IR) 
sequence and the following parameters: axial images, FOV = 35 × 35 mm, No slices = 14, 
slice thickness = 1 mm (zero slice gap), image bandwidth = 156 kHz, TR = 4500 ms, TI = 8 
values (6, 14.6, 35.4, 86.1, 209, 508, 1230, 3000 ms), NA = 2, image matrix = 192 × 192, TA 
= 12 min. During imaging, animals were anesthetised with 2% isofluorane and respiration and 
body temperature were monitored via SA physiological monitoring systems (SA Instruments, 
Stony Brook, NY, USA). Body temperature was monitored by a rectal probe and maintained 
at 35 ± 1 °C. T1 maps were generated in ImageJ (Rasband, W., 1997, US National Institutes 
of Health, http:/rsb.info.nih.gov/ij/) by fitting the acquired data to the following equation: S = 
S0(1-2exp(-TI/T1)), where TI is the inversion time and T1 is the longitudinal relaxation time. In 
order to assign the signal with the appropriate sign for the fitting process, the chi square value 
of the fit was evaluated during the fitting. ROIs were then drawn on the T1 maps to delineate 
the whole tumor, but with consideration to avoid the edges of the tumor and so contamination 
from neighboring tissues and partial volume effects.  
6.5 In vitro studies from chapter 3 
6.5.1 In vitro cell culture and imaging 
Krebs HEPES buffer was made up to 500 mL with deionized water in a 500 mL Duran 
bottle (4.06 g, NaCl ( 140 mM), 0.1332 mg KCl (3.6 mM), 0.012 mg MgSO4 (0.2 mM), 0.03 
mg NaH2PO4 (0.5 mM), 0.084 g, NaHCO3 (2 mM) and 1.19 g HEPES (10 mM)). [GdL5] was 
diluted in 10% ethanol and Krebs HEPES buffer solution. 4.7 mg of the probe was dissolved 
in 376 µL of absolute ethanol. This was then made up to 3.76 mL with Krebs HEPES buffer 
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to give a 1mM stock solution. 1 µM 4’,6-diamidino-2-phenylindole nuclear stain solution 
(DAPI) was made up with Krebs HEPES buffer (10 mg of stain in 10 mL buffer to make a 1 
mM stock solution. 10 µL of stock in 10 mL of buffer makes a 1 mM solution.). The same 
was carried out for 3’,6’-fluorandiol membrane stain (fluorescein). 1 mM MitoTracker Green 
stock was made using anhydrous DMSO (50 µg of MitoTracker in 73 µL of DMSP). Working 
solution (1 µM) was made using the media solution (1 µL of MitoTracker in 999 µL of 
media). 1 mM zinc chloride solution was made up with Krebs HEPES buffer (0.017 g ZnCl in 
125 mL buffer). 
All cells were cultured using an RPMI 1640 media (500 mL) with 50 mL 10 % Fetal 
Bovine Serum (FBS), glutamine (5 mL) and 1% PenStrep (5 mL) solution. Testing included 
the human ovarian cell line A2780 as a cancerous tissue containing minimal zinc. All cells 
were grown in 75 mL flasks which were incubated in a 37 °C, 5% CO2 incubator. 
Enough cells were grown to allow for 8 x 105 cells/ mL.  A class 2 safety hood was set up 
and 1 mL of the cell solution was transferred into separate Eppendorf tubes.  The tubes were 
centrifuged for 3 minutes at 1500 rpm. The supernatant was removed and the cells were 
washed in 1mL of PBS which involved reconstituting the cells in PBS, centrifuging them and 
then removing the supernatant.  The cells were then reconstituted in 1ml media containing the 
probe [GdL5] (20 µM).  The tubes were then incubated for 20 minutes, centrifuged and the 
media removed.  The cells were washed PBS, then reconstituted with 1mL media containing 
DAPI dye and incubated for 5 minutes.  The cells were then spun down, washed with PBS, 
reconstituted with 1mL media containing fluorescein dye and incubated for 5 minutes.  The 
cells were then spun down washed and reconstituted in 1 mL of media.  250 µL of this 
solution was then transferred to a live tissue culture dish.   
A separate Eppendorf tube containing 1 mL of cells was prepared separately using the 
same method except no DAPI or fluorescein dye was added instead only the [GdL5] probe 
was added along with MitroTracker Green dye (880 mL of media + 20 µL of Probe + 100 µL 
of working MitroTracker stock solution).  The cells were incubated for 20 minutes and then 
250 µL was transferred to a live tissue culture dish.   
The dishes containing the cells were placed onto a confocal microscope and viewed at 
X63.  The filters used for viewing included rhodamine, DAPI, fluorescein and MitroTracker 
Green.  After the initial images were taken 250 µL of zinc solution was added to the dish.  
The images were then retaken.  
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6.6 In vitro studies from chapter 4 
HEK cells and INS1 beta cells on coverslips were washed twice in  Krebs-HEPES-
bicarbonate (KHB) buffer (140mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.2 mM MgSO4, 
1.5 mM CaCl2, 10 mM HEPES, 25 mM NaHCO3), which was warmed, bubbled with 95:5 
O2/CO2, set to pH 7.4, and contained 3 mM glucose. Cells were then loaded with compounds 
for 30 minutes in KHB buffer (100 mM for [GdL6]). Cells were maintained at 37 °C 
throughout with a heating stage (MC60, LINKAM, Scientific Instruments). Images were 
captured at 550 nm monochromatic excitation wavelength (Polychrome IV, Till photonics) 
using an Olympus IX-70 wide-field microscope with a 40×/1.35NA oil immersion objective 
and a zyla sCMOS camera (Andor Technology) controlled by Micromanager software. 
Emitted light was filtered using a T570lp dichroic mirror and ET620/60m emission filter 
(Chroma Technology). For co-localisation experiments, cells were loaded with compounds as 
described above and with Yellow/Blue Lysosensor (Life Technologies) at 1 µM. Images were 
captured on a Nikon Eclipse Ti microscope equipped with a Crest X-Light spinning disc 
system and Orca Flash4.0 camera (Hamamatsu). [GdL6] was excited with a 561 nm laser line 
and emitted light was filtered with a ET630/75m emission filter, Lysosensor was excited with 
a 405 nm laser line and emitted light was filtered with a AT460/50m emission filter (emission 
filters from Chroma). 
6.7 Synthesis of compounds in chapter 2 
6.7.1 3 
DO3A-t-Bu-ester (0.16 g, 0.28 mmol) and K2CO3 (0.05 g, 0.34 
mmol) were dissolved in MeCN (5 mL) and stirred for 5 min. 2 
(0.15 g, 0.28 mmol) in MeCN (15 mL) was added dropwise. The 
reaction mixture was heated to reflux temperatures for 24 h. The 
resulting solution was filtered and the filtrate concentrated under 
reduced pressure. The crude product was purified by silica gel chromatography with 1-20% 
MeOH/DCM, 1% NH3 solution (28%), affording 3 as a beige solid (0.21 g, 37%). 1H NMR 
(400 MHz, CDCl3) δ (ppm): 1.18 (t, 12 H, 3JHH = 7.1 Hz), 1.43 (s, 27 H), 2.09-2.15 (m, 2H), 
2.29-3.06 (m, 16 H), 3.13-3.19 (m, 2H), 3.36 (q, 8H, 3JHH = 7.4 Hz), 3.50 (s, 6H). 6.23-6.43 
(m, 6H), 7.04-7.08 (m, 1H), 7.41-7.47 (m, 2H), 7.81-7.84 (m, 1H); 13C NMR (100 MHz, 
CDCl3) δ (ppm): 12.6, 28.0, 30.9, 36.0, 44.3, 46.2, 49.6, 51.0, 53.5, 55.8, 56.4, 65.2, 82.0, 
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82.4, 97.9, 105.1, 107.8, 122.6, 123.8, 128.0, 128.7, 131.0, 132.4, 148.8, 153.4, 153.5, 168.4, 
172.5; ESI-HRMS: calcd for C56H83N7O8 982.6381, found m/z 982.6398. 
6.7.2 L1 
3 (0.20 g, 1 mmol) was dissolved in CH2Cl2 (2 mL) and 
trifluoroacetic acid (2 mL) was added dropwise. The solution 
was stirred at room temperature, open to air, for 24 h. The 
solvents were removed in vacuo and the residue redissolved in 
CH2Cl2. This was repeated with diethyl ether and again with CH2Cl2 until L1 was obtained as 
a bright pink solid (0.16 g, 96%). 1H NMR (400 MHz, CDCl3) δ (ppm): 1.17 (t, 12 H, 3JHH = 
7.2 Hz), 3.06-3.71 (m, 24H), 4.20 (m, 2H), 6.54-6.75 (m, 6H), 7.14 (d, 1H), 7.60-7.64 (m, 
2H), 7.80 (d, 1H); 13C NMR (100 MHz, CDCl3) δ (ppm):  11.06, 34.14, 45.42, 45.63, 48.18, 
49.33, 51.97, 52.26, 54.41, 110.36, 122.90, 124.22, 126.14, 128.62, 128.82, 129.83, 133.57, 
153.00, 153.35, 160.78, 169.12. ESI-HRMS calcd. For C44H60N7O8 814.4503, found m/z 
814.4503. 
6.7.3 [GdL1] 
L1 (0.04 g, 0.05 mmol) and GdCl3.6H2O (0.01 g, 0.03 mmol) were 
dissolved in water (2 mL) and the pH adjusted to 5.5 using 1 M 
NaOH solution. The reaction was stirred at room temperature for 
24 h. The reaction precipitate was filtered and then dissolved in 
DCM. The organic layer was washed with water and then dried 
over MgSO4. Addition of ether to this solution precipitated [GdL1] as a pale beige powder 
(0.022 g, 84%). ESI-HRMS: calcd for C44H57N7O8Gd 969.3510, found m/z 969.3569. 
6.7.4 [EuL1] 
The complex was prepared by an analogous method as for [GdL1] 
using L1 (0.029 g, 0.036 mmol) and EuCl3.6H2O (0.013 g, 0.036 
mmol) to yield [EuL1] as a pale beige solid (0.025 g, 71%). ESI-
HRMS: calcd for C44H57N7O8Eu 964.3481, found 964.3464. 
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6.7.5 [TbL1] 
The complex was prepared by an analogous method as for [GdL1] 
using L1 (0.26 g, 0.32 mmol) and TbCl3.6H2O (0.06 g, 0.16 
mmol) to yield [TbL1] as a pale beige solid (0.12 g, 80%). ESI-
HRMS: calcd for C44H57N7O8Tb 970.3522, found 970.3555. 
 
6.7.6 5 
(0.50 g, 1.03 mmol) was dissolved in DCM (10 mL), NEt3 (0.1 mL, 
1.24 mmol) added and reaction mixture cooled to 0°C using an ice bath. 
Chloroacetyl chloride (0.1 mL, 1.24 mmol) in DCM (5 mL) was then 
added dropwise. The reaction mixture was allowed to come to room temperature. The 
solution was stirred at room temperature for 5 h, then the solvent was removed under reduced 
pressure. The resultant solid was dissolved in DCM (20 mL) and washed with water (10 mL x 
2) and brine. The organic extract was dried over MgSO4 and evaporated to give a purple solid 
(5) (0.36 g, 62%). 1H NMR (400 MHz, CDCl3) δ (ppm) = 1.18 (t, 12H, 3JHH = 7.0 Hz), 3.10 
(t, 2H, 3JHH = 7.1 Hz), 3.34 (q, 10H, 3JHH = 7.2 Hz), 3.95 (s, 2H), 6.31-6.47 (m, 6H), 7.08-
7.11 (m, 1H), 7.46-7.48 (m, 2H), 7.93-7.96 (m, 1H). 13C NMR (100 MHz, CDCl3) δC = 12.42, 
39.50, 40.39, 41.43, 42.42, 45.01, 65.65, 98.87, 108.96, 123.08, 123.88, 128.41, 128.53, 
130.22, 133.03, 148.26, 153.17, 153.55, 166.80, 169.46, 169.85. ESI-HRMS: calcd for 
C32H38ClN4O3 561.2632, found m/z 561.2646. 
6.7.7 6 
Tris-tert-butyl-DO3A (0.32 g, 0.59 mmol) and K2CO3 (0.08 
g, 0.59 mmol) were dissolved in MeCN (20 mL) and left to 
stir for 5 min. 5 in MeCN (20 mL) was then added dropwise. 
The reaction mixture was heated to reflux for 24 h. The 
resulting solution was filtered and the filtrate concentrated under reduced pressure. The crude 
product was purified by silica gel chromatography using 1-20% MeOH/DCM. 1% NH3 
solution (33%), affording 6 as a beige solid (0.12 g, 21%). 1H NMR (400 MHz, CDCl3) δ 
(ppm) = 1.18 (t, 12H, 3JHH = 7.0 Hz), 1.40 (s, 27H), 1.98-2.92 (m, 28H), 3.28 (q, 8H, 3JHH = 
7.1 Hz), 6.24-6.41 (m, 6H), 7.01-7.04 (m, 1H), 7.35-7.45 (m, 2H), 7.76-7.83 (m, 1H). 13C 
NMR (100 MHz, CDCl3) δC =12.53, 27.86, 30.94, 40.00, 40.55, 44.31, 49.01, 50.27, 51.13, 
55.66, 56.22, 65.43, 81.52, 97.68, 104.84, 108.17, 122.73, 123.84, 128.38, 130.05, 132.84, 
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148.8, 153.18, 169.63, 170.58, 171.01, 172.31. ESI-HRMS: calcd for C58H87N8O9 1039.6596, 
found m/z 1039.6676.  
6.7.8 L2 
6 (0.30 g, 0.3 mmol) was stirred in CH2Cl2 (1 mL) and 
trifluoroacetic acid (1 mL, excess) was added dropwise. 
The solution was stirred at room temperature, open to air, 
for 24 h. The solvents were then removed in vacuo, and the 
residue redissolved in CH2Cl2. This was again removed and 
diethyl ether added. After removal of diethyl ether, this process was repeated. L2 was 
afforded as a pink solid (0.23 g, 92%). 1H NMR (400 MHz, MeOD) δ (ppm) = 1.15 (t, 12H, 
3JHH = 6.0 Hz), 2.84 (t, 2H, 3JHH = 7.0 Hz), 2.97-3.95 (m, 26H), 3.54 (q, 8H, 3JHH = 6.0 Hz), 
6.60-6.66 (m, 6H), 7.11 (d, 1H), 7.59 (m, 2H), 7.90 (d, 1H); 13C NMR (100 MHz, CDCl3) δC 
= 10.88, 38.29, 39.01, 45.44, 46.52, 50.41, 53.10, 110.98, 115.25, 122.42, 123.66, 128.55, 
128.91, 133.06, 153.05, 161.17, 161.51, 169.20. ESI-HRMS: calcd for C46H63N8O9 871.4702, 
found m/z 871.4718. 
6.7.9 [GdL2] 
L2 (0.19 g, 0.02 mmol) and GdCl3.6H2O (0.08 g, 0.02 mmol) 
were dissolved in water (2 mL) and the pH adjusted to 5.5 
using 1 M NaOH(aq). The reaction was left stirring at room 
temperature overnight. The solution was removed in vacuo 
until a small volume was left. This crude solution was purified using Sephadex G10 
chromotography affording [GdL2] as a pale beige solid (0.04 g, 20%). ESI-HRMS: m/z calcd 
for C46H60GdN8O9 1026.3724, found m/z 1026.3834. 
6.7.10 [EuL2] 
The complex was prepared by an analogous method as for 
[GdL2] using L2 (0.10 g, 0.01 mmol) and EuCl3.6H2O (0.042 
g, 0.01 mmol) to yield [EuL2] as a pale beige solid (0.02 g, 
17%). ESI-HRMS (MeOH): m/z: calculated for C46H60N8O9Eu 
1021.3696, found 1021.3746. 
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6.7.11 [TbL2] 
The complex was prepared by an analogous method as for 
[GdL2] using L2 (0.20 g, 0.02 mmol) and TbCl3.6H2O (0.086 
g, 0.02 mmol) to yield [TbL2] as a pale beige solid (0.03 g, 
14%). ESI-HRMS (MeOH): m/z: calculated for C46H60N8O9Tb 
1027.3737, found 1027.3805. 
6.7.12 [YbL2] 
The complex was prepared by an analogous method as for 
[GdL2] using L2 (0.20 g, 0.02 mmol) and YbCl3.6H2O (0.089 
g, 0.02 mmol) to yield [YbL2] as a pale beige solid (0.04 g, 
18%). ESI-HRMS (MeOH): m/z: calculated for 
C46H60N8O9Yb 1042.3872, found 1042.3872. 
 
6.7.13 7 
To a solution of N-methylethylenediamine (0.77 g, 10.4 mmol) in EtOH (15 
mL) was added triethylamine (2.8 mL, 20.1 mmol) under a N2 atmosphere at 
room temperature. A solution of di-tert-butyl dicarbonate (2.16 g, 9.90 mmol) in EtOH (5 
mL) was added dropwise at 0°C over 30 min. The resulting solution was stirred at 0°C for 30 
min. and then at room temperature for 24 hr. The reaction mixture was filtered, solvent 
evaporated under vacuum and residue purified by silica gel chromatography 
(chloroform:methanol, 30:1, v/v to chloroform:methanol:triethylamine, 150:10:3, v/v) to 
obtain a yellow oil (1.7 g, 94%). 1H NMR (400 MHz, CDCl3) δ (ppm) = 1.44 (s, 9H), 2.81 (t, 
2H, 3JHH = 6.4 Hz), 2.86 (s, 3H), 3.25 (m, 2H). 13C NMR (100 MHz, CDCl3) δC = 28.21, 
34.46, 39.95, 51.67, 79.16, 155.92. ESI-HRMS: calcd for C8H18N2O2 = 175.1446, found m/z = 
175.1447. 
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6.7.14 8 
To a stirring solution of rhodamine B (2.64 g, 5.51 mmol), 7 (0.96 
g, 5.51 mmol) and triethylamine (1.85 mL, 13.1 mmol) in 
dichloromethane (60 mL) was added HBTU (2.50 g, 6.59 mmol). 
The mixture was stirred for 2 hr. at room temperature and then 
diluted with dichloromethane (30 mL). The solution was washed with brine (50 mL x 2), 
dried over MgSO4, filtered and concentrated to dryness. Purification of the residue was 
carried out on a silica gel column (CH2Cl2:MeOH, 99:1) and afforded the compound as a dark 
purple foam (2.57 g, 78%). 1H NMR (400 MHz, CDCl3) δ (ppm) = 1.19 (t, 12H, 3JHH = 6.8 
Hz), 1.38, (s, 9H), 2.70 (s, 3H), 2.96 (t, 2H, 3JHH = 7.2 Hz), 3.23 (t, 2H, 3JHH = 7.2 Hz), 3.36 
(q, 8H, 3JHH = 6.8 Hz), 6.30 (dd, 2H, 3JHH = 8.8 Hz, 4JHH = 2 Hz), 6.40 (d, 2H, 4JHH = 2.4 Hz), 
6.45 (d, 2H, 3JHH = 8.8 Hz), 7.10 (m, 1H), 7.46 (m, 2H), 7.92 (m, 1H). 13C NMR (100 MHz, 
CDCl3) δC = 12.55, 28.34, 34.26, 37.76, 44.38, 47.02, 79.30, 97.71, 105.42, 108.12, 122.68, 
123.83, 128.10, 128.85, 131.25, 132.43, 148.77, 153.32, 155.47, 157.76, 167.99. ESI-HRMS: 
calcd for C36H47N4O4 = 599.3611, found m/z 599.3612. Anal. calcd for C36H47N4O4: C, 72.09; 
H, 7.90; N, 9.34%. Found C, 71.03; H, 7.79; N, 9.53%. 
 
6.7.15 9 
To a stirring solution of trifluoroacetic acid (10 mL) at 0°C was added 8 
(3.50 g, 5.84 mmol) in dichloromethane (40 mL). The reaction mixture 
was stirred at room temperature for 2 hr. after which all solvent was 
removed under reduced pressure. The residue was re-dissolved in DCM 
and washed with water (50 mL x 2), dried over MgSO4 and concentrated to dryness giving a 
dark purple foam (2.42 g, 83%).1H NMR (400 MHz, CDCl3) δ (ppm) = 1.20 (t, 12 H, 3JHH = 
7.2 Hz), 2.58 (s, 3H), 2.79 (t, 2H, 3JHH = 4.4 Hz), 3.34 (overlapped, 2H), 3.37 (q, 8H, 3JHH = 
7.2 Hz), 6.30 (dd, 2H, 3JHH = 8.8 Hz, 4JHH = 2.8 Hz), 6.41 (d, 2H, 4JHH = 2.8 Hz), 6.45 (d, 2H, 
3JHH = 8.8 Hz), 7.14 (m, 2H), 7.51 (m, 2H), 7.90 (m, 2H). 13C NMR (100 MHz, CDCl3) δC = 
12.59, 34.29, 38.28, 44.36, 47.02, 97.70, 108.08, 122.65, 123.81, 128.06, 128.83, 132.38, 
148.65, 157.75. ESI-HRMS: calcd for C31H39N4O2 = 499.3073, found m/z 499.3077. Anal. 
calcd for C31H39N4O2: C, 74.52; H, 7.87; N, 11.21%. Found C, 74.31; H, 7.52; N, 11.08%. 
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6.7.16 10 
9 (12.0 g, 24.1 mmol) was dissolved in DCM (200 mL) to which 
NEt3 (3.4 mL, 24.1 mmol). The reaction mixture was cooled to 0°C. 
Chloroacetyl chloride (1.9 mL, 24.1 mmol) in DCM (50 mL) was 
then added. The reaction mixture was allowed to come to room 
temperature and stirred for 5 h. Solvent was then removed under reduced pressure whereby 
the resultant was dissolved in DCM and washed with water (20 mL x 3) and brine. The 
organic layer was dried over MgSO4 and concentrated. Purification on a silica gel column 
(CH2Cl2:MeOH, 90:10) afforded the compound as a dark purple foam (5.94 g, 43%). 1H 
NMR (400 MHz, CDCl3) δ (ppm) = 1.19 (t, 12 H, 3JHH = 7.2 Hz), 2.80 (s, 3H), 3.13 (s, 3H), 
3.25 (m, 2H), 3.37 (q, 8H, 3JHH = 7.2 Hz), 3.77 (s, 2H), 6.30 (dd, 2H, 3JHH = 8.8 Hz, 4JHH = 
2.8 Hz), 6.42 (m, 4H), 7.15 (m, 1H), 7.50 (m, 1H), 7.94 (m, 1H). 13C NMR (100 MHz, 
CDCl3) δC = 12.59, 34.26, 38.26, 44.38, 47.02, 97.71, 108.11, 122.65, 123.83, 128.06, 128.83, 
132.38, 148.65, 157.76, 163.05. ESI-HRMS: calcd for C33H40ClN4O3 = 575.3151, found m/z 
575.3091. Anal. calcd for C33H40ClN4O3: C, 68.79; H, 7.00; N, 9.72%. Found C, 68.02; H, 
7.08; N, 9.52%. 
6.7.17 11 
Tris-tert-butyl-DO3A (4.2 g, 7.06 mmol) and K2CO3 (2.2g, 
15.9 mmol) were dissolved in CH3CN (100 mL) and stirred 
for 5 min. 10 (4.06 g, 7.06 mmol) in CH3CN (50 mL) was 
then added dropwise. The reaction mixture was refluxed for 
48 h. After cooling to room temperature, the solution was 
filtered and dried under reduced pressure. The crude product was purified by silica gel 
column chromatography (CH2Cl2:MeOH, 99:1 to CH2Cl2:MeOH:NEt3, 80:15:5) yielding 11 
as an orange powder (4.1 g, 56%). 1H NMR (400 MHz, CDCl3) δ (ppm) = 1.20 (t, 12H, 3JHH = 
7.2 Hz), 1.48 (s, 27H), 2.80 (s, 3H), 2.88 – 2.96 (m, 16H), 3.13 (m, 2H), 3.32 (s, 2H), 3.34 
(m, 2H), 3.38 (q, 8H, 3JHH = 7.2 Hz), 3.51 (s, 2H), 6.29 (m, 2H), 6.39 (d, 2H, 3JHH = 6.6 Hz), 
6.41 (s, 2H), 7.11 – 7.13 (m, 1H), 7.50 (m, 2H), 7.93 (m, 1H). 13C NMR (100 MHz, CDCl3) 
δC = 12.70, 2783, 30.91, 37.27, 39.95, 43.13, 44.40, 47.28, 58.11, 108.29, 122.13, 122.74, 
126.92, 129.09. ESI-HRMS: calcd for C59H89N8O9 = 1053.6753, found m/z 1053.6793. Anal. 
calcd for C59H89N8O9: C, 67.21; H, 8.51; N, 10.63%. Found C, 67.11; H, 8.32; N, 10.56%. 
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6.7.18 L3 
11 (6.6 g, 6.3 mmol) was dissolved in DCM (20 mL) and 
trifluoroacetic acid (5 mL, excess) was added dropwise. The 
solution was stirred at room temperature, open to air for 24 h. 
The solvent was then removed under reduced pressure. The 
crude product was purified by dissolving impurities into 
diethyl ether and decantation (3 x 10 mL) until a pink solid was obtained (7.61 g, TFA salts 
present). 1H NMR (400 MHz, CDCl3) δ (ppm) = 1.20 (t, 12H, 3JHH = 8 Hz), 2.83 (s, 3H), 2.84 
– 3.31 (m, 16H), 3.18 (m, 2H), 3.28 (m, 2H), 3.49 (s, 2H), 3.51 (s, 2H), 3.54 (q, 8H, 3JHH = 8 
Hz), 6.68 (m, 2H), 6.78 (m 2H), 6.88 (m, 2H), 7.16 – 7.20 (m, 1H), 7.63 – 7.66 (m, 2H), 7.93 
– 7.97 (m, 1H). 13C NMR (100 MHz, CDCl3) δC = 11.40, 37.07, 37.14, 37.19, 44.12, 47.32, 
47.79, 58.59, 95.48, 111.99, 122.60, 129.02, 129.25. Anal. calcd for 
C47H65N8NaO9.(CF3CO2H)5: C, 46.28; H, 4.77; N, 7.58%. Found C, 46.62; H, 4.47; N, 
7.49%. 
6.7.19 [GdL3] 
L3 (0.5 g, 0.56 mmol) and GdCl3.6H2O (0.22 g, 0.59 mmol) 
were dissolved in water (10 mL) and the pH adjusted to 5.5 
using 2 M NaOH solution. The reaction was left stirring at 
60°C overnight. The solution was filtered and the filtrate was 
concentrated to ~1 mL. This crude solution was purified 
using Sephadex G10 chromotography affording [GdL3] as a bright pink solid (0.1 g, 18%). 
ESI-HRMS: m/z calcd for C47H62GdN8O9 = 1040.3881, found m/z 1040.3910. Anal. calcd for 
C47H62GdN8O9: C, 54.26; H, 6.01; N,10.77 %. Found C, 54.18; H, 5.88; N, 10.69 %. 
6.7.20 [EuL3] 
The complex was prepared by an analogous method as for 
[GdL3] using L3 (0.5 g, 0.56 mmol) and EuCl3.6H2O (0.21 
g, 0.59 mmol) to yield [EuL3] as a bright pink solid (0.062 
g, 11%). ESI-HRMS: m/z: calcd for C47H62EuN8O9 = 
1035.3852, found m/z 1035.3844. Anal. calcd for 
C47H62EuN8O9: C, 54.54; H, 6.04; N, 10.83 %. Found C, 54.43; H, 5.91; N, 10.75 %. 
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6.7.21 [TbL3] 
The complex was prepared by an analogous method as for 
[GdL3] using L3 (0.5 g, 0.56 mmol) and TbCl3.6H2O (0.22 
g, 0.59 mmol) to yield [TbL3] as a bright pink solid (0.14 
g, 24%). ESI-HRMS: m/z: calcd for C47H62N8O9Tb = 
1041.3893, found m/z 1041.3990. Anal. calcd for 
C47H62N8O9Tb: C, 54.18; H, 6.00; N, 10.75 %. Found C, 54.13; H, 5.87; N, 10.71 %. 
6.8 Synthesis of compounds in chapter 3 
6.8.1 12 
BPEN (1.45 g, 6.14 mmol) was dissolved in DCM (30 mL), NEt3 (0.94 
mL, 6.75 mmol) was added and the reaction mixture was cooled to 0°C. 
Chloroacetyl-chloride (0.54 mL, 6.75 mmol) was then added dropwise. 
The reaction mixture was allowed to come to room temperature and stirred for 2 hr. The 
solvent was then removed in DCM (20 mL) and salts filtered. After removal of DCM the 
resultant was purified by alumina (I) chromatography (DCM:MeOH, 99:1, v/v) to afford 12 
as a pale yellow oil (1.25 g, 64%). 1H NMR (400 MHz, CDCl3) δ (ppm) = 2.93 (t, 2H, 3JHH = 
5.6 Hz), 3.47 (m, 2H), 4.04 (s, 2H), 4.07 (s, 4H), 7.34 (m, 2H), 7.55 (d, 2H, 3JHH = 7.6 Hz), 
7.80 (td, 2H, 3JHH = 8 Hz, 4 Hz), 8.66 (d, 2H, 3JHH = 5.2 Hz). 13C NMR (100 MHz, CDCl3) δC 
= 37.17, 42.59, 53.30, 58.55, 123.47, 124.62, 138.31, 147.54, 156.11, 166.72. ESI-HRMS: 
calcd for C16H20N4OCl = 319.1326, found m/z 319.1339. 
6.8.2 13 
Tris-tert-butyl-DO3A (0.90 g, 1.4 mmol) and K2CO3 (0.2 g, 1.6 
mmol) were dissolved in CH3CN (30 mL) and left to stir for 5 
min. 12 (0.50 g, 1.6 mmol) in CH3CN (10 mL) was then added 
dropwise. The reaction mixture was set to reflux for 24 h. The 
resulting solution was filtered and the filtrate was concentrated 
under reduced pressure. The crude product was purified by alumina (I) chromatography 
(DCM:MeOH, 99:1, v/v to 90:1, v/v) affording 13 as a pale beige solid (0.68 g, 54 %). 1H 
NMR (400 MHz, CDCl3) δ (ppm) = 1.37 (s, 27H), 2.17 – 3.41 (m, 28H), 3.80 (s, 4H), 7.09 (m 
,2H), 7.33 (d, 2H, 3JHH = 8 Hz), 7.56 (td, 2H, 3JHH = 7.6, 1.6 Hz), 8.48 (d, 2H, 3JHH = 4.4 Hz). 
13C NMR (100 MHz, CDCl3) δC = 28.14, 37.51, 42.67, 44.00, 45.04, 47.09, 49.26, 51.10, 
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51.43, 52.17, 57.67, 59.91, 81.54, 122.21, 123.62, 149.99, 158.88, 165.86, 169.81, 170.50, 
171.73. ESI-HRMS: calcd for C42H68N8O7 = 797.5289, found m/z 797.5290. Anal. calcd for 
C42H68KN8O7: C, 57.64; H, 7.83; N, 12.80%. Found C, 56.90; H, 7.80; N, 12.85%. 
6.8.3 L4 
To a stirring solution of trifluoroacetic acid (5 mL) at 0°C was 
added 13 (0.15 g, 0.19 mmol) in dichloromethane (5 mL). The 
reaction mixture was stirred at room temperature for 2 hours, after 
which all solvent was removed under reduced pressure. The crude 
product was purified by dissolving impurities into diethyl ether and decantation (3 x 10 mL) 
to leave a white powder (0.17 g, TFA salts present). 1H NMR (400 MHz, D2O) δ (ppm) = 2.26 
(br m, 2H), 2.79-3.83 (br m, 24 H), 4.10 (s, 8H), 7.85 (t, 2H, 3JHH = 6.8 Hz), 7.95 (d, 2H, 3JHH 
= 8 Hz), 8.40 (t, 2H, 3JHH = 7.6 Hz), 8.56 (d, 2H, 3JHH = 5.6 Hz). 13C NMR (100 MHz, D2O) 
δC = 36.66, 49.25, 51.34, 53.98, 55.29, 117.70, 126.31, 127.35, 141.83, 147.83, 152.40, 
162.98, 174.05, 174.60. ESI-HRMS: calcd for C30H45N8O7 = 629.2411, found m/z 629.3428. 
6.8.4 [GdL4] 
L4 (0.10 g, 0.16 mmol) and GdCl3.6H2O (0.059 g, 0.16 mmol) 
were dissolved in water (4 mL) and the pH adjusted to 5.5 using 2 
M NaOH solution. The mixture was stirred at room temperature for 
24 h. The pH was then increased to 10 by the addition of 2 M 
NaOH to precipitate uncomplexed Gd3+, the pH was brought down to 7.4 and water removed 
under reduced pressure. The residue was purified on a Sephadex G10 desalting resin (water) 
to yield [GdL4] as a white hydroscopic powder (9.1 mg, 7%). ESI-HRMS: calcd for 
C30H42GdN8O7 = 784.2418, found m/z 784.2446. r1 (H2O, 298 K, 400 MHz) = 4.55 mmol-1s-1. 
λabs = 262 nm. 
6.8.5 [EuL4] 
The complex was prepared by an analogous method as for [GdL4] 
using L4 (0.03 g, 0.05 mmol) and EuCl3.6H2O (0.02 g, 0.04 mmol) 
to yield [EuL4] as a white hygroscopic solid (0.016 g, 44%). ESI-
HRMS: calcd for C30H42EuN8O7 = 779.2389, found m/z 779.2407. 
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6.8.6 [TbL4] 
The complex was prepared by an analogous method as for [GdL4] 
using L4 (0.03 g, 0.05 mmol) and TbCl3.6H2O (0.02 g, 0.05 mmol) 
to yield [TbL4] as a white hygroscopic solid (0.013 g, 35%). ESI-
HRMS: calcd for C30H42TbN8O7 = 785.2430, found m/z 785.2437. 
6.8.7 14 
Bis-tert-butyl-DO2A (1.50 g, 3.8 mmol), and K2CO3 (0.52 g, 3.8 
mmol) were dissolved in CH3CN (130 mL) and left to stir for 5 
min. 5 (2.11 g, 3.8 mmol) was then added. The reaction mixture 
was set to reflux for 24 h. The resulting solution was filtered and 
the filtrate concentrated under reduced pressure. The crude product was purified by alumina 
(I) chromatography (DCM:MeOH, 99:1, v/v to 98:2, v/v) affording 14 as pale pink solid (1.59 
g, 46%). 1H NMR (400 MHz, CDCl3) δ (ppm) = 1.17 (t, 12H, 3JHH = 7.2 Hz), 1.47 (s, 18H), 
2.40 – 3.10 (series of multiplets, 24H), 3.22 (m, 2H), 3.32 (q, 8H, 3JHH = 7.2 Hz), 6.30 (dd, 
2H, 4JHH = 2.6 Hz, 3JHH = 8.8 Hz), 6.39 (d, 2H, 4JHH = 2.6 Hz), 6.50 (d, 2H, 3JHH = 8.8 Hz), 
7.06 (m, 1H), 7.43 (m, 2H), 7.92 (m, 1H), 8.08 (br s, 1H). 13C NMR (100 MHz, CDCl3) δC = 
12.65, 28.22, 37.70, 39.86, 44.33, 48.78, 52.44, 53.42, 55.86, 56.85, 57.21, 64.90, 80.91, 
97.82, 105.32, 108.20, 122.85, 123.74, 127.95, 128.70, 130.61, 132.44, 148.80, 153.14, 
153.98, 168.56, 170.89, 171.98. ESI-HRMS: calcd for C52H77N8O7 = 925.5915, found m/z 
925.5920. Anal. calcd for C52H76N8O7: C, 67.50; H, 8.28; N, 12..11%. Found C, 67.39; H, 
8.17; N, 12.02%. 
6.8.8 15 
14 (1.20 g, 1.3 mmol) and K2CO3 (0.20 g, 1.6 
mmol) were dissolved in CH3CN (40 mL) and left 
to stir for 5 min. 12 (0.50 g, 1.5 mmol) in CH3CN 
(10 mL) was then added dropwise. The reaction 
mixture was set to reflux for 24 h. The resulting 
solution was filtered and the filtrate concentrated under reduced pressure. The crude product 
was purified by alumina (III) chromatography (DCM:MeOH, 99:1, v/v to 90:10, v/v) 
affording 14 as a beige solid (0.68 g, 34%). 1H NMR (400 MHz, CDCl3) δ (ppm) = 1.14 (t, 
12H, 3JHH = 6.8 Hz), 1.35 (s, 18H), 2.47 – 3.56 (series of multiplets, 28H), 3.32 (q, 8H, 3JHH = 
6.8 Hz), 3.82 (s, 4H), 6.35 (br m, 6H), 7.04 (m, 1H), 7.12 (m, 2H), 7.40 (m, 2H), 7.64 (m, 
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4H), 7.80 (m, 1H), 8.46 (d, 2H, 3JHH = 4.8 Hz), 9.81 (t, 1H, NH, 3JHH = 5.3 Hz), 10.57 (t, 1H, 
NH, 3JHH = 5.5 Hz). 13C NMR (100 MHz, CDCl3) δC = 12.63, 27.97, 38.03, 38.95, 39.85, 
44.29, 48.78, 50.27, 53.25, 56.83, 57.04, 59.96, 65.17, 86.25, 97.74, 122.04, 122.96, 123.34, 
123.71, 127.88, 130.00, 132.64, 136.69, 148.80, 154.08, 159.20, 169.07, 173.52, 174.54. ESI-
HRMS: calcd for C68H94N12NaO8 = 1229.7215, found m/z 1229.7219. 
6.8.9 L5 
15 (0.44 g, 0.36 mmol) was dissolved in CH2Cl2 
(10 mL) and trifluoroacetic acid (10 mL) added 
dropwise. The solution was stirred at room 
temperature, open to air for 24 h. The solvents 
were removed under reduced pressure and the 
crude product was purified by dissolving impurities into diethyl ether, followed by 
decantation (3 x 10 mL), to leave a bright pink powder (0.13 g, TFA salts present). 1H NMR 
(400 MHz, D2O) δ (ppm) = 1.03 (t, 12H, 3JHH = 7.2 Hz), 2.69 – 3.46 (series of multiplets, 
32H), 3.55 (q, 8H, 3JHH = 7.2 Hz), 4.12 (s, 4H), 6.98 (d, 2H, 3JHH = 8.8 Hz), 7.12 (m, 2H), 
7.16 (dd, 2H, 3JHH = 8.4 Hz, 4JHH = 2.4 Hz), 7.51 (d, 2H, 3JHH = 2 Hz), 7.56 (m, 2H), 7.79 (t, 
2H, 3JHH = 6.8 Hz), 7.87 (m, 1H), 7.94 (d, 2H, 3JHH = 8 Hz). 13C NMR (100 MHz, D2O) δC = 
9.63, 14.08, 53.82, 54.98, 65.98, 110.00, 111.93, 112.19, 114.83, 117.73, 118.26, 120.33, 
126.30, 127.25, 130.80, 138.46, 141.74, 147.25, 152.04, 152.45, 161.22, 162.57, 162.93. ESI-
HRMS: calcd for C60H78N12O8 = 1095.6144, found m/z 1095.6125. 
6.8.10 [GdL5] 
L5 (0.30 g, 0.27 mmol) and GdCl3.6H2O (0.10 g, 
0.27 mmol) were dissolved in water (12 mL), and 
the pH adjusted to 5.5 using 2 M NaOH solution. 
After stirring at room temperature for 24 hours, the 
precipitate formed was filtered and washed with water. It was then dissolved in 50:50, v/v, 
MeOH/water mixture and the pH of the solution adjusted to 10 by addition of 2 M NaOH to 
precipitate uncomplexed Gd(OH)3. After the pH was lowered to 5.5, DOWEX Mac-3 weak 
acid-cation exchange resin beads were added and the solution was stirred for 10 min. with 
maintaining of pH at 5.5. After removal of the beads, the pH was raised to 7.4 and solvent 
removed to give [GdL5] as a pale brown powder (0.092 g, 29%). ESI-HRMS: calcd for 
C60H76GdN12O8 = 1250.5150, found m/z 1250.5151. 
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6.9 Synthesis of compounds in chapter 4 
6.9.1 16 
BPEN (0.80 g, 3.39 mmol) and NEt3 (0.47 mL, 3.37 mmol) were 
dissolved in CH3CN (60 mL) and left to stir for 5 min. 2 (1.5 g, 
2.81 mmol) was then added and the reaction mixture was set to 
reflux for 16 h. After cooling to room temperature the reaction 
mixture was filtered and solvent removed under reduced pressure. The residue was dissolved 
in DCM and washed with water (2 x 30 mL), organic layer dried over MgSO4 and solvent 
removed under reduced pressure. Purification of the residue was carried out on a silica gel 
column (CH2Cl2:MeOH, 99:1, v/v to CH2Cl2:MeOH:NEt3, 94:5:1, v/v) affording the 
compound as a brown solid (0.42 g, 21%). 1H NMR (400 MHz, CDCl3) δ (ppm) = 1.17 (t, 
12H, 3JHH = 7.2 Hz), 3.11 (t, 2H, 3JHH = 7.2 Hz), 3.23 (t, 2H, 3JHH = 4.4 Hz), 3.34 (q, 8H, 3JHH 
= 7.2 Hz), 3.46 (t, 2H, 3JHH = 4.8 Hz), 4.03 (s, 4H), 4.09 (t, 2H, 3JHH = 7.6 Hz), 6.29 (dd, 2H, 
3JHH = 8.8 Hz, 4JHH = 2.4 Hz), 6.37 (d, 2H, 4JHH = 2.4 Hz), 6.55 (d, 2H, 3JHH = 8.8 Hz), 6.98 
(m, 1H), 7.16 (m, 2H), 7.28 (m, 2H), 7.70 (m, 4H), 7.84 (d, 1H, 3JHH = 7.2 Hz), 8.56 (d, 2H, 
3JHH = 6.4 Hz). 13C NMR (100 MHz, CDCl3) δC = 12.64, 44.33, 46.42, 46.63, 46.98, 57.54, 
61.29, 64.45, 66.26, 97.70, 108.03, 121.80, 123.02, 124.70, 125.31, 127.30, 128.82, 130.99, 
131.17, 136.40, 148.50, 148.98, 152.84, 154.60, 159.33, 160.28. ESI-HRMS: calcd for 
C44H52N7O2 = 710.4182, found m/z 710.4170. 
6.9.2 18 
Tris-t-Bu-DO3A free base (2.6 g, 5.05 mmol) was dissolved in 
CH3CN (50 mL) and chloroacetamide 17 (0.76 g, 5.55 mmol) 
was added. After 5 min stirring at room temperature, NEt3 was 
added (0.77 mL, 5.55 mmol) and the mixture was stirred for 
another 24 h. Solvent was removed under vacuum and the 
residue dissolved in DCM. It was then washed with water (1 x 
20 mL), brine (1 x 20 mL), the organic layer dried over MgSO4 and solvent removed. The 
solid residue was then dissolved in a small amount of CHCl3 (~ 3 mL) and ether added (~ 40 
mL) to precipitate 18. This was filtered and dried to give the desired product as a white solid 
(1.39 g, 45 %). 1H NMR (400 MHz, CDCl3) δ (ppm) = 1.48 (s, 27 H), 1.8-3.4 (series of broad 
multiplets, 26 H), 3.78 (t, 2H, 3JHH = 4.4 Hz). ESI-MS: 616 [M]+, 308 [M]2+. Note: full 
characterisation not carried out as compound not novel, only the method used is novel. 
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6.9.3 30 
BPEN (1.5 g, 6.4 mmol) was dissolved in CH3CN (20 mL) and 
K2CO3 was added (1.3 g, 9.5 mmol). After stirring for 10 min, 
2-(Boc-amino)ethyl bromide (1.6 g, 7.0 mmol) and the reaction 
refluxed overnight. The reaction mixture was then cooled, 
filtered and solvent removed under vacuum. The residue was dissolved in DCM and washed 
with water (1 x 20 mL), dried over MgSO4 and evacuated to dryness. Purification of the 
residue was carried out on a silica gel column (CH2Cl2:MeOH:NEt3, 100:1:1, v/v/v) affording 
30 as a colourless viscous oil (0.89 g, 36%). 1H NMR (400 MHz, CDCl3) δ (ppm) = 1.45 (s, 
9H), 2.64 (t, 2H, 3JHH = 5.2 Hz). 2.74 (m ,2H), 2.76 (m, 2H), 3.12 (br s, 1H, NH), 3.24 (m , 
2H), 5.69 (br s, 1H, NH), 7.15 (dt, 2H, 3JHH = 2, 5.2 Hz), 7.39 (d, 2H, 3JHH = 8 Hz), 7.63 (dt, 
2H, 3JHH = 1.2, 8 Hz), 8.56 (d, 2H, 3JHH = 4.4 Hz). 13C NMR (100 MHz, CDCl3) δC = 28.47, 
39.71, 46.31, 48.56, 53.68, 60.54, 78.98, 122.06, 123.18, 136.44, 149.18, 156.20, 159.33. 
ESI-MS: 386.2 [M]+. 
6.9.4 31 
30 (0.6 g, 1.6 mmol) was dissolved in CH3CN (30 mL) 
and NEt3 (5mL, excess) followed by KI (0.65 g, 3.9 
mmol) were added. After stirring for 5 min 2 (1 g, 3.1 
mmol) was added and the reaction was set to reflux 
overnight. The reaction mixture was then cooled and 
solvent removed. Residue dissolved in DCM and washed 
with water (2 x 20 mL), dried over MgSO4 and evacuated to dryness. This crude reaction 
mixture was then purified using silica gel chromatography (CH2Cl2:MeOH, 99.5:0.5 to 90:10, 
v/v) yielding 31 as a pale brown solid (0.30 g, 23 %). 1H NMR (400 MHz, CDCl3) δ (ppm) = 
1.16 (t, 12 H, 3JHH = 7.2 Hz), 1.39 (s, 9H), 2.22 (br, 2H), 2.36 (br, 2H), 2.48 (br, 2H), 2.95 (br, 
2H), 3.11 (br, 2H), 3.34 (q, 8H, 3JHH = 7.2 Hz), 6.27 (dd, 2H, 3JHH = 8.8 Hz, 4JHH = 2.4 Hz), 
6.37 (m, 4H), 7.11 (m, 3H), 7.46 (m, 4H), 7.62 (t, 2H, 3JHH = 6.8 Hz), 7.90 (m, 1H), 8.47 (br, 
2H). 13C NMR (100 MHz, CDCl3) δC = 12.58, 28.43, 37.94, 38.16, 38.25, 44.35, 50.55, 
51.76, 52.78, 60.37, 65.14, 79.30, 97.69, 108.09, 122.56, 122.72, 123.39, 128.16, 128.73, 
132.44, 136.80, 148.95, 153.47, 156.07. ESI-HRMS: calcd for C51H65N8O4= 853.5129, found 
m/z 853.5134. 
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6.9.5 32 
TFA (5 mL, excess) was cooled to 0 °C and 31 (0.29 g, 
0.34 mmol) in DCM (5 mL) was added dropwise. The 
reaction mixture was stirred at room temperature for two 
hours. After this time, the solvent was removed, residue 
dissolved in DCM and washed with water (2 x 20 mL). 
The organic layer was then dried over MgSO4 and evacuated to dryness to give 32 as a brown 
solid (0.21 g, 80 %). 1H NMR (400 MHz, CDCl3) δ (ppm) = 1.16 (t, 12 H, 3JHH = 7.2 Hz), 
2.24 (t, 2H, 3JHH = 8 Hz), 2.30 (t, 2H, 3JHH = 6 Hz), 2.41 (m , 2H), 2.52, (m , 2H), 2.57 (m, 
2H), 3.13 (t, 2H, 3JHH = 8 Hz), 3.34 (q, 8H, 3JHH = 7.2 Hz), 3.74 (s, 4H), 6.28 (dd, 2H, 3JHH = 
8.8 Hz, 4JHH = 2.4 Hz), 6.39 (m, 4H), 7.11 (m 3H), 7.45 (, 4H), 7.61 (t, 2H, 3JHH = 8 Hz), 7.89 
(m, 1H), 8.52 (d, 2H, 3JHH = 4.4 Hz). 13C NMR (100 MHz, CDCl3) δC = 12.61, 37.98, 39.62, 
44.36, 52.01, 52.26, 52.74, 60.62, 64.84, 97.72, 105.67, 108.03, 121.93, 122.61, 122.96, 
123.81, 128.01, 128.96, 123.81, 128.01, 128.96, 131.65, 132.22, 136.40, 148.78, 149.01, 
153.21, 153.47, 159.56, 167.55. ESI-HRMS: calcd for C46H57N8O2= 753.4604, found m/z 
753.4588. 
6.9.6 33 
32 (0.19 g, 0.25 mmol) was dissolved in DCM (10 mL) 
and cooled to 0 °C. NEt3 (0.035 mL, 0.25 mmol)) was 
added and the mixture was stirred for 5 min. Chloroacetyl 
chloride (0.02 mL, 0.25 mmol) in DCM (2 mL) was then 
added dropwise and the reaction mixture was stirred at 
room temperature for 2 hours. After this time, the solvent 
was removed, residue dissolved in DCM and washed with water (2 x 20 mL). The organic 
layer was then dried over MgSO4 and evacuated to dryness to give 33 as a brown solid (0.17 
g, 83 %). 1H NMR (400 MHz, CDCl3) δ (ppm) = 1.18 (t, 12 H, 3JHH = 6.8 Hz), 2.18 (t, 2H, 
3JHH = 7.2 Hz), 2.39 (t, 2H, 3JHH = 5.6 Hz), 2.47 (m, 2H), 2.55 (m, 2H), 3.11 (m, 4H), 3.34 (q, 
8H, 3JHH = 6.8 Hz), 3.75 (s, 4H), 3.99 (s, 2H), 6.28 (dd, 2H, 3JHH = 8.8 Hz, 4JHH = 2.4 Hz), 
6.38 (m, 4H), 7.12, (m, 3H), 7.44 (d, 2H, 3JHH = 7.6 Hz), 7.47 (m, 2H), 7.53 (t, 1H, NH), 7.62 
(td, 2H, 3JHH = 7.6, 1.6 Hz), 7.89 (m, 1H), 8.49 (d, 2H, 3JHH = 4.4 Hz). 13C NMR (100 MHz, 
CDCl3) δC = 12.59, 37.24, 38.17, 42.69, 44.35, 51.73, 51.83, 51.93, 52.05, 60.71, 65.01, 
97.72, 105.61, 108.08, 121.91, 122.68, 122.98, 123.86, 128.10, 128.94, 132.35, 136.35, 
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148.81, 148.94, 153.49, 159.56, 165.96. ESI-HRMS: calcd for C48H58N8O3Cl = 829.4320, 
found m/z 829.4333. 
6.9.7 34 
Tris-t-Bu-DO3A free base (0.49 g, 0.96 
mmol) and K2CO3 (0.062 g, 0.47 mmol) in 
CH3CN (20 mL) were stirred for 5 min. 33 
(0.19 g, 0.22 mmol) in CH3CN (1 mL) was 
then added. The reaction mixture was 
refluxed for 48 hours. After cooling to room 
temperature, the reaction mixture was filtered and evacuated to dryness. This crude reaction 
mixture was then purified using silica gel chromatography (CH2Cl2:MeOH, 99.5:0.5 to 90:10, 
v/v) yielding 34 as a pale brown solid (0.08 g, 26 %). 1H NMR (400 MHz, CDCl3) δ (ppm) = 
1.08 (t, 12H, 3JHH = 6.8 Hz), 1.40 (s, 27 H), 2.10 (t, 2H, 3JHH = 6.8 Hz), 2.35 (m, 2H), 2.41 (m, 
4H), 3.04 (br, 2H), 3.11 (br, 2H), 2.05 – 2.95 (br m, 24 H), 3.25 (q, 8H, 3JHH = 6.8 Hz), 3.63 
(s, 4H), 6.19 (dd, 2H, 3JHH = 9.2 Hz, 4JHH = 2.8 Hz), 6.30 (m, 4H), 7.06 (m, 3H), 7.36 (d, 2H, 
3JHH = 7.6 Hz), 7.43 (m, 2H), 7.56 (td, 2H, 3JHH = 7.6, 1.6 Hz), 7.80 (m, 1H), 7.89 (t, 1H, 
NH), 8.41 (d, 2H, 3JHH = 4 Hz). 13C NMR (100 MHz, CDCl3) δC = 12.49, 28.01, 37.24, 38.12, 
43.10, 44.22, 51.30, 51.72, 51.86, 52.76, 53.00, 55.57, 56.14, 57.76, 58.09, 60.30, 65.09, 
81.55, 81.67, 97.59, 105.38, 107.90, 121.85, 122.41, 122.93, 123.87, 128.07, 128.75, 131.25, 
132.44, 136.30, 136.37, 148.70, 153.02, 153.40, 159.37, 163.51, 167.96, 170.65, 171.10, 
172.51. ESI-HRMS: calcd for C74H107N12O9 = 1307.8248, found m/z 1307.8361. 
6.9.8 L6 
To a stirring solution of trifluoroacetic acid 
(5 mL) at 0°C was added 34 (0.08 g, 0.06 
mmol) in dichloromethane (5 mL). The 
reaction mixture was stirred at room 
temperature for 2 hours, after which all 
solvent was removed under reduced 
pressure. The crude product was purified by 
dissolving impurities into diethyl ether and decantation (3 x 10 mL) to leave a bright pink 
powder (0.09 g, TFA salts present). 1H NMR (400 MHz, CH3OH) δ (ppm) = 1.13 (t, 12H, 
3JHH = 6.8 Hz), 3.0 – 3.8 (br m, 36 H), 3.45 (q, 8H, 3JHH = 6.8 Hz), 4.10 (s, 4H), 6.65 (m, 2H), 
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7.01 (m, 3H), 7.18 (m, 2H), 7.59 (m, 2H), 7.66 (m, 2H), 7.88 (m, 3H), 8.09 (t, 2H, 3JHH = 6 
Hz), 8.65 (d, 2H, 3JHH = 4.8 Hz). 13C NMR (100 MHz, CH3OH) δC = 12.54, 36.52, 47.19, 
48.51, 50.92, 52.89, 53.52, 53.57, 58.49, 97.56, 103.69, 113.15, 115.72, 124.59, 125.58, 
126.76, 130.62, 130.66, 133.17, 135.37, 143.48, 147.21, 154.49, 156.26, 170.80. ESI-HRMS: 
calcd for C62H80N12O9 = 1139.6406, found m/z 1139.6539. 
6.9.9 [GdL6] 
L6 (0.05 g, 0.04 mmol) and GdCl3.6H2O 
(0.016 g, 0.04 mmol) were dissolved in water 
(3 mL), and the pH adjusted to 5.5 using 2 M 
NaOH solution. After stirring at 60 °C for 24 
hours, the precipitate formed was filtered. 
After raising the pH to ~ 7.4, further 
precipitate was formed which was filtered and 
combined with the original precipitate. After washing with water, the residue was dissolved in 
1:99, MeOH:water solution and DOWEX Mac-3 weak acid-cation exchange resin beads were 
added. The solution was stirred for 10 min. with maintaining of pH at 5.5. After removal of 
the beads, the pH was raised to 7.4 and solvent removed to give [GdL6] as a pale brown 
powder (0.015 g, 26%). ESI-MS: 1294.6 [M]+, 627.8 [M]2+. 
6.9.10 [EuL6] 
The complex was prepared by an analogous 
method as for [GdL6] using L6 (0.04 g, 0.03 
mmol) and EuCl3.6H2O (0.01 g, 0.03 mmol) 
to yield [EuL6] as a pale brown solid (0.007 g, 
17%). ESI-HRMS: calcd for C62H79EuN12O9 = 
1289.5611, found m/z 1289.5664. 
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